Sentence,class,file
1995;26(1):61-6.  http://dx.doi.org/10.1016/0003-6870(94)00003-H 20.,Non-OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
PMid:21996320. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
2005;60(2):148-56. http://dx.doi.org/10.1093/ gerona/60.2.148 30.,Non-OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
PMid:20200012. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
PMid:19162342.  http://dx.doi.org/10.1016/j.archger.2008.12.002 33.,OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
PMid:20736056. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
PMid:15389720. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
1994;4(1):47-59. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5a/4e/rbfis-18-02-0183.PMC4183246.pdf
2014 Mar-Apr; 18(2):152-164. http://dx.doi.org/10.1590/ S1413-35552012005000154 Introduction Advances in the health area and neonatal intensive  care have led to increased survival rates among low- birth-weight preterm infants (PTIs)1-3.,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
2014 Mar-Apr; 18(2):152-164  http://dx.doi.org/10.1590/S1413-35552012005000154,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:11321240. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:10845113. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:14510318. http://dx.doi.org/10.1016/ S0146-0005(03)00055-7 5.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:16344661. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:8078162. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:7819684. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:6497433. http://dx.doi.org/10.1136/adc.59.10.957 13.,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:1509112. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:17950130. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:305471. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:76807.  http://dx.doi.org/10.1016/S0140-6736(78)90204-0 159  Braz J Phys Ther.,OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
PMid:6830270. http://dx.doi.org/10.1136/ adc.58.1.20 23.,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
2008;8:285-90. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/f9/rbfis-18-02-0152.PMC4183247.pdf
2014 Mar-Apr; 18(2):119-126. http://dx.doi.org/10.1590/ S1413-35552012005000152 Introduction Postural alignment promotes the support  and mobility of the segments of the body1.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
2014 Mar-Apr; 18(2):119-126  http://dx.doi.org/10.1590/S1413-35552012005000152,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
1995;74:70-92. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
1987;11:68-73.  http://dx.doi.org/10.3109/03091908709062798 8.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
2002;78:89-103. http://dx.doi.org/10.1590/ S0021-75572002000700012 11.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:10768540. http://dx.doi.org/10.1053/mr.2000.3782 12.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
2003;17:136-41. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:20850213. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:22699691. http://dx.doi.org/10.1590/ S1413-35552012005000026 16.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:17057441.  http://dx.doi.org/10.1097/01.PEP.0000068117.48023.18 17.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
2009;13(4):350-5. http://dx.doi.org/10.1590/ S1413-35552009005000047 19.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
Available from:  http://sapo.incubadora.fapesp.br/portal .,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
Available from: http://www.R-project.org /.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
http://dx.doi.org/10.1007/s00586-010-1554-z 28.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:16386157. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:21068635. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
PMid:19453691. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/14/rbfis-18-02-0119.PMC4183248.pdf
2014 Mar-Apr; 18(2):127-136. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
2014 Mar-Apr; 18(2):127-136  http://dx.doi.org/10.1590/S1413-35552012005000146,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
http://dx.doi.org/10.1136/ thorax.57.10.847 7.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:23543648. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
2009;13(3):183-204. http://dx.doi.org/10.1590/ S1413-35552009005000034 9.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
Oxford:  Oxford University Press; 1998. http://dx.doi.org/10.1093/ acprof:oso/9780195122978.001.0001  134 Braz J Phys Ther.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:12358326. http://dx.doi.org/1 0.1183/09031936.02.00532002 11.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:11998990. http://dx.doi.org/10 .1183/09031936.02.00279602 12.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
1988;93(3):580-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:12091180. http://dx.doi.org/10.1164/ ajrccm.166.1.at1102 14.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:22218712.  http://dx.doi.org/10.1590/S1413-35552011000600008 15.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:19802464.  http://dx.doi.org/10.1590/S0100-879X2009005000032 16.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:21778120.  http://dx.doi.org/10.1016/j.jamda.2011.06.009 19.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:22421506. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:12231489.  http://dx.doi.org/10.1164/rccm.2107031 26.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:20417082. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:20956179. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:15665324.  http://dx.doi.org/10.1164/rccm.200407-855OC 30.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:12576356. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:14738227. http://dx.doi.org/10.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:9872834. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
2007;11(2):147-151. http://dx.doi.org/10.1590/ S1413-35552007000200010 135  Braz J Phys Ther.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:17507545. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
http://dx.doi.org/10.1016/ S0954-6111(08)70005-2 39.,OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
PMid:9817708. http://dx.doi.org/10.1164/ ajrccm.158.5.9804004 40.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
http://dx.doi.org/10.1513/ pats.200708-125ET 41.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
1977;1(6077):1645-8. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d8/3e/rbfis-18-02-0127.PMC4183249.pdf
2014 Mar-Apr; 18(2):201-209. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2014 Mar-Apr; 18(2):201-209  http://dx.doi.org/10.1590/S1413-35552012005000150,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:22218711.  http://dx.doi.org/10.1590/S1413-35552011000600006 2.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:23541823.  http://dx.doi.org/10.1016/j.bpobgyn.2013.02.005 3.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:21600958. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:20580844. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:20044193. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2010;37(1):23-6. http://dx.doi.org/10.1590/ S0101-60832010000100005 10.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2010;23(2):317-23. http://dx.doi.org/10.1590/ S0102-79722010000200014 11.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2001;11:180-7. http://dx.doi.org/10.1016/ S0959-4388(00)00194-X 12.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:20447478.  http://dx.doi.org/10.1016/j.nlm.2010.04.008 13.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:20189547. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2011;25:25- 35. http://dx.doi.org/10.1590/S1807-55092011000500004 16.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2011;13(5):392-403. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:16165229. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:23175439. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
1975;12(3):189- 98. http://dx.doi.org/10.1016/0022-3956(75)90026-6 23.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:14595482. http://dx.doi.org/10.1590/ S0004-282X2003000500014 24.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
1971;9(1):97- 113. http://dx.doi.org/10.1016/0028-3932(71)90067-4 25.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:12559834. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2012;25(3):358- 63. http://dx.doi.org/10.1590/S0103-21002012000300007 28.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:19545918. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2010;14(3):267-75. http://dx.doi.org/10.1590/ S1413-35552010000300004 34.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
2012;26(3):511-21. http://dx.doi.org/10.1590/ S1807-55092012000300016 36.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:23394362. http://dx.doi.org/10.1080/0022289 5.2012.740098 37.,Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
PMid:18096651. http://dx.doi.org/10.2522/ptj.20070131 39.,OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
"2006;12(6):351-5. http://dx.doi.org/10.1590/ S1517-86922006000600010 Correspondence Pâmela B. Mello-Carpes   Universidade Federal do Pampa   Laboratório de Estresse, Memória e Comportamento   BR 472, km 592   CP 118, CEP 97500-970, Uruguaiana, RS, Brasil   e-mail: pamelacarpes@unipampa.edu.br 209  Braz J Phys Ther.",Non-OADS,/arxiv_data1/oa_pdf/98/3f/rbfis-18-02-0201.PMC4183250.pdf
"2014 Mar-Apr; 18(2):111-118. http://dx.doi.org/10.1590/ S1413-35552012005000148 Introduction According to data from the World Health  Organization (WHO), the world’s population over  the age of 60 will increase from 605 million to 2  billion between 2000 and 20501.",Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2014 Mar-Apr; 18(2):111-118  http://dx.doi.org/10.1590/S1413-35552012005000148,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:17641451. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:11601951. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:17103296.  http://dx.doi.org/10.1007/s00198-006-0256-1 10.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMID: 12180242. http://dx.doi.org/10.1016/ S0749-0690(02)00004-6 11.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2011;16:342-40. http://dx.doi.org/10.1136/ bmj.d3411 14.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:20854564. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:21044715.  http://dx.doi.org/10.1016/j.apmr.2010.08.004 16.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:19011727.  http://dx.doi.org/10.1007/s00198-008-0794-9 17.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMID: 18166695. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:16078954. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:15341550. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMID: 20128337. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2007;13(1):60-6.  http://dx.doi.org/10.1590/S1517-86922007000100014 28.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:19093923.  http://dx.doi.org/10.1111/j.1532-5415.2008.02014.x 29.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2010;31(2):143-52. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2007;56(4):265-72. http://dx.doi.org/10.1590/ S0047-20852007000400005 31.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
PMid:22587850. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
"2008;63(1):76-82. http://dx.doi.org/10.1093/ gerona/63.1.76 Correspondence Adriana C. Lunardi   Universidade de São Paulo   Faculdade de Medicina   Departamento de Fisioterapia   Rua Cipotânea, 53   CEP 05360-000, São Paulo, SP, Brazil   e-mail: adrianalunardi@usp.br  118 Braz J Phys Ther.",Non-OADS,/arxiv_data1/oa_pdf/db/a6/rbfis-18-02-0111.PMC4183251.pdf
2014 Mar-Apr; 18(2):137-143. http://dx.doi.org/10.1590/ S1413-35552012005000147 Introduction Musculoskeletal injuries are common among elite  athletes.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
2014 Mar-Apr; 18(2):137-143  http://dx.doi.org/10.1590/S1413-35552012005000147,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:17513916. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:18400875. http://dx.doi.org/10.1136/ bjsm.2008.046441 3.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:21829986. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:19783812. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:19376475. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
"2007;13(4):217-21. http://dx.doi.org/10.1590/ S1517-86922007000400001 8. van Mechelen W, Hlobil H, Kemper HC.",Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:1509229.  http://dx.doi.org/10.2165/00007256-199214020-00002 9.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:16616614. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:20836582. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
"PMid:20942507.  http://dx.doi.org/10.2165/11536890-000000000-00000 12. van Wilgen CP, Verhagen EA.",OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:21471144. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:22464114. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:637184.  http://dx.doi.org/10.1177/036354657800600103 18.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:2610274. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:20231599. http://dx.doi.org/10.1136/ bjsm.2009.066316 21.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
PMid:22235907. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
2009;129(3):120-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/11/80/rbfis-18-02-0137.PMC4183252.pdf
2014 Mar-Apr; 18(2):165-173  http://dx.doi.org/10.1590/S1413-35552012005000151,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
Available  from: http://www.goldcopd.org/uploads/users/files/ GOLDReport_April12011.pdf .,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
Pmid:21881745. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:23063203.  http://dx.doi.org/10.1016/j.rmed.2012.08.016 5.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:17982531. http://dx.doi.org/10.1590/ S1806-37132007000400008 10.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:12186831.  http://dx.doi.org/10.1164/rccm.166.4.518 11.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:10412550. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:23288114. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:12091180. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:18760164. http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:14999112. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
2000;26(3):119-28.  http://dx.doi.org/10.1590/S0102-35862000000300004 19.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:19180335. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:18392462. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
Available from: http://publications.nice.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:15778487. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
Pmid:17054186. http://dx.doi.org/10.1002/14651858.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
2004;30(3):274-85.  http://dx.doi.org/10.1590/S1806-37132004000300015 28.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:15074454. http://dx.doi.org/10.1682/ JRRD.2003.10.0059 29.,OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
PMid:17166985. http://dx.doi.org/10.1378/ chest.130.6.1704 30.,Non-OADS,/arxiv_data1/oa_pdf/25/00/rbfis-18-02-0165.PMC4183253.pdf
2014 Mar-Apr; 18(2):174-182. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
2014 Mar-Apr; 18(2):174-182  http://dx.doi.org/10.1590/S1413-35552012005000144,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:17645682. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
2007;19:97-104. http://dx.doi.org/10.1590/ S0104-56872007000100011 3.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
1992;17:231-6. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:22465405.  http://dx.doi.org/10.1016/j.apmr.2012.03.017 7.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:21252307. http://dx.doi.org/10.2522/ ptj.20100255 8.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:15126738. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:12574761. http://dx.doi.org/10.1067/mhn.2003.23 12.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
2004;18:125-31. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
2003;69:535-540. http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:23670327. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:8002795. http://dx.doi.org/10.1590/ S0004-282X1994000100001 18.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:15021773. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:20609000. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
PMid:17169569. http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/57/rbfis-18-02-0174.PMC4183254.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Blood Medicine 2014:5 175–184Journal of Blood Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  175Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JBM.S6823 4Hemophilia A in Brazil – epidemiology   and treatment developments Adriana Aparecida Ferreira1 isabel Cristina Gonçalves  Leite2 Maria T eresa Bustamante- T eixeira2 Maximiliano Ribeiro  Guerra2 1Foundation and Center for  Hematology and Hemotherapy  of Minas Gerais (Hemominas),   2Department of Collective Health,   Federal University of Juiz de Fora,    Juiz de Fora, Minas Gerais, Brazil Correspondence: Adriana Aparecida  Ferreira   Rua Barão de Cataguases,   s/n, Juiz de Fora, Minas Gerais,   CeP 36015-370, Brasil   email adriana.hemato@gmail.co mAbstract:  Hemophilia A is an inherited disorder characterized by deficiency of coagulation  factor VIII, which predisposes patients to bleeding events.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available from: http://ibge.gov.br/home/geociencias/cartografia/ default_territ_area.sht m. Accessed May  8, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available from: http://data.worldbank.org/ indicator/SI.POV .GINI/countries/1W-BR?display=grap h. Accessed  July 21, 2014.",OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
Available from: http://conselho.saude.,Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available from: http://www.hemomi - nas.mg.gov.br/hemominas/menu/cidadao/doacao/breve_historia.htm l.  Accessed July  21, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available from: http://www.ibge.gov.br/home/ estatistica/ populacao/censo2010/default.sht m. Accessed July  21, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available  from: http://www.brasil.gov.br/@@busca?SearchableText =hemofili a.  Accessed July  21, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Available from: http://www1.anvisa.gov.br/anvisa/hemocad/Relatorio- UHMultiParametros.js p. Accessed: August 13, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Journal of Blood Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/Journal-of-blood-medicine-journa lThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects  of all topics pertaining to blood based medicine including but not limited to:  Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,  and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of  blood related medicine; Legal aspects of blood medicine; Historical perspec - tives.",Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
Available from: http://www.aids.gov.br/publicacao/2013/politica- brasileira-de-enfrentamento-da-aids-201 2.,Non-OADS,/arxiv_data1/oa_pdf/d1/ca/jbm-5-175.PMC4183441.pdf
"Communicative & Integrative Biology 2014; 7:e28423; http://dx.doi.org/10.4161/cib.28423Discovering electrophysiology in photobiology A brief overview of several photobiological processes   with an emphasis on electrophysiology vadim  volkov* Faculty of Life Sciences and Computing; London Metropolitan University; London, UK Keywords:  Photobiology, electrophysiology, polarized light, rod cells, dark noise, statistics of photons, optogenetics, quantum dots The mini-review gives special attention to holistic approach  and mechanisms of processes.",Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Biochem 1997; 66:717-49;   PMID:9242922 ; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Plant Physiol Plant Mol Biol  2000; 51:83-109;  PMID :15012187 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Biol Chem 1969; 244:3290-302; http://www.jbc.org/con - tent/244/12/3290.long ; PMID:4307313 .,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Genet 2004; 38:87-117;  PMID :15568973 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Trends Plant Sci 2012; 17:230- 7; PMID:22326562 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biophys J 1975; 15:955- 62; http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC1334761/ ; PMID:1182271 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Proc Natl Acad Sci U S  A 2002; 99:8689-94; PMID:12060707 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Science  2002; 296:2395-8;  PMID:12089443 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Plant Biol 2008; 59:167-89;   PMID:18444900 ; http://dx.doi.org/10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Mol Biol 2013; 425:1795- 814; PMID:23376098 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Exp Bot  2006; 57:1079-95;  PMID:16513814 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
rupress.org/content/25/6/819.long ; PMID:19873316 ;  http://dx.doi.org/10.1085/jgp.25.6.819 .,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Biochem 2006; 75:743-67;   PMID:16756510 ; http://dx.doi.org/10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Genome Biol 2005; 6:213;   PMID:15774036 ; http://dx.doi.org/10.1186/ gb-2005-6-3-213 19.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biophys Chem 1995; 55:115-26; PMID:7632872 ;  http://dx.doi.org/10.1016/0301-4622(94)00145-A 22.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Entomol 2001; 46:471-510;   PMID:11112177 ; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Biol Chem 2012; 287:15164-73 ;  PMID:22411992 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Science 2000; 289:739- 45; PMID:10926528 ; http://dx.doi.org/10.1126/ science.289.5480.739 26.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature 2011; 471:651- 5; PMID:21389988 ; http://dx.doi.org/10.1038/ nature09789 27.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Invest Ophthalmol Vis Sci 2006; 47:5138-52; PMID:17122096 ; http://dx.doi.org/10.1167/ iovs.06-0849 29.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature  1985; 313:310-3;  PMID:2578616 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Proc Natl Acad Sci U S A 1981; 78:152- 6; http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC319009/ ; PMID:6264430 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Neuron 2006; 51:409-16;  PMID:16908407 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biomed Opt Express 2011; 2:2926-33;  PMID:22076256 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J  Physiol 1987; 394:529-72; http://jp.physoc.org/content/394/1/529.long ; PMID:2832596 .,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Phys Rev Lett 2012; 109:113601;   PMID:23005626 ; http://dx.doi.org/10.1103/ PhysRevLett.109.113601 37.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biophys  J 1998; 75:1836-57;  PMID:9746525 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Science 2006; 313:530-3;  PMID:16873665 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Annu Rev Cell Dev Biol 1999; 15:231-68;   PMID:10611962 ; http://dx.doi.org/10.1146/ annurev.cellbio.15.1.231 40.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Trends  Neurosci 2012; 35:356-63;  PMID:22498302 ;  http://dx.doi.org/10.1016/j.tins.2012.03.004 41.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Prog Brain Res 2009; 175:317- 32; PMID:19660665 ; http://dx.doi.org/10.1016/ S0079-6123(09)17522-2 42.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Proc Natl Acad Sci U S A 2012; 109:15012-7;   PMID:22891310 ; http://dx.doi.org/10.1073/ pnas.1207035109 43.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Neuron 2002; 33:15-22; PMID:11779476 ;  http://dx.doi.org/10.1016/S0896-6273(01)00574-8 44.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Neuron 2006; 50:23- 33; PMID:16600853 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nat Neurosci 2008; 11:667-75; PMID:18432197 ;  http://dx.doi.org/10.1038/nn.2117 46.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature  2005; 433:741-5;  PMID:15674244 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Science 2005; 307:600- 4; PMID :15681390 ; http://dx.doi.org/10.1126/ science.1105121 49.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature 2005; 433:745-9; PMID:15674243 ;  http://dx.doi.org/10.1038/nature03345 50.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Gen Physiol 1987; 89:353- 78; http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2215907/pdf/jg893353.pdf ; PMID :3559515 ;  http://dx.doi.org/10.1085/jgp.89.3.353 .,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature 1993; 366:64-6;  PMID:8232538 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biophys J 2002; 83:184-93; PMID:12080111 ;  http://dx.doi.org/10.1016/S0006-3495(02)75160-6 54.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Physiol 2002; 539:837-46; PMID:11897853 ;  http://dx.doi.org/10.1113/jphysiol.2001.013207 55.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Neuron 2000; 26:181- 6; PMID:10798402 ; http://dx.doi.org/10.1016/ S0896-6273(00)81148-4 56.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Curr Biol  2005; 15:55-8 ;  PMID :15649365 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Philos Trans R Soc  Lond B Biol Sci 2011; 366:619-26; PMID:21282165 ;  http://dx.doi.org/10.1098/rstb.2010.0201 62.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Philos Trans R Soc Lond B Biol Sci 2011; 366:709- 23; PMID:21282175 ; http://dx.doi.org/10.1098/ rstb.2010.0197 63.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
New J Phys 2007; 9:99;  http://dx.doi.org/10.1088/1367-2630/9/4/099 64.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nature 1960;  186:839-40;  PMID:14423793 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biol Lett 2006; 2:494-6; PMID:17148271 ;  http://dx.doi.org/10.1098/rsbl.2006.0542 70.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Exp Biol 2009; 212:2133-40;   PMID:19561202 ; http://dx.doi.org/10.1242/ jeb.020800 71.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nat Photonics 2012; 6:759-63; PMID:23160173 ;  http://dx.doi.org/10.1038/nphoton.2012.260 72.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
"Experientia (Basel) 1949; 5:142-8; http://dx.doi.org/10.1007/BF02174424 73. von Helversen O, Edrich W. Der Polarisationsempffinger im Bienenauge: ein  Ultraviolettrezeptor.",Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp Physiol 1974; 94:33- 47; http://dx.doi.org/10.1007/BF00610156 74.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Proc Biol Sci  2012; 279:535-42;  PMID:21733901 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp Physiol  A Neuroethol Sens Neural Behav Physiol 1980;  141:19-30; http://dx.doi.org/10.1007/BF00611874 76.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Philos Trans R Soc Lond B Biol Sci 2000; 355:1187- 90; PMID:11079395 ; http://dx.doi.org/10.1098/ rstb.2000.0664 77.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp Physiol 1974;  95:13-27; http://dx.doi.org/10.1007/BF00624348 78.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp Physiol 1974; 95:1-12; http://dx.doi.org/10.1007/ BF00624347 79.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp  Physiol A Neuroethol Sens Neural Behav Physiol  1987; 161:645-58; http://dx.doi.org/10.1007/ BF00605006 80.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Curr Opin Neurobiol 2002; 12:707- 14; PMID:12490263 ; http://dx.doi.org/10.1016/ S0959-4388(02)00384-7 81.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Comp Physiol A Neuroethol Sens Neural  Behav Physiol 2010; 196:335-48; PMID:20229246 ;  http://dx.doi.org/10.1007/s00359-010-0516-6,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Philos Trans R Soc Lond B Biol Sci 2011;  366:627-37;  PMID:21282166 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Curr Biol 2012; 22:12-20;   PMID:22177904 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Exp Biol 1971; 55:371-83; http://jeb.biologists.org/ content/55/2/371.long ; PMID:5114029 .,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Neurophysiology 1984; 16:628-33; http://dx.doi.org/10.1007/BF01052682 86.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nat Rev Neurosci 2005; 6:703-12;  PMID:16100517 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Planta 1969; 87:170- 9; PMID:24504725 ; http://dx.doi.org/10.1007/ BF0038697491.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Planta 1983a; 158:357-64;  PMID:24264756 ;  http://dx.doi.org/10.1007/BF00397338 92.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Physiol Plant 1984; 61:327-30; http://dx.doi.org/10.1111/j.1399-3054.1984.tb06335.x 94.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
"Problems of Contemporary Science and Practice, Vernadsky University 2009; 6(20); http:// vernadsky.tstu.ru/en/vjpusk/2009/vjpusk-06.php http://vernadsky.tstu.ru/pdf/2009/06/ rus_02_2009_06.pdf 96.",Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Cell Motil Cytoskeleton  2006; 63:162-71;  PMID:16450411 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Ann Rev Mar Sci 2010; 2:443-93;   PMID:21141672 ; http://dx.doi.org/10.1146/ annurev-marine-120308-08102899.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics  1998; 64:2129-33; http://dx.doi.org/10.1103/ PhysRevE.57.2129 100.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Appl Opt 2000; 39:183-92; PMID:18337887 ;  http://dx.doi.org/10.1364/AO.39.000183 101.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Proc Natl Acad Sci U S A 2005; 102:87-92; PMID:15618401 ; http://dx.doi.org/10.1073/ pnas.0406777102 102.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
J Opt Soc Am  1982a; 72:419-31;  PMID:7077429 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Biol Cybern 1982b; 44:157- 65; PMID :7115793 ; http://dx.doi.org/10.1007/ BF00344271 104.,Non-OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Sci Rep 2013; 3:1397;  PMID:23466520 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
Nano Lett 2014; 14:982- 6; PMID:24422516 ; http://dx.doi.org/10.1021/ nl404400d,OADS,/arxiv_data1/oa_pdf/80/60/cib-7-e28423.PMC4183612.pdf
"All analyses werecompleted using SEER*Stat version 7.0.5 statistical software (Surveillance Research Program, National Cancer Institute, http://www.seer.cancer.gov/ seerstat) and Stata version 11.2 (StataCorp LP, College Station, TX, USA).",OADS,/arxiv_data1/oa_pdf/ba/4a/bcj201463a.PMC4183772.pdf
"http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER datasubmission posted to the SEER web site in April 2014.",OADS,/arxiv_data1/oa_pdf/ba/4a/bcj201463a.PMC4183772.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Risk of SPM in different ethnicities with MM S Ailawadhi et al 4 Blood Cancer Journal © 2014 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/ba/4a/bcj201463a.PMC4183772.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Letter to the Editor 4 Blood Cancer Journal © 2014 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/60/02/bcj201464a.PMC4183773.pdf
This mutation coincides with a germline single-nucleotide polymorphism that occurs with an approximately 22% allele frequency in the general population (http://genome.ucsc.edu/).,Non-OADS,/arxiv_data1/oa_pdf/51/06/bjc2014268a.PMC4183835.pdf
"All statistical analyses were performed in R version 2.13.0 (The R Foundation for Statistical Computing, http://www.r-project.org/ foundation).",OADS,/arxiv_data1/oa_pdf/90/9f/bjc2014363a.PMC4183836.pdf
Cathie March Centre for Census and Survey Research CCSR Working Paper http://www.ccsr.ac.uk/research/documents/2008-01.pdf.,OADS,/arxiv_data1/oa_pdf/90/9f/bjc2014363a.PMC4183836.pdf
http://www.ncin.org.uk/publications/routes_to_diagnosis.,Non-OADS,/arxiv_data1/oa_pdf/90/9f/bjc2014363a.PMC4183836.pdf
"http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates+by+Ethnic+Group.Accessed 19 December 2013. von Wagner C, Good A, Wright D, Rachet B, Obichere A, Bloom S, Wardle J (2009) Inequalities in colorectal cancer screening participation in the firstround of the national screening programme in England.",Non-OADS,/arxiv_data1/oa_pdf/90/9f/bjc2014363a.PMC4183836.pdf
"The gel was than stained with 0.5 mgm l/C01ethidium bromide for 20 min, images were captured using the GelDoc system (Bio-Rad, Hemel Hempstead, UK) and a trans illuminator and analysed by ImageJ (http://imagej.nih.gov/ij/; gel analysing options).",OADS,/arxiv_data1/oa_pdf/b7/14/bjc2014378a.PMC4183837.pdf
"For each sample, two images of DAPI and two corresponding images of gH2AX were recorded on a Leica Epi-fluorescence Microscope using Image Spot Advance software and analysed by ImageJ and a custom macro, PZFociEZ (http://www.pzfociez.com/), to count the number of foci/nucleus in at least 100 nuclei per assay.",OADS,/arxiv_data1/oa_pdf/b7/14/bjc2014378a.PMC4183837.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER PARP inhibitors potentiate camptothecin in S phase 1326 www.bjcancer.com | DOI:10.1038/bjc.2014.378,Non-OADS,/arxiv_data1/oa_pdf/b7/14/bjc2014378a.PMC4183837.pdf
http://www.kela.fi/in/internet/english.nsf/NET/100203115310PN.,Non-OADS,/arxiv_data1/oa_pdf/d5/37/bjc2014381a.PMC4183838.pdf
Finland in figures: Population structure [online] available athttp://www.stat.fi/til/vaerak/index.html[30 July 2011].,OADS,/arxiv_data1/oa_pdf/d5/37/bjc2014381a.PMC4183838.pdf
ATC/DDD index database [online] available at http://www.whocc.no/ddd/definition_and_general_considera/ [30 July 2011].,OADS,/arxiv_data1/oa_pdf/d5/37/bjc2014381a.PMC4183838.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)Prostate cancer risk and NSAID use BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2014.381 1431,Non-OADS,/arxiv_data1/oa_pdf/d5/37/bjc2014381a.PMC4183838.pdf
Available at http://ganjoho.jp/professional/statistics/statistics.htmlaccessed on 9 May 2014) (Japanese).,OADS,/arxiv_data1/oa_pdf/01/b1/bjc2014399a.PMC4183840.pdf
"Bethesda MD, http://ser.cancer.gov/csr/1975_2010, based onNovember 2012 SEER data submission, posted to the SEER web site, April2010: National Cancer Institute.",Non-OADS,/arxiv_data1/oa_pdf/69/4e/bjc2014407a.PMC4183842.pdf
"Additionally, we produced time-dependent receiver operating characteristics (ROC) curves (Heagerty et al, 2000) (http://cran.rproject.org/web/ packages/survivalROC/index.html, February 2013) for the raw and the cross-validated indices.",OADS,/arxiv_data1/oa_pdf/94/34/bjc2014409a.PMC4183843.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Epigenetic and DDR changes affect anti-myeloma therapy 1304 www.bjcancer.com | DOI:10.1038/bjc.2014.410,Non-OADS,/arxiv_data1/oa_pdf/82/a6/bjc2014410a.PMC4183844.pdf
"Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc) APPENDIX 1 Incidence model Incidence Iacin the 5-year age group aand the 5-year birth cohort cwas analysed with the Poisson regression using the following model: ln E(I ac)¼mþaaþbcþga; c¼1935–1939 Ia¼50–59, 60–64 ;c¼1935–1939 , where /C15mis a baseline, that is, the incidence in the youngest 5-year age group (40–44 years), and the oldest 5-year birth cohort (1920–1924), /C15aais the effect of other 5-year age groups ( a¼45–49, 50–54, 55–59, 60–64, 65–69 and 70–74 years) compared with the baseline m, /C15bcis the effect of other 5-year birth cohorts ( c¼1925–1929, 1930–1934, and 1935–1939) compared with the baseline mand /C15ga; c¼1935–1939 is the effect of screening in the invited age group 50–59 years ( a¼50–54 or a¼55–59 years) and in the post- screening age group 60–64 years within the cohort (1935–1939), and further /C15Ia¼50–59, 60–64 ;c¼1935–1939 is an indicator divided into two partsJforg50–59, 1935–1939 , the indicator Ia¼50–59; c¼1935–1939 ¼1, if a¼50–54 or a¼55–59 years; and 0, otherwise Jforg60–64, 1935–1939 , the indicator Ia¼60–64; c¼1935–1939 ¼1, if a¼60–64 years; and 0, otherwise.",Non-OADS,/arxiv_data1/oa_pdf/06/49/bjc2014413a.PMC4183845.pdf
Available at http://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html.,Non-OADS,/arxiv_data1/oa_pdf/ff/5c/bjc2014414a.PMC4183846.pdf
"Available at http://www.cdcgov/nchs/data/nhanes/nhanes_03_04/nhanes_analytic_guidelines_dec_2005pdf.NCHS (2013) National Center for Health Statistics, Specifying Weighting Parameters.",OADS,/arxiv_data1/oa_pdf/ff/5c/bjc2014414a.PMC4183846.pdf
"Available at: http://www.cdc.gov/nchs/tutorials/nhanes/SurveyDesign/Weighting/intro.htm (assessed March 20, 2014).",OADS,/arxiv_data1/oa_pdf/ff/5c/bjc2014414a.PMC4183846.pdf
Available at http://www.nhlbinihgov/ health/public/heart/obesity/lose_wt/riskhtm (accessed 10 March 2014).,Non-OADS,/arxiv_data1/oa_pdf/ff/5c/bjc2014414a.PMC4183846.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER EMT in extrahepatic cholangiocarcinoma 1372 www.bjcancer.com | DOI:10.1038/bjc.2014.415,Non-OADS,/arxiv_data1/oa_pdf/69/b9/bjc2014415a.PMC4183847.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Prognostic utility of BAP1 protein expression in uveal melanoma 1380 www.bjcancer.com | DOI:10.1038/bjc.2014.417,Non-OADS,/arxiv_data1/oa_pdf/60/3b/bjc2014417a.PMC4183849.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Prognostic significance of chromosome 9p deletion in ccRCC 1390 www.bjcancer.com | DOI:10.1038/bjc.2014.420,Non-OADS,/arxiv_data1/oa_pdf/b1/98/bjc2014420a.PMC4183850.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)Suppression of STAT3 signalling cascade by lupeol BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2014.422 1337,Non-OADS,/arxiv_data1/oa_pdf/86/73/bjc2014422a.PMC4183851.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)Prostate cancer cell malignancy BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2014.426 1349,Non-OADS,/arxiv_data1/oa_pdf/7e/c4/bjc2014426a.PMC4183852.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Antagonistic effects of dasatinib 1318 www.bjcancer.com | DOI:10.1038/bjc.2014.432,Non-OADS,/arxiv_data1/oa_pdf/de/1a/bjc2014432a.PMC4183853.pdf
"We recruited 1017 incident cases of BC diagnosed in the Oncology Departments of 23 hospital members of the Spanish Breast Cancer Research Group, GEICAM (http://www.geicam.org/).",Non-OADS,/arxiv_data1/oa_pdf/1b/a8/bjc2014434a.PMC4183855.pdf
org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Spanish Mediterranean diet and breast cancer risk 1462 www.bjcancer.com | DOI:10.1038/bjc.2014.434,Non-OADS,/arxiv_data1/oa_pdf/1b/a8/bjc2014434a.PMC4183855.pdf
"A total of 154 clinical samples were collected from the Chinese Glioma Genome Atlas (http://www.cgcg.org.cn/), including 83 primary glioblastomas (P), eight anaplastic astrocytomas (AA), 58 astrocytomas (A) and five normal brain tissue samples (N).",OADS,/arxiv_data1/oa_pdf/10/3e/bjc2014435a.PMC4183856.pdf
"Publicly available data set was also used to verify the expression of integrin b1 and ERK in gliomas, which can be accessed at http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc=GSE4290.",OADS,/arxiv_data1/oa_pdf/10/3e/bjc2014435a.PMC4183856.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)Exogenous IGFBP-2 in glioma cells BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2014.435 1409,Non-OADS,/arxiv_data1/oa_pdf/10/3e/bjc2014435a.PMC4183856.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)BRITISH JOURNAL OF CANCER Host immunity in solitary fibrous tumours 1362 www.bjcancer.com | DOI:10.1038/bjc.2014.437,Non-OADS,/arxiv_data1/oa_pdf/dc/9b/bjc2014437a.PMC4183857.pdf
Friedman Y (2012) DrugPatentWatch http://www.drugpatentwatch.com.,Non-OADS,/arxiv_data1/oa_pdf/c8/76/bjc2014448a.PMC4183859.pdf
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)Lag time in testing of new drugs with radiotherapy BRITISH JOURNAL OF CANCER www.bjcancer.com | DOI:10.1038/bjc.2014.448 1309,Non-OADS,/arxiv_data1/oa_pdf/c8/76/bjc2014448a.PMC4183859.pdf
http://www.eortc.be/services/ doc/ctc/ctcaev3.pdf .,Non-OADS,/arxiv_data1/oa_pdf/00/96/520_2014_Article_2282.PMC4183888.pdf
Available  from: http://www.who.int/childgrowth [Last accessed on 2014 Jan 21].,Non-OADS,/arxiv_data1/oa_pdf/3a/9a/AJM-4-88.PMC4183902.pdf
Available from: http://www.kff.org/entmedia/ mh012010pkg.cfm [Last accessed on 2014 Jan 22].,Non-OADS,/arxiv_data1/oa_pdf/3a/9a/AJM-4-88.PMC4183902.pdf
Available  from: http://www.proquest.Umi.com.,Non-OADS,/arxiv_data1/oa_pdf/29/0f/AJM-4-94.PMC4183903.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/10/68/ijbsv10p1024.PMC4183923.pdf
http://www.fda.gov/Drugs/DrugSafety/   PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm192649.htm   172.,Non-OADS,/arxiv_data1/oa_pdf/10/68/ijbsv10p1024.PMC4183923.pdf
"The network constru c- tion algorithm was described previously [36, 42] and  detailed information is available at  http://www.genetics.ucla.edu/labs/horvath/Coexp ression Network/.",OADS,/arxiv_data1/oa_pdf/04/79/ijbsv10p1039.PMC4183924.pdf
"To investigate the diverse expression pattern during five fetal stages in two breeds, we a p- plied maSigPro analysis in SEA (http://sea.bioinfo.cipf.es/) to our data.",Non-OADS,/arxiv_data1/oa_pdf/04/79/ijbsv10p1039.PMC4183924.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/d7/51/ijbsv10p1051.PMC4183925.pdf
"Up to  April 18th, 2014, there have been about 20,255 Nucl e- otide sequences including 186 ESTs deposited in NCBI (http://www.ncbi.nlm.nih.gov/) for Bactrocera   genus.",OADS,/arxiv_data1/oa_pdf/d7/51/ijbsv10p1051.PMC4183925.pdf
This  is an open -access  article  distributed  under  the terms  of the Creative  Commons  License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/15/e9/ijbsv10p1064.PMC4183926.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/3.0/Simvastatin attenuates inﬂammation in asthma J-N Liu et al 11 Experimental & Molecular Medicine",Non-OADS,/arxiv_data1/oa_pdf/a3/23/emm201455a.PMC4183942.pdf
"To view a copy of this license, visithttp://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on Experimen tal & Molecular Medicine website (http://www.nature.com/emm)An anti-glycosylated NT-proBNP antibody YL e e et al 9 Experimental & Molecular Medicine",Non-OADS,/arxiv_data1/oa_pdf/7c/1b/emm201457a.PMC4183943.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Arterial smooth muscle PLC- γ1s i g n a l i n gi nP E RJ i a n g et al 10 Experimental & Molecular Medicine",Non-OADS,/arxiv_data1/oa_pdf/d8/a5/emm201459a.PMC4183944.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/IH-induced β-cell apoptosis and antioxidant intervention Y Fang et al 5 © 2014 Macmillan Publishers Limited Nutrition & Diabetes (2014) 1 –5",Non-OADS,/arxiv_data1/oa_pdf/3f/7b/nutd201428a.PMC4183969.pdf
Available from http://www.idf.org/diabetesatlas.,Non-OADS,/arxiv_data1/oa_pdf/ff/3d/nutd201430a.PMC4183971.pdf
Available from http://www.harlan.com/download.axd/ 3a69f6f83e174fff84b859f746b1b0fd.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ff/3d/nutd201430a.PMC4183971.pdf
Available from http://www.testdiet.com/Diets/ High-Fat-DIO/index.html.,Non-OADS,/arxiv_data1/oa_pdf/ff/3d/nutd201430a.PMC4183971.pdf
Available from http://riskfactor.cancer.gov/diet/foodsources/.,Non-OADS,/arxiv_data1/oa_pdf/ff/3d/nutd201430a.PMC4183971.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/From high-fat-fed rodents to human obesity M Lai et al 10 Nutrition & Diabetes (2014) 1 –10 © 2014 Macmillan Publishers Limited",Non-OADS,/arxiv_data1/oa_pdf/ff/3d/nutd201430a.PMC4183971.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Table 2.",Non-OADS,/arxiv_data1/oa_pdf/8a/3b/nutd201435a.PMC4183976.pdf
"We used a commercially available, af ﬁnity puri ﬁed polyclonal goat antibody (AF2659; R&D Systems), produced by immunization withrecombinant human Nectin-4 from Gly27 to Val351, also including the extracellular domain and ending with the transmembrane one (http://www.uniprot.org/uniprot/Q96NY8).",Non-OADS,/arxiv_data1/oa_pdf/2b/35/oncsis201432a.PMC4183981.pdf
Current Controlled Trials 2013; http://clinicaltrials.gov/ct2/show/ NCT01409135/.,Non-OADS,/arxiv_data1/oa_pdf/2b/35/oncsis201432a.PMC4183981.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Nectin-4 and breast cancer metastasis R Lattanzio et al 7 © 2014 Macmillan Publishers Limited Oncogenesis (2014), 1 –7",Non-OADS,/arxiv_data1/oa_pdf/2b/35/oncsis201432a.PMC4183981.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)Role of ﬁlamin in tumor growth S Bandaru et al 9 © 2014 Macmillan Publishers Limited Oncogenesis (2014), 1 –9",Non-OADS,/arxiv_data1/oa_pdf/70/6f/oncsis201433a.PMC4183982.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/ca/28/thnov04p1153.PMC4183994.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/83/55/thnov04p1164.PMC4183995.pdf
This  is an open -access  article  distributed  under  the terms  of the Creative  Commons  License (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/56/c6/thnov04p1176.PMC4183996.pdf
This is an open- access article distributed under the terms of the Creative Commons Licens e (http://creativecommons.org/  licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/55/1e/thnov04p1193.PMC4183997.pdf
"Supplementary Material   Additional File 1:   Supplementary Table  1, Supplementary Figures 1 -3.  http://www.thno.org/v04p 1193s1.pdf   Abbreviations   CRC, colorectal cancer; CRA, colorectal adeno- mas; miRNA, mature microRNAs; MRE, microRNA  response element; 3’ -UTRs, 3’ untranslated regions;  ISH, In situ hybridization; IHC, Immunohistochemi s- try; ROC, receiver operating characteristic .",Non-OADS,/arxiv_data1/oa_pdf/55/1e/thnov04p1193.PMC4183997.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/1a/5a/thnov04p1209.PMC4183998.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/4c/73/thnov04p1211.PMC4183999.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/9e/d0/thnov04p1233.PMC4184000.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c1/17/thnov04p1239.PMC4184001.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/b9/0c/thnov04p1250.PMC4184002.pdf
"To view a copy of this license, visit http:// creativecommons.org/licenses/by/3.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Metaexoproteome of the soil-microbe interface AS Johnson-Rollings et al 2150 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/d7/90/ismej2014130a.PMC4184004.pdf
"To view a copyof this license, visit http://creativecommons.org/ licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Transduction capabilities of viunalikeviruses MA Matilla et al 2147 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/9a/db/ismej2014150a.PMC4184006.pdf
"The Antarctic margin marine sedi-ments ( n¼4; sites #4, 11, 14, 15) were collected in February 2012 during the British Services Antarctic Expedition (http://www.bsae 2012.co.uk/science.html).",Non-OADS,/arxiv_data1/oa_pdf/81/a0/ismej201443a.PMC4184009.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/ Supplementary Information accompanies this paper on The ISME Journal website (http://www.nature.com/ismej)Environmental Microviridae M Hopkins et al 2103 The ISME Journal",Non-OADS,/arxiv_data1/oa_pdf/81/a0/ismej201443a.PMC4184009.pdf
"Owing to methodological shortcomings this interpretation isquestioned by the members of the International Group forthe Study of Lithium (IGSLi), an association of experts onlong-term treatment with lithium (http://www.igsli.org).",Non-OADS,/arxiv_data1/oa_pdf/c9/c0/ki2014178a.PMC4184023.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ The Authors Reply: We thank Licht et al.",Non-OADS,/arxiv_data1/oa_pdf/c9/c0/ki2014178a.PMC4184023.pdf
"During the initial access use, the application of 17- or 16-Gclinical investigation http://www.kidney-international.org &2014 International Society of Nephrology Correspondence: Aileen H. Grassmann, EMEALA Medical Board, Fresenius Medical Care, Else-Kroener-Strasse 1, 61352 Bad Homburg, Germany.E-mail: aileen.grassmann@fmc-ag.com Received 27 June 2013; revised 4 February 2014; accepted 13 February 2014; published online 9 April 2014 790 Kidney International (2014) 86,7 9 0 – 7 9 7",Non-OADS,/arxiv_data1/oa_pdf/22/25/ki201496a.PMC4184025.pdf
http://www.kidney.,Non-OADS,/arxiv_data1/oa_pdf/22/25/ki201496a.PMC4184025.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Kidney International (2014) 86, 790– 797 797MT Parisotto et al.",Non-OADS,/arxiv_data1/oa_pdf/22/25/ki201496a.PMC4184025.pdf
"Several validation studies have addressed this (reviewed in Roberts 9); however,clinical investigation http://www.kidney-international.org &2014 International Society of Nephrology Correspondence: Rosanna Coppo, City of the Health and the Science of Turin Health Agency, Regina Margherita Children’s Hospital, Piazza Polonia94, 10126 Turin, Italy.",Non-OADS,/arxiv_data1/oa_pdf/2d/11/ki201463a.PMC4184028.pdf
Supplementary material is linked to the online version of the paper athttp://www.nature.com/ki REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/2d/11/ki201463a.PMC4184028.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ 836 Kidney International (2014) 86,8 2 8 – 8 3 6clinical investigation R Coppo et al.",Non-OADS,/arxiv_data1/oa_pdf/2d/11/ki201463a.PMC4184028.pdf
RobertKoch-Institut.AuftretenundVerbreitungvonMRSAin Deutschland2010.EpidemiolBull.2011;(26):233-44.Available from:http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/ 2011/26/Art_01.html 24.,Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
2008;(42):363-4.Availablefrom:http://www.rki.de/DE/Content/ Infekt/EpidBull/Archiv/2008/Auschnitte/MRSA_2008_42.pdf60.,Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
Available from:http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/ 2007/Ausschnitte/ESBL_28_07.pdf 74.,Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
Availablefrom:http://www.bvl.bund.de/ SharedDocs/Downloads/08_PresseInfothek/Germap_2008.html 175.,Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
"VorkommenundCharakterisierungvonExtended- Spectrum-Beta-Laktamase(ESBL)-produzierendenEscherichia colibeiLebensmittellieferndenTieren[PhD-Thesis].Berlin: InstitutfürMikrobiologieundTierseuchendesFachbereichs VeterinärmedizinderFreienUniversitätBerlin,Bundesamtfür VerbraucherschutzundLebensmittelsicherheit;2010.Available from:http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_ 000000020799 176.",Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
Available from:http://www.ecdc.europa.eu/en/activities/surveillance/ EARS-Net/database/Pages/database.aspx 180.,OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
Availablefrom:http://edoc.ub.uni- muenchen.de/11531/ 188.,Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
"DOI: 10.3205/dgkh000241, URN:urn:nbn:de:0183-dgkh0002410 Thisarticleisfreelyavailablefrom http://www.egms.de/en/journals/dgkh/2014-9/dgkh000241.shtml Published: 2014-09-30 Copyright ©2014 Dahmsetal .",Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
"This is anOpenAccess articledistributedunder thetermsoftheCreative CommonsAttributionLicense (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en).You arefree:toShare—tocopy,distributeandtransmitthework,provided theoriginalauthorandsourcearecredited.",Non-OADS,/arxiv_data1/oa_pdf/aa/a3/HIC-09-21.PMC4184042.pdf
"1) (See video, Supplemental Digital   Content 1, which shows the front and side views of a 29-year-old woman exhibiting a static fold after she underwent double eyelid surgery using the tarsal fixation technique as she opens and closes her eyes, http://links.lww.com/PRSGO/A0.)",Non-OADS,/arxiv_data1/oa_pdf/c8/b0/gox-1-1d.PMC4184050.pdf
"2) (See video,   Supplemental Digital Content 2, which shows the front and quarter views of the same patient exhibit-ing a dynamic fold after she received double eyelid surgery using septoaponeurosis junctional thicken-ing fixation as she opens and closes her eyes, http://links.lww.com/PRSGO/A1.)",Non-OADS,/arxiv_data1/oa_pdf/c8/b0/gox-1-1d.PMC4184050.pdf
"See video, Supplemental Digital con tent 1,  which shows the front and side views of a 29-year-old woman exhibiting a static fold after she underwent double eyelid sur - gery using the tarsal fixation technique as she opens and closes her eyes, http://links.lww.com/PRSGO/A0.",Non-OADS,/arxiv_data1/oa_pdf/c8/b0/gox-1-1d.PMC4184050.pdf
"See video, Supplemental Digital con tent 2,  which shows the front and quarter views of the same patient ex - hibiting a dynamic fold after she received double eyelid surgery using septoaponeurosis junctional thickening fixation as she opens and closes her eyes, http://links.lww.com/PRSGO/A1.",Non-OADS,/arxiv_data1/oa_pdf/c8/b0/gox-1-1d.PMC4184050.pdf
"We excluded 529 patients whose additional diagnosesindicated an infection of the kidney or urinary tract, andrequested hospital discharge letters, postmortem reports, andhttp://www.kidney-international.org clinical investigation &2014 International Society of Nephrology Correspondence: Lianne Parkin, Department of Preventive and Social Medicine, Dunedin School of Medicine, PO Box 913, University of Otago,Dunedin 9054, New Zealand.",Non-OADS,/arxiv_data1/oa_pdf/6e/7b/ki201474a.PMC4184187.pdf
Supplementary material is linked to the online version of the paper athttp://www.nature.com/ki REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/6e/7b/ki201474a.PMC4184187.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ 844 Kidney International (2014) 86,8 3 7 – 8 4 4clinical investigation M-L Blank et al.",Non-OADS,/arxiv_data1/oa_pdf/6e/7b/ki201474a.PMC4184187.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)Targeting EN1 in basal-like breast cancer AS Beltran et al 4777 &2014 Macmillan Publishers Limited Oncogene (2014) 4767 – 4777",Non-OADS,/arxiv_data1/oa_pdf/6b/d8/onc2013422a.PMC4184217.pdf
Links to code and docu- mentation are provided at http://lpm.hms.harvard.edu and http:// wall-lab.stanford.edu.,OADS,/arxiv_data1/oa_pdf/8a/21/btu385.PMC4184253.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8a/21/btu385.PMC4184253.pdf
"COSMOS’ internal data structures are stored in an SQL database using the Django framework (https://djangoproject.com) and is distributed with a Web application for monitoringthe state of both running and completed workflows, querying individual job states, visualizing DAGs and debugging failed jobs (Supplementary Figs S2–S5).",OADS,/arxiv_data1/oa_pdf/8a/21/btu385.PMC4184253.pdf
Availability and implementation: The GATB library is written in C ++ and is available at the following Web site http://gatb.inria.fr under the A-GPL license.,OADS,/arxiv_data1/oa_pdf/80/bd/btu406.PMC4184257.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/80/bd/btu406.PMC4184257.pdf
An extensive documentation with tutorials is available toguide designers in the process of developing new NGS tools fromthe GATB building blocks: http://gatb-core.gforge.inria.fr (seealso Supplementary File 2 for technical implementation details).,Non-OADS,/arxiv_data1/oa_pdf/80/bd/btu406.PMC4184257.pdf
http://www.hdfgroup.,Non-OADS,/arxiv_data1/oa_pdf/80/bd/btu406.PMC4184257.pdf
Availability and implementation: The software package is available under GNU General Public License v3 and is freely available togetherwith test datasets https://savannah.nongnu.org/projects/bammds/.,OADS,/arxiv_data1/oa_pdf/8d/4c/btu410.PMC4184259.pdf
"It is using R (http://www.r-project.org/), parallel (http://www.gnu.org/- software/parallel/), samtools (https://github.com/samtools/samtools).",Non-OADS,/arxiv_data1/oa_pdf/8d/4c/btu410.PMC4184259.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/ by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8d/4c/btu410.PMC4184259.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/b6/0b/10.1177_2047981614530285.PMC4184380.pdf
"Published by Oxford University Press, on behalf of the Society of Systematic Biologists.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.For commercial re-use, please contact journals.permissions@oup.comDOI:10.1093/sysbio/syu039Advance Access publication June 20, 2014 Probabilistic Graphical Model Representation in Phylogenetics SEBASTIAN HÖHNA1,2,∗,TRACY A. H EATH3,4,BASTIEN BOUSSAU3,5,M ICHAEL J. L ANDIS3,FREDRIK RONQUIST6,AND JOHN P. H UELSENBECK3,7 1Department of Mathematics, Stockholm University, Stockholm, SE-106 91 Stockholm, Sweden;2Department of Evolution and Ecology, University of California, Davis, Storer Hall, One Shields Avenue, Davis, CA 95616, USA;3Department of Integrative Biology, University of California, Berkeley, CA 94720, USA;4Department of Ecology and Evolutionary Biology, University of Kansas, Lawrence, KS 66045, USA;5Bioinformatics and Evolutionary Genomics, Université de Lyon, Villeurbanne, France;6Department of Bioinformatics and Genetics, Swedish Museum of Natural History, SE-10405 Stockholm, Sweden; and7Department of Biological Science, King Abdulaziz University, Jeddah, Saudi Arabia; ∗Correspondence to be sent to: Sebastian Höhna, Department of Mathematics, Stockholm University, Stockholm, SE-106 91 Stockholm, Sweden; E-mail: Sebastian.Hoehna@gmail.com.",Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
The Supplementary Material ( http://dx.doi.org/ 10.5061/dryad.nt898) presents similar analyses with amuch better taxonomic sampling of 274 species.,Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
"(2012 ), pruned to contain only the ﬁve species of interest or the 274 species in our dataset (SupplementaryMaterial; http://dx.doi.org/10.5061/dryad.nt898).",OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
"In the SupplementaryMaterial ( http://dx.doi.org/10.5061/dryad.nt898), we provide scripts for performing Bayesian inference withthis model and the complete dataset; it turns out thereis a 50/50 chance that the ancestor of mammals had abaculum.",Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
"We provide in the SupplementaryMaterial (http://dx.doi.org/10.5061/dryad.nt898) theexample of a Brownian motion model of the evolution ofcontinuous characters to convey this point ( Felsenstein 1985 ), and show here in more detail the example of a model of sequence evolution.",Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
S.1; http://dx.doi.org/10.5061/dryad.nt898).,Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
"The example is extended in the SupplementaryMaterial ( http://dx.doi.org/10.5061/dryad.nt898) by the commonly used mixture model for rate variationacross sites, the GTR+ /Gamma1model ( Yang 1994 ,1996 ) (see Supplementary Fig.",Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
S.2; http://dx.doi.org/10.5061/ dryad.nt898).,Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
"As an exampleconsider the common case of a multilocus analysisusing a multispecies coalescent model, an uncorrelatedrelaxed clock and a GTR+ /Gamma1substitution model, which would contain, among others, Supplementary Figure S2and Figure S3 (http://dx.doi.org/10.5061/dryad.nt898)merged together.",Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
S.3;http://dx.doi.org/10.5061/dryad.nt898).,Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
S.2;http://dx.doi.org/10.5061/dryad.nt898).,Non-OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
S UPPLEMENTARY MATERIAL Data available from the Dryad Digital Repository at http://dx.doi.org/10.5061/dryad.nt898.,OADS,/arxiv_data1/oa_pdf/79/d6/syu039.PMC4184382.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a3/42/ijn-9-4551.PMC4184407.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4551–4567International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4551OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6839 9Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Bae et al Running head recto: Topical delivery of a growth factor nanocomplex for wound healing DOI: http://dx.doi.org/10.2147/IJN.S68399 Enhanced regenerative healing efficacy of a highly  skin-permeable growth factor nanocomplex   in a full-thickness excisional mouse wound model Abstract:  Exogenous administration of growth factors has potential benefits in wound   healing; however, limited percutaneous absorption, inconsistent efficacy, and the need for high  doses have hampered successful clinical use.",Non-OADS,/arxiv_data1/oa_pdf/a3/42/ijn-9-4551.PMC4184407.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a3/42/ijn-9-4551.PMC4184407.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a3/42/ijn-9-4551.PMC4184407.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/38/69/ijn-9-4533.PMC4184408.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4533–4550International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4533OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/ 10.2147/IJN.S6722 8Preclinical evaluation of recombinant human  IFNα2b-containing magnetoliposomes   for treating hepatocellular carcinoma hui Ye1,2 Jiansong T ong2 Jianzhang Wu3 Xia Xu4 shenjie Wu5 Botao Tan6 Mengjing shi5 Jianguang Wang1 Weibo Zhao5 heng Jiang5 sha Jin5 1school of Basic Medical sciences,   Wenzhou Medical University,   Wenzhou, People’s republic of  china; 2Department of cellular  and Molecular Biology, scripps  research Institute, la Jolla, ca, Usa;   3Pharmaceutical college, Wenzhou  Medical University, Wenzhou, 4school  of Medicine, Zhejiang University,   hangzhou, 5school of the 1st clinical  Medical sciences, Wenzhou Medical  University, Wenzhou, 6school of  Medicine, lishui University, lishui,   People’s republic of chinaAbstract:  Magnetoliposomes are phospholipid vesicles encapsulating magnetic nanoparticles  that can be used to encapsulate therapeutic drugs for delivery into specific organs.",Non-OADS,/arxiv_data1/oa_pdf/38/69/ijn-9-4533.PMC4184408.pdf
"In general, these methods cause  rapid degradation of IFN α2b in the body and induce severe side effects, due to the  systemic distribution of drugs in the body causing bone marrow suppressions and  neurologic disorders.15 Conventional targeting and drug-delivery methods for HCC are limited to common  liposomes, nanoparticles (NPs), and intravenous emulsions.15,17–19 Therefore, the surge  of interest in this field has greatly expanded the extent of research on magnetic NPs correspondence: hui Ye school of Basic Medical sciences,  Wenzhou Medical University, Ouhai,  Wenzhou, Zhejiang 325035, People’s  republic of china email huiye1109@gmail.co mJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Y e et al Running head recto: Growth inhibition of HCC by rhIFN α2b-containing magnetoliposomes DOI: http://dx.doi.org/10.2147/IJN.S67228",Non-OADS,/arxiv_data1/oa_pdf/38/69/ijn-9-4533.PMC4184408.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/38/69/ijn-9-4533.PMC4184408.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/38/69/ijn-9-4533.PMC4184408.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/7e/69/10.1177_2047981614543284.PMC4184409.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/0b/f2/10.1177_2047981614544404.PMC4184414.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/fe/51/10.1177_2047981614536158.PMC4184415.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).1Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA 2Department of Radiology, Mount Carmel West Medical Center, Columbus, OH, USA Corresponding author: Mina S Makary, Department of Radiology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, 4th Floor, Columbus,OH 43210, USA.Email: mina.makary@osumc.eduActa Radiologica Short Reports 3(5) 1–3 !The Foundation Acta Radiologica 2014Reprints and permissions:sagepub.co.uk/journalsPermissions.navDOI: 10.1177/2047981614539324 arr.sagepub.com",Non-OADS,/arxiv_data1/oa_pdf/ed/3d/10.1177_2047981614539324.PMC4184419.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).1Department of Radiology, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea 2Department of Radiology and Medical Engineering, Kyungpook National University School of Medicine, Daegu, Republic of Korea Corresponding author: Sung Won Youn, Department of Radiology, Catholic University of Daegu School of Medicine, 3056-6 Daemyung-4 Dong, Nam-gu, Daegu 705-718,Republic of Korea.Email: ysw10adest@cu.ac.krActa Radiologica Short Reports 2014, Vol.",Non-OADS,/arxiv_data1/oa_pdf/2a/9f/10.1177_2047981614536559.PMC4184434.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/0d/be/10.1177_2047981614531755.PMC4184436.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/d0/1f/10.1177_2047981614534231.PMC4184437.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).1Center for Epidemiology and Screening, Department of Public Health, University of Copenhagen, Copenhagen, Denmark 2Danish Institute for Study Abroad, Copenhagen, Denmark 3Diagnostic Imaging Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark Corresponding author: Zorana Jovanovic Andersen, Center for Epidemiology and Screening, Department of Public Health, University of Copenhagen, ØsterFarimagsgade 5, 1014 Copenhagen K, Denmark.Email: Zorana.Andersen@sund.ku.dkActa Radiologica Short Reports 2014, Vol.",Non-OADS,/arxiv_data1/oa_pdf/b7/6d/10.1177_2047981614536558.PMC4184441.pdf
"10, International Agency for Research on Cancer, http://globocon.iarc.fr (2010, cited 6 November 2013).",Non-OADS,/arxiv_data1/oa_pdf/b7/6d/10.1177_2047981614536558.PMC4184441.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).1Department of Radiology, Lagos State University College of Medicine and Lagos State University T eaching Hospital, Ikeja, Lagos, Nigeria 2Department of Surgery (Neurosurgery Unit), Lagos State University College of Medicine and Lagos State University T eaching Hospital, Ikeja,Lagos, Nigeria Corresponding author: Olufemi Emmanuel Idowu, Neurosurgery Division, Department ofSurgery, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria.Email: oeidowu412@yahoo.comActa Radiologica Short Reports 3(5) 1–6 !The Foundation Acta Radiologica 2014Reprints and permissions:sagepub.co.uk/journalsPermissions.navDOI: 10.1177/2047981614530288 arr.sagepub.com",Non-OADS,/arxiv_data1/oa_pdf/e5/19/10.1177_2047981614530288.PMC4184453.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).1Department of General Surgery, Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia 2Department of Radiology, Prince Mohammed bin Abdulaziz Hospital, Riyadh, Saudi Arabia Corresponding author: Jareer H Abu-Hmeidan, Department of General Surgery, Prince Mohammed bin Abdulaziz Hospital, Al Imam Ahmad Ibn Hanbal Street,Ar Rawabi, Riyadh 11676, Saudi Arabia.Email: hmeidanj@pmah.med.saActa Radiologica Short Reports 3(7) 1–4 !The Foundation Acta Radiologica 2014Reprints and permissions:sagepub.co.uk/journalsPermissions.navDOI: 10.1177/2047981614540142 arr.sagepub.com",Non-OADS,/arxiv_data1/oa_pdf/5a/26/10.1177_2047981614540142.PMC4184457.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page(http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/15/b6/10.1177_2047981614543219.PMC4184462.pdf
"Multilocus sequence typing (http://www.pasteur.fr/recher- che/genopole/PF8/mlst/Kpneumoniae.html) was performed on a representative isolate, which was determined to belong tosequence type (ST) 231 (Table 1).",OADS,/arxiv_data1/oa_pdf/71/81/nmi20001-0013.PMC4184486.pdf
"This solution mixes with the saliva andstabilizes the saliva sample for long-term storage atroom temperature or in low-temperature freezers.Genotyping of SNPs was conducted by LGC Genomics (formerly KBiosciences) in the UnitedKingdom (http://www.lgcgenomics.com) using theKASPar chemistry, a competitive allele speciﬁcpolymerase chain reaction (PCR) SNP genotypingsystem performed with Förster resonance energytransfer quencher cassette oligos.",Non-OADS,/arxiv_data1/oa_pdf/dd/cc/sm20002-0107.PMC4184490.pdf
Methods Our questionnaire was created using the Survey-Monkey template (http://www.surveymonkey.com).,OADS,/arxiv_data1/oa_pdf/39/72/sm20002-0121.PMC4184492.pdf
"(http://www.eunuch.org, an online community interested in “testicles, testosterone, castration,eunuchs and related topics”) for 6 months from Julythrough December 2008.",Non-OADS,/arxiv_data1/oa_pdf/39/72/sm20002-0121.PMC4184492.pdf
Methods Participants The participants were recruited by references tothe “GAy MEn Sex StudieS” (GAMESSS) website(http://www.gamesss.be) through various media.Links to the survey were posted on the websites ofmost gay organizations and a number of commer-cial gay-oriented websites [12].,Non-OADS,/arxiv_data1/oa_pdf/b2/53/sm20001-0087.PMC4184502.pdf
"Fibros., in press.published online http://dx.doi.org/10.1016/j.jcf.2012.05.006.M.E.",OADS,/arxiv_data1/oa_pdf/8b/be/rcr20001-0052.PMC4184528.pdf
Unlocked (www.healthunlocked.com) and Ginger.IO (http://ginger.io/) are sophisticated examples of how innovative digital technology and a detailed understand-ing of the interface between patients and healthcaresystems can channel the power of individual patients todrive tangible improvements in care.,Non-OADS,/arxiv_data1/oa_pdf/8b/ae/ccr30001-0001.PMC4184531.pdf
Available at http://www.pharmabiz.com/NewsDetails.aspx?,Non-OADS,/arxiv_data1/oa_pdf/8b/ae/ccr30001-0001.PMC4184531.pdf
Available at http://who-umc.org/Graphics/24734.pdf (accessed 19 June 2013).,Non-OADS,/arxiv_data1/oa_pdf/fa/4f/ccr30001-0020.PMC4184536.pdf
Available at http://onlinelibrary.wiley.,Non-OADS,/arxiv_data1/oa_pdf/2c/7a/acn30001-0171.PMC4184546.pdf
"Striatal density was assessedusing ImageJ software 26,27(http://rsbweb.nih.gov/ij/plu- gins/track/track.html) to measure TH staining density at the comparable striatal region from four consecutive sec- tions taken from three individual mice in each group.",OADS,/arxiv_data1/oa_pdf/f7/17/acn30001-0199.PMC4184549.pdf
"Received: 12 May 2014; Accepted: 13 June 2014 Annals of Clinical and Translational Neurology 2014; 1(8): 534–543 doi: 10.1002/acn3.81 aData used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu/As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/ or provided data but did not participate in analysis or writing of this report.",OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wpcontent/ uploads/ how_to_apply/ADNI_Acknowledgement_ List.pdf.,OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
Methods Study design Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.ucla.edu).,OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
"For up-to-date information, see http://www.adni-info.org.",Non-OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
Inclusion/exclusion criteriafor ADNI-2 subjects are described in detail at http://www.adni-info.org.,Non-OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
Full protocols and data are available online(http://adni.loni.ucs.edu).,OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
"described and validated previously.21,22The biomarker data sets used in this study (“UPENNBIOMK5.csv” and “UPENNBIOMK6.csv”) and additional analysis details andquality control procedures are available at http://adni.loni.usc.edu/.",OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
21Full methodological details of this procedure are described at http://adni.loni.,Non-OADS,/arxiv_data1/oa_pdf/0d/dc/acn30001-0534.PMC4184556.pdf
Results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (http://www.eucast.org/ﬁleadmin/src/media/PDFs/ EUCAST_ﬁles/Breakpoint_tables/Breakpoint_table_v_3.1.pdf).,OADS,/arxiv_data1/oa_pdf/65/8d/nmi20002-0042.PMC4184589.pdf
the Lahey database (http://www.lahey.org/studies).,Non-OADS,/arxiv_data1/oa_pdf/65/8d/nmi20002-0042.PMC4184589.pdf
aInterpretation according to the EUCAST clinical breakpoints (http://www.eucast.org/ﬁleadmin/src/media/PDFs/EUCAST_ﬁles/Breakpoint_tabl es/Breakpoint_table_v_3.1.pdf).,OADS,/arxiv_data1/oa_pdf/65/8d/nmi20002-0042.PMC4184589.pdf
"Multilocus sequence typing performed as described else- where (http://pubmlst.org) identiﬁed isolates A and B as belonging to sequence type (ST) 258, being the most commonly identiﬁed ST among KPC-producing K. pneumoniae worldwide.",Non-OADS,/arxiv_data1/oa_pdf/e2/3f/nmi20002-0050.PMC4184591.pdf
Available at http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/87/8c/ccr30002-0066.PMC4184594.pdf
"Available at: http://www.cdc.gov/uscs (accessed June 10, 2012).",OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Availableat: http://seer.cancer.gov/statfacts/html/breast.html (accessedJune 10, 2012).",Non-OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed June 6,2013).",OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Available at: http://www.sos.ne.gov/rules-and-regs/regsearch/Rules/Health_and_Human_Services_System/Title-175/Chapter-08.pdf (accessed June 10, 2012).",Non-OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Available at: http://www.bd.com/ds/productCenter/446252.asp (accessed June 6, 2013).",Non-OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5912a1.htm (accessed June 14, 2013).",OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"November 14, 2011.Available at: http://www.aruplab.com/ (accessed October 1,2012).",Non-OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"Avail-able at: http://www.who.int/reproductivehealth/publications/sexual_health/deﬁning_sexual_health.pdf (accessed June 30,2013).",Non-OADS,/arxiv_data1/oa_pdf/89/f1/sm20002-0008.PMC4184610.pdf
"H2: Women’s online communities will reﬂect more emotional and less functional motivations 1These are literal quotes from contributions to online com- munities about labia reduction surgery (ﬁrst quote from:http://www.cosmopolitan.co.uk/community/forums/thread/1406999, second quote from http://www.experienceproject.com/group_stories.php?g =106234, third quote [translated from Dutch] from: http://www.medischforum.nl/onderwerp/9915/0/).",Non-OADS,/arxiv_data1/oa_pdf/a2/11/sm20002-0016.PMC4184612.pdf
2012 10 Experience Project§“I had labiaplasty” American Feb. 2009–March 2013 15 *http://www.medischforum.nl/onderwerp/9915/0/ †http://www.cosmopolitan.co.uk/community/forums/thread/1406999 ‡http://www.network54.com/Forum/287637/thread/1120209987/last-1329620198/Labia +reduction +surgery +experience §http://www.experienceproject.com/group_stories.php?g =10623418 Zwier Sex Med 2014;2:16–23 © 2014 The Author.,Non-OADS,/arxiv_data1/oa_pdf/a2/11/sm20002-0016.PMC4184612.pdf
"Available at: http://www.who.int/mediacentre/factsheets/fs360/en (accessed September 3,2013).",Non-OADS,/arxiv_data1/oa_pdf/a0/c1/sm20002-0024.PMC4184613.pdf
"Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002492 (accessed August 12, 2013).",Non-OADS,/arxiv_data1/oa_pdf/82/3b/sm20002-0031.PMC4184614.pdf
"Recently, diagnostic criteria for psitta- cosis have been published by the USA Centers for Disease Control (CDC) National Notiﬁable Disease Surveillance System (NNDSS), classifying cases as conﬁrmed or probable according to culture, species-speciﬁc nucleic acid testing (NAT) and serology (http://www.cdc.gov/nndss, under psitta- cosis).",Non-OADS,/arxiv_data1/oa_pdf/7e/51/nmi20002-0007.PMC4184616.pdf
"Quantiﬁcation was performed using a standard curve of bovine serum albumin (Biorad, Reinach BL, Switzerland) and analysis by Image J software (http://rsb.info.nih.gov/ij/).",OADS,/arxiv_data1/oa_pdf/ea/f0/nmi20002-0013.PMC4184618.pdf
"Analysis of the raw data was performed by Mascot Distiller 2.3.2 and Mascot 2.3 (Matrix Science, London, UK) against the Uniprot database (http://www.uniprot.org) restricted to Waddlia chondrophila WSU 86-1044 and against a custom-built database containingthe sequence of common contaminants (enzymes, keratins).",OADS,/arxiv_data1/oa_pdf/ea/f0/nmi20002-0013.PMC4184618.pdf
Finishing was achieved using the CLC genomics software (http://www.clcbio.com/).,OADS,/arxiv_data1/oa_pdf/6d/79/nmi20002-0025.PMC4184619.pdf
"In France, tetanus is a reportable but rare disease because of compulsory vaccination (French vaccine calendar 2012: http://www.sante.gouv.fr/calendri- er-vaccinal-detaille-2012.html).",Non-OADS,/arxiv_data1/oa_pdf/6d/79/nmi20002-0025.PMC4184619.pdf
"As of 12 September 2013, a total of 114 laboratory-con- ﬁrmed cases of MERS-CoV infection, including 54 deaths, havebeen reported (http://www.who.int/csr/don/2013_09_07/en/ index.html).",OADS,/arxiv_data1/oa_pdf/64/95/nmi20002-0027.PMC4184620.pdf
All imported cases had a travel history to theMiddle East and therefore current recommendations for investigation of MERS-CoV cases include residence in or history of travel to Middle Eastern countries (http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/64/95/nmi20002-0027.PMC4184620.pdf
"Direct trafﬁc from the Barcelona international airport includes 30 weekly ﬂights to the Middle East, accounting for more than 600 000 passengers in 2012(http://www.bcnair-route.com/index.php/en/intercontinental- ﬂights).",Non-OADS,/arxiv_data1/oa_pdf/64/95/nmi20002-0027.PMC4184620.pdf
"The acute respiratory infections surveillance programme in Catalonia, PIDIRAC (daily information system for acute respiratory infections in Catalonia), performs surveillanceduring the inﬂuenza activity season from October to May (http://www.gencat.cat/temes/cat/salut.htm).",Non-OADS,/arxiv_data1/oa_pdf/64/95/nmi20002-0027.PMC4184620.pdf
"A recently published real-time RT-PCRprotocol for MERS-CoV [10] was implemented in our labora- tory, and evaluated using an in vitro transcribed RNA kindly provided by C. Drosten through the European Virus Archive platform (http://www.european-virus-archive.com).",OADS,/arxiv_data1/oa_pdf/64/95/nmi20002-0027.PMC4184620.pdf
"This is where the CARE Guidelines for Case Reports and the associated checklist (http://www.care-statement.org/care-checklist) are invaluable in helping to ensure thorough and consistent reporting of information, which potentially makes aggregation of case reports easier.",Non-OADS,/arxiv_data1/oa_pdf/47/c6/ccr30002-0023.PMC4184623.pdf
"References 1. WHO global status report on alcohol and health, 2011. http://www.who.int/substance_abuse/publications/ global_alcohol_report/en/ 2.",Non-OADS,/arxiv_data1/oa_pdf/c0/d5/ccr30002-0045.PMC4184628.pdf
Available at http://www.fda.gov/ Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm183764.htm (accessed 8 August 2013).,Non-OADS,/arxiv_data1/oa_pdf/9d/5f/ccr30002-0149.PMC4184652.pdf
Linear regression of MRI parameters with clinical scores All regression analyses were performed using R software (http://www.R-project.org).,OADS,/arxiv_data1/oa_pdf/f7/b1/acn30001-0423.PMC4184670.pdf
Available at: http://www.cdc.gov/concussion/sports/facts.,Non-OADS,/arxiv_data1/oa_pdf/4c/b5/acn30001-0433.PMC4184671.pdf
"Available at:http://www.cebm.net (accessed August 5, 2013).",Non-OADS,/arxiv_data1/oa_pdf/33/c0/sm20002-0060.PMC4184677.pdf
"Available at: http://www.aafp.org/online/en/home/policy/policies/p/primarycare.html (accessed Novem-ber 11, 2009).",Non-OADS,/arxiv_data1/oa_pdf/33/c0/sm20002-0060.PMC4184677.pdf
NC_012920.1) and sequences present inMITOMAP (http://mitomap.org/MITOMAP) and mtSNP(http://mtsnp.tmig.or.jp/mtsnp/index_e.shtml) using Seq-Scape software (Applied Biosystems).,OADS,/arxiv_data1/oa_pdf/15/75/acn30001-0361.PMC4184687.pdf
"10,11SIFT and Poly- Phen, which predict the function of non-synonymousvariants (http://genetics.bwh.harvard.edu/pph/), alsorevealed that the p.P19S mutation “probably” damagesthe function of the NDUFA1 protein (damaging score,0.956).",OADS,/arxiv_data1/oa_pdf/15/75/acn30001-0361.PMC4184687.pdf
Amino acid sequences of MT-ND6 gene products were aligned by ClustalW program (http://www.ebi.ac.,OADS,/arxiv_data1/oa_pdf/15/75/acn30001-0361.PMC4184687.pdf
uk/Tools/msa/clustalw2/) and NCBI/homologene (http://www.ncbi.nlm.nih.gov/homologene).,OADS,/arxiv_data1/oa_pdf/15/75/acn30001-0361.PMC4184687.pdf
"A more rigorous place of birth adjustment would, however, yield small cells with too few cases, as there are 428 municipalities in Norway, with a median number of inhabitants of less than 4500 people (http://www.kartverket.no/Kunnskap/ Fakta-om-Norge/Fylker-og-kommuner/Tabell/).",Non-OADS,/arxiv_data1/oa_pdf/29/a2/acn30001-0376.PMC4184690.pdf
"Minimal inhibitory concentration values for ciproﬂoxacin, cefotaxime, ceftazidime, gentamicin, and amikacin were determined by E-test; results were interpreted according to EUCAST guidelines (http://www.eucast.org).",OADS,/arxiv_data1/oa_pdf/c6/9b/nmi20001-0044.PMC4184694.pdf
"Available at http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf (accessed 20 February 2012) Girish S, Martin SW, Peterson MC, Zhang LK, Zhao H, Balthasar J, et al.",Non-OADS,/arxiv_data1/oa_pdf/9c/25/prp20002-e00033.PMC4184705.pdf
Available at http://www.produktresume.,Non-OADS,/arxiv_data1/oa_pdf/bc/f3/prp20002-e00036.PMC4184708.pdf
"Available at http://www.drugs.com/ dosage/vigabatrin.html (accessed November 19, 2013).",Non-OADS,/arxiv_data1/oa_pdf/bc/f3/prp20002-e00036.PMC4184708.pdf
"Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm179855.htm (accessed September 27, 2013).",Non-OADS,/arxiv_data1/oa_pdf/bc/f3/prp20002-e00036.PMC4184708.pdf
"Available at: http://www.nrhm.gov.in/images/pdf/ programmes/family-planing/guidelines/Guidelines%20for%20administration%20of%20Emergency%20Contraceptive%20Pills%20(ECP)%20by%20health%20care%20providers.pdf (accessed January 9, 2012).",Non-OADS,/arxiv_data1/oa_pdf/7d/bf/sm20001-0016.PMC4184713.pdf
"He was able to walk at 18 months old,This case report is an illustration of an invited review available in Respirology :http://dx.doi.org/10.1111/resp.12330.",Non-OADS,/arxiv_data1/oa_pdf/ae/45/rcr20002-0095.PMC4184737.pdf
"This ﬁrstyear was complicated by recurrent infection, necessitatingThis case report is an illustration of an invited review available in Respirology :http://dx.doi.org/10.1111/resp.12370.",Non-OADS,/arxiv_data1/oa_pdf/92/7e/rcr20002-0120.PMC4184745.pdf
"For imaging processing details, see http://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferMethodsCitation.",Non-OADS,/arxiv_data1/oa_pdf/56/ab/acn30001-0497.PMC4184779.pdf
Available at http://www.ncats.nih.gov/research/ reengineering/rescue-repurpose/rescue-repurpose.html (accessed 29 May 2014).13.,OADS,/arxiv_data1/oa_pdf/6a/f0/acn30001-0512.PMC4184781.pdf
Available at http://hdl.loc.gov/loc.uscongress/ legislation.113hr3116 (accessed 29 May 2014).,Non-OADS,/arxiv_data1/oa_pdf/6a/f0/acn30001-0512.PMC4184781.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial u se, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783",OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"The positive binding of anti-human antibodies to mouse cell lysates and FBS-derived EVs could most likely be explained by the very high homology among species for the epitopes studied, which is up to 95% (CLUSTALW-multiple sequence alignment tool: www.ebi.ac.uk).Fetal bovine serum exosomes Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783",OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"Spearman Rank gave a signiﬁcant correlation of Rs /C300.82.Fetal bovine serum exosomes Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783",OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"2012;1:18396, http://dx.doi.org/10.3402/jev.v1i0.18396 7.",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"J Transl Med.2011;9:9.Fetal bovine serum exosomes Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"2013;2:20677, http://dx.doi.org/10.3402/jev.v2i0.20677 15.",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"2014;3:23111, http://dx.doi.org/10.3402/jev.v3.2311117.",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"2012;1:18389, http://dx.doi.org/10.3402/jev.v1i0.18389 21.",Non-OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 24783 - http://dx.doi.org/10.3402/jev.v3.24783",OADS,/arxiv_data1/oa_pdf/0c/a4/JEV-3-24783.PMC4185091.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"A p-value ofB0.05 was considered statistically significant.Microvesicle counts correlate with function Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348 3 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"PPL /C30phospholipid Procoag assay clotting time; ETP /C30endogenous thrombin potential; MVs/C30microvesicles; PMVs /C30platelet microvesicles.Microvesicle counts correlate with function Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348 5 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"PPL /C30phospholipid Procoag assay clotting time; ETP /C30endogenous thrombin potential; MVs /C30microvesicles; PMVs/C30platelet-derived microvesicles.Microvesicle counts correlate with function Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348 7 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"2014;3:20795, http://dx.doi.org/10.3402/jev.v3.20795.",Non-OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"2010; 6:89/C198.Microvesicle counts correlate with function Citation: Journal of Extracellular Vesicles 2014, 3: 25348 - http://dx.doi.org/10.3402/jev.v3.25348 9 (page number not for citation purpose)",OADS,/arxiv_data1/oa_pdf/1d/d2/JEV-3-25348.PMC4185095.pdf
"1052-3057/$ - see front matter /C2112014 by National Stroke Association http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.03.002 Journal of Stroke and Cerebrovascular Diseases , Vol.",Non-OADS,/arxiv_data1/oa_pdf/0c/9c/main.PMC4185096.pdf
"Available at, http://research.ncl.",Non-OADS,/arxiv_data1/oa_pdf/0c/9c/main.PMC4185096.pdf
Available at: http://www.scst.org.uk/resources/ consensus_guideline_for_recording_a_12_lead_ecg_Rev_ 072010b.pdf .,Non-OADS,/arxiv_data1/oa_pdf/0c/9c/main.PMC4185096.pdf
Different nomenclatures have been proposed and de- bated for b-lactamases which includes several hundreds of enzymes (http://www.lahey.org/studies/webt.asp).,Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, distribution, and re production in any medium, provided the original work is properly cited.1 Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"In the Nordic countries,Alma Brolund 2 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555",OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"A schematic illustration of a plasmid.ESBL-producing Enterobacteriaceae from a Nordic perspective Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
TheEuropean network of national surveillance systems ofantimicrobial resistance summarizes the levels of invasive infections caused by resistant bacteria in the European countries in a yearly report available on the ECDChomepage: http://ecdc.europa.eu/.,Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"The climate affects thefrequency of infections and also the rate of dissemination.Economical status, household conditions and populationdensity also clearly play a role.Alma Brolund 4 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"Source: ECDC/EARS-Net 2001 and 2012.ESBL-producing Enterobacteriaceae from a Nordic perspective Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"New treatment options can buy us time to address this important issue that constitutes a major public health problem.Alma Brolund 6 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"APMIS 2008; 116: 302 /C18.ESBL-producing Enterobacteriaceae from a Nordic perspective Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"Clin MicrobiolInfect 2014; [Epub ahead of print].Alma Brolund 8 (page number not for citation purpose)Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555",OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"Antimicrob Agents Chemother 2012; 56: 4703 /C16.ESBL-producing Enterobacteriaceae from a Nordic perspective Citation: Infection Ecology and Epidemiology 2014, 4: 24555 - http://dx.doi.org/10.3402/iee.v4.24555 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9e/2f/IEE-4-24555.PMC4185132.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25156 - http://dx.doi.org/10.3402/jchimp.v4.25156 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/4f/89/JCHIMP-4-25156.PMC4185141.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25156 - http://dx.doi.org/10.3402/jchimp.v4.25156",Non-OADS,/arxiv_data1/oa_pdf/4f/89/JCHIMP-4-25156.PMC4185141.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), pe rmitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25093 - http://dx.doi.org/10.3402/jchimp.v4.25093 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9b/b6/JCHIMP-4-25093.PMC4185142.pdf
"Fnu Kelash and James Mulinda 2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25093 - http://dx.doi.org/10.3402/jchimp.v4.25093",Non-OADS,/arxiv_data1/oa_pdf/9b/b6/JCHIMP-4-25093.PMC4185142.pdf
"Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-ﬂuorouracil or chloro-zotocin in the treatment of advanced islet-cell carcinoma.N Engl J Med 1992; 326(8): 519 /C123.Insulinoma: A rare cause of hypoglycemia in a young female Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25093 - http://dx.doi.org/10.3402/jchimp.v4.25093 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/9b/b6/JCHIMP-4-25093.PMC4185142.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitt ing all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24562 - http://dx.doi.org/10.3402/jchimp.v4.24562 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/02/c9/JCHIMP-4-24562.PMC4185143.pdf
"The tumor is strongly and diffusely TTF-1 positive (c), as is characteristicof primary adenocarcinoma of the lung.Ning Jin and Peter J. Sloane 2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24562 - http://dx.doi.org/10.3402/jchimp.v4.24562",Non-OADS,/arxiv_data1/oa_pdf/02/c9/JCHIMP-4-24562.PMC4185143.pdf
"(1).Evaluation of pulmonary pGGN Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24562 - http://dx.doi.org/10.3402/jchimp.v4.24562 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/02/c9/JCHIMP-4-24562.PMC4185143.pdf
"Maeda R, Ishii G, Y oshida J, Hishida T, Nishimura M, Nagai K. Inﬂuence of cigarette smoking on histologicalNing Jin and Peter J. Sloane 4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24562 - http://dx.doi.org/10.3402/jchimp.v4.24562",Non-OADS,/arxiv_data1/oa_pdf/02/c9/JCHIMP-4-24562.PMC4185143.pdf
"Radiol Med 2013; 118: 1071/C181.Evaluation of pulmonary pGGN Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24562 - http://dx.doi.org/10.3402/jchimp.v4.24562 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/02/c9/JCHIMP-4-24562.PMC4185143.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"As described by these quotes from students: Initially I was using Micromedex†a lot to review mechanisms or look up side effects of drugs ... Iu s e d VisualDx a lot when looking at rashes; I used it a couple of times with patients to see if the imagesI had looked similar to what their rash initially lookedReal-time use of the iPad by third-year medical students Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"Amount of time spent and perceived expertise using the iPad†.Real-time use of the iPad by third-year medical students Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"6 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
Available from: http://manhattanresearch.com/ news-and-events/press-releases/physician-iphone-ipad-adoption [cited 1 May 2014].,Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
Available from: http://obssr.od.nih.gov/mixed_methods_research/ [cited 16 May 2014].,OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"Med Ref Serv Q 2014; 33(1): 17 /C128.Real-time use of the iPad by third-year medical students Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25184 - http://dx.doi.org/10.3402/jchimp.v4.25184 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/38/26/JCHIMP-4-25184.PMC4185144.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"PRISMA ﬂow diagram showing the screening and inclusion of the studies.Efficacy of NSAIDs for the prevention of AMS Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"Comparator: NSAIDs versus placebo.Efficacy of NSAIDs for the prevention of AMS Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
Available from: http://www.cochrane-handbook.org [cited 2 June 2013].,OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"6 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"West J Med 1988; 148(5): 541 /C15.Efficacy of NSAIDs for the prevention of AMS Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24927 - http://dx.doi.org/10.3402/jchimp.v4.24927 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/81/3d/JCHIMP-4-24927.PMC4185145.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25104 - http://dx.doi.org/10.3402/jchimp.v4.25104 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/15/4f/JCHIMP-4-25104.PMC4185146.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25104 - http://dx.doi.org/10.3402/jchimp.v4.25104",Non-OADS,/arxiv_data1/oa_pdf/15/4f/JCHIMP-4-25104.PMC4185146.pdf
"J Invasive Cardiol 2010; 22: 559 /C160.Spontaneous coronary artery dissection causing ACS Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25104 - http://dx.doi.org/10.3402/jchimp.v4.25104 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/15/4f/JCHIMP-4-25104.PMC4185146.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25090 - http://dx.doi.org/10.3402/jchimp.v4.25090 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/d2/59/JCHIMP-4-25090.PMC4185147.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25090 - http://dx.doi.org/10.3402/jchimp.v4.25090",Non-OADS,/arxiv_data1/oa_pdf/d2/59/JCHIMP-4-25090.PMC4185147.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24811 - http://dx.doi.org/10.3402/jchimp.v4.24811 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/60/64/JCHIMP-4-24811.PMC4185148.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24811 - http://dx.doi.org/10.3402/jchimp.v4.24811",Non-OADS,/arxiv_data1/oa_pdf/60/64/JCHIMP-4-24811.PMC4185148.pdf
"CT of the abdomen with oral contrast shows marked hepatic steatosis and ascites.Gelatinous transformation of bone marrow Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24811 - http://dx.doi.org/10.3402/jchimp.v4.24811 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/60/64/JCHIMP-4-24811.PMC4185148.pdf
"4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24811 - http://dx.doi.org/10.3402/jchimp.v4.24811",Non-OADS,/arxiv_data1/oa_pdf/60/64/JCHIMP-4-24811.PMC4185148.pdf
"Am J Clin Pathol 2002; 118(4): 582 /C18.Gelatinous transformation of bone marrow Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 24811 - http://dx.doi.org/10.3402/jchimp.v4.24811 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/60/64/JCHIMP-4-24811.PMC4185148.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitt ing all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"Flowchart depicting the algorithmic approach to episodic abdominal pain that was used in the described case.Drug-induced visceral angioedema Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"ACE inhibition leads to diversion of substrates toward secondary enzymes rather than primary metabolizing enzymes thereby producing physiologically active metabolites.LMW/C30low molecular weight; HMW /C30high molecular weight; B1 /C30bradykinin 1; B2 /C30bradykinin 2.Drug-induced visceral angioedema Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
Available from: http://books.google.com/books?,Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"6 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
Available from: http://www.uptodate.com/contents/ace-inhibitor- induced-angioedema?source /C30preview&anchor /C30H20393882& selectedTitle /C301/C2150#H20393882 [cited 12 September 2013].,Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"BMJ 2011; 343: d4891.Drug-induced visceral angioedema Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25260 - http://dx.doi.org/10.3402/jchimp.v4.25260 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3c/31/JCHIMP-4-25260.PMC4185149.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all no n- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25955 - http://dx.doi.org/10.3402/jchimp.v4.25955 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/3a/3c/JCHIMP-4-25955.PMC4185156.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitt ing all non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25261 - http://dx.doi.org/10.3402/jchimp.v4.25261 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/98/34/JCHIMP-4-25261.PMC4185157.pdf
"2 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25261 - http://dx.doi.org/10.3402/jchimp.v4.25261",Non-OADS,/arxiv_data1/oa_pdf/98/34/JCHIMP-4-25261.PMC4185157.pdf
"Optical coherence tomography image of the left anterior descending artery demonstrating intimal ﬂap (in-dicated by white arrow).Spontaneous coronary artery dissection Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25261 - http://dx.doi.org/10.3402/jchimp.v4.25261 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/98/34/JCHIMP-4-25261.PMC4185157.pdf
"4 (page number not for citation purpose)Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25261 - http://dx.doi.org/10.3402/jchimp.v4.25261",Non-OADS,/arxiv_data1/oa_pdf/98/34/JCHIMP-4-25261.PMC4185157.pdf
"Circulation 2012; 126:579/C188.Spontaneous coronary artery dissection Citation: Journal of Community Hospital Internal Medicine Perspectives 2014, 4: 25261 - http://dx.doi.org/10.3402/jchimp.v4.25261 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/98/34/JCHIMP-4-25261.PMC4185157.pdf
http://dx.doi.org/10.1016/S1474-4422(03)00304-1 .,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
"Ashburner, J. VBM Tutorial 2010. http://www.fil.ion.ucl.ac.uk 3.",Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
IEEE International Symposium on Biomedical Imaging; 2004. p. 1283-1286. http://www.stat.wisc.edu/~mchung/softwares/pvalue/permutation.tstat.hippocampus.pdf 5.,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
2009. p. 2277-2285. http://papers.nips.cc/paper/3858-efficient- moments-based-permutation-tests.pdf 6.,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1002/hbm.460020402 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/ 10.1097/00004647-199601000-00002 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1002/hbm.1058 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1093/brain/awt091 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1109/TMI.2009.2014863 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
2000; 11(6):805– 821. http://dx.doi.org/10.1006/nimg.2000.0582 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://www3.stat.sinica.edu.tw/statistica/oldpdf/A18n417.pdf .,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1016/S0140-6736(04)15441-X .,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1148/radiographics.20.3.g00ma19893 .,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1016/j.neuroimage.2005.09.046 .,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
New York: Springer; 2001. http://dx.doi.org/10.1007/978-1-4757-3449-2 22.,Non-OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
http://dx.doi.org/10.1111/1467-9868.00346 .Zhou et al.,OADS,/arxiv_data1/oa_pdf/1a/d7/nihms593089.PMC4185212.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
"Models were generated with the automated modeling pipelines accessible through the I-TASSER webserver ( http:// zhanglab.ccmb.med.umich.edu/I-TASSER/ ) (Zhang, 2007; Roy et al., 2010) and the bioinformatics toolkit ( http://toolkit.tuebingen.",OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
"Primers were designed using Frodo ( http://frodo.wi.mit.edu/primer3/ ) (Koressaar and Remm, 2007; Untergasser et al., 2012).",Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1093/nar/ gkh131 .,Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1093/bioinformatics/btm091 .,Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1002/prot.23177 .,Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1006/jmbi.1993.1626 .,OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1093/nar/ gks596 .,Non-OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
http://dx.doi.org/10.1016/j.jsb.2011.09.006 .,OADS,/arxiv_data1/oa_pdf/60/0c/nihms-621547.PMC4185229.pdf
"Key Words :  Curcumin · Spinal cord neural progenitor cell · Mitogen activated protein kinase.Laboratory Investigation • Received : April 1, 2014  • Revised : May 12, 2014  • Accepted : July 15, 2014 • Address for reprints : Kyoung-Tae Kim, M.D., Ph.D.  Department of Neurosurgery, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu 700-721, Korea  Tel : +82-53-200-5657,  Fax : +82-53-423-0504,  E-mail : nskimkt7@gmail.com • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 1-4, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.1 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/ee/e3/jkns-56-1.PMC4185312.pdf
"Department of Neurosurgery, College of Medicine, Yeungnam University, 170 Hyeonchung-ro, Nam-gu, Daegu 705-802, Korea  Tel : +82-53-620-3790,  Fax : +82-53-620-3770,  E-mail : olkim@med.yu.ac.kr • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 11-15, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.11 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/36/c4/jkns-56-11.PMC4185313.pdf
"Department of Neurosurgery, Ulsan University Hospital, 877 Bangeojin Sunhwando-ro, Dong-gu, Ulsan 682-714, Korea  Tel : +82-52-250-7139,  Fax : +82-52-250-7138,  E-mail : iulyo@uuh.ulsan.kr • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 16-20, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.16 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/5b/92/jkns-56-16.PMC4185314.pdf
"Key Words :  Spondylitis · Osteomyelitis · Pyogenic · Tuberculosis · Spinal infection.Clinical Article • Received : January 10, 2014  • Revised : June 18, 2014  • Accepted : July 15, 2014 • Address for reprints : Seung-Won Choi, M.D., Ph.D.  Department of Neurosurgery, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon 301-721, Korea  Tel : +82-42-280-8096,  Fax : +82-42-280-7363,  E-mail : swchoi@cnu.ac.kr • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 21-27, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.21 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/c9/30/jkns-56-21.PMC4185315.pdf
"Key Words :  Postoperative delirium · Cognitive function test · Bispectral index.Clinical Article • Received : April 7, 2014  • Revised : June 18, 2014  • Accepted : July 15, 2014 • Address for reprints : Seung Won Park, M.D., Ph.D.   Department of Neurosurgery, College of Medicine, Chung-Ang University, 102 Heukseok-ro, Dongjak-gu, Seoul 156-755, Korea  Tel : +82-2-6299-3190,  Fax : +82-2-821-8409,  E-mail : nspsw@cau.ac.kr • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 28-33, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.28 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/bd/23/jkns-56-28.PMC4185316.pdf
"Key Words :  Brain abscess · Glasgow Coma Scale · Glasgow Outcome Scale · Hyperglycemia.Clinical Article • Received : April 9, 2014  • Revised : June 20, 2014  • Accepted : July 15, 2014 • Address for reprints : Kyung-Jae Park, M.D., Ph.D.  Department of Neurosurgery, Korea University Medical Center, College of Medicine, Korea University, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea  Tel : +82-2-920-5729,  Fax : +82-2-929-0629,  E-mail : kyungjae99@hanmail.net • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 34-41, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.34 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/2b/d3/jkns-56-34.PMC4185317.pdf
"Department of Neurosurgery, Ajou University College of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon 443-380, Korea  Tel : +82-31-219-5231,  Fax : +82-31-219-5238,  E-mail : ns9@naver.com • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 42-47, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.42 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/af/34/jkns-56-42.PMC4185318.pdf
"Department of Neurosurgery, Stroke and Neurological Disorders Centre, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine,   8 92 Dongnam-ro, Gangdong-gu, Seoul 134-727, Korea  Tel : +82-2-440-6286,  Fax : +82-2-440-8404,  E-mail : toast2000@hanmail.net • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 48-50, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.48 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/94/5e/jkns-56-48.PMC4185319.pdf
"Key Words :  C7 · Cervical spine · Intralaminar screw.Laboratory Investigation • Received : November 19, 2013  • Revised : March 29, 2014  • Accepted : July 15, 2014 • Address for reprints : Ilsup Kim, M.D., Ph.D.   Department of Neurosurgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon 442-723, Korea   Tel : +82-31-245-8207,  Fax : +82-31-245-5208,  E-mail : nsman72@hanmail.net • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 5-10, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.5 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/d1/4f/jkns-56-5.PMC4185320.pdf
"Key Words :  Meningeal carcinomatosis · Leptomeningeal carcinomatoses · Carcinomatous meningitis · Signet ring cell carcinoma ·                       Vestibular schwannoma · Neurofibromatoses.Case Report • Received : November 25, 2013  • Revised : March 18, 2014  • Accepted : July 15, 2014 • Address for reprints : Jeong-Taik Kwon, M.D., Ph.D.  Department of Neurosurgery, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 156-755, Korea  Tel : +82-2-6299-3190,  Fax : +82-2-821-8409,  E-mail : jtkwon@cau.ac.kr  • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 51-54, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.51 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/ca/e2/jkns-56-51.PMC4185321.pdf
"Department of Neurosurgery, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, 77 Sakju-ro, Chuncheon 200-704, Korea  Tel : +82-33-240-5173,  Fax : +82-33-242-9970,  E-mail : yiyaseo@naver.com • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 55-57, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.55 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kr",Non-OADS,/arxiv_data1/oa_pdf/f4/29/jkns-56-55.PMC4185322.pdf
"Key Words :  Spinal tumor · Fibrous meningioma · Non-dural based.Case Report • Received : July 3, 2013  • Revised : September 17, 2013  • Accepted : December 30, 2013 • Address for reprints : Youn-Kwan Park, M.D., Ph.D.  Department of Neurosurgery, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 152-703, Korea  Tel : +82-2-2626-3096,  Fax : +82-2-863-1684,  E-mail : kiwi765@hanmail.net  • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56 (1)  : 58-60, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.58 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/0d/d1/jkns-56-58.PMC4185323.pdf
"Department of Neurosurgery, College of Medicine, Dong-A University, 26 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea  Tel : +82-51-240-5241,  Fax : +82-51-242-6714,  E-mail : ns2000@donga.ac.kr  • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 61-65, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.61 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/1e/1a/jkns-56-61.PMC4185324.pdf
"Key Words :  Anterior spine surgery · Sympathetic dysfunction · Sympathetic block.Case Report • Received : February 12, 2014  • Revised : May 27, 2014  • Accepted : July 15, 2014 • Address for reprints : Hahck Soo Park, MD., Ph.D.  Department of Anesthesiology and Pain Medicine, School of Medicine, Ewha Womans University, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 158-710, Korea  Tel : +82-2-2650-2689,  Fax : +82-2-2655-2924,  E-mail : ingoo97@lycos.co.kr • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 66-70, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.66 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/40/e5/jkns-56-66.PMC4185325.pdf
"Key Words :  Mesencephalotomy · Facial pain · Magnetic resonance imaging.Case Report • Received : November 26, 2013  • Revised : March 29, 2014  • Accepted : July 15, 2014 • Address for reprints : Byung-chul Son, M.D., Ph.D.  Department of Neurosurgery, Seoul St. Mary’s Hospital, Catholic Neuroscience Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero,   S eocho-gu, Seoul 137-701, Korea  Tel : +82-2-2258-6122,  Fax : +82-2-594-4248,  E-mail : sbc@catholic.ac.kr  • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)     w hich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.J Korean Neurosurg Soc 56  (1) : 71-74, 2014http://dx.doi.org/10.3340/jkns.2014.56.1.71 Copyright © 2014 The Korean Neurosurgical Society  Print ISSN 2005-3711  On-line ISSN 1598-7876 www.jkns.or.kronline © ML Comm",Non-OADS,/arxiv_data1/oa_pdf/46/cd/jkns-56-71.PMC4185326.pdf
"From August 2008 to January 2009,Freely available online Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia University Libraries/Information Services1",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
Tourette Syndrome Clinical Triad Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia University Libraries/Information Services2,Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia University Libraries/Information Services3,Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Mov Disord 2009;24:15– 24, doi: http://dx.doi.org/10.1002/mds.22378.",OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Dev Med Child Neurol 2000;42:436–447, doi: http://dx.doi.org/10.1017/S0012162200000839.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Pediatrics 1998;102:14–19, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Neurology 1992;42: 784–788, doi: http://dx.doi.org/10.1212/WNL.42.4.784.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Ann Neurol 1987;22:383–385, doi: http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome.Arch Pediatr Adolesc Med 2006;160:65–69, doi: http://dx.doi.org/10.1001/ archpedi.160.1.65.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
Tourette Syndrome Clinical Triad Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia University Libraries/Information Services4,Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Neurology 2003;61:936–940, doi: http://dx.doi.org/10.1212/01.WNL.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Arch Neurol 1998;55:409–414, doi: http://dx.doi.org/10.1001/archneur.55.3.409.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Arch Neurol 1985;42:1079–1080, doi: http://dx.doi.org/10.1001/archneur.",Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"Ann Neurol 1983;14:693–694, doi: http://dx.doi.org/10.1002/ana.410140619.12.Biederman J, Mick E, Faraone SV.",OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
"J Psychosom Res 2008;65:461–472, doi: http://dx.doi.org/10.1016/j.jpsychores.",OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
Tremor and Other Hyperkinetic Movements http://www.tremorjournal.orgThe Center for Digital Research and ScholarshipColumbia University Libraries/Information Services5,Non-OADS,/arxiv_data1/oa_pdf/c3/87/tre-04-243-5933-2.PMC4185327.pdf
doi:10.1136/ bmjopen-2014-006084 ▸Prepublication history for this paper is available online.To view these files please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2014-006084).,Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1. de Vries EN, Ramrattan MA, Smorenburg SM, et al.",Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
2009. http://www.gmc-uk.org/FINAL_Report_prevalence_and_causes_of_prescribing_errors.pdf_28935150.pdf (accessed 10/03/2014).,Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
2009. http://www.nrls.npsa.nhs.uk/ EasySiteWeb/getresource.axd?AssetID=61626&type=full&servicetype= ... (accessed 10/03/2014).,Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
2009. http://www.nmhdu.org.uk/silo/files/getting-the-medicines-right--jul-2009.pdf (accessed 10/03/2014).,Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
2012. http://www.health.org.uk/public/cms/75/76/313/3337/Reducing%20prescribing%20errors%20-%20evidence%20scan.pdf?,Non-OADS,/arxiv_data1/oa_pdf/65/cc/bmjopen-2014-006084.PMC4185335.pdf
To view please visitthe journal (http://dx.doi.org/ 10.1136/bmjopen-2014- 005628).,Non-OADS,/arxiv_data1/oa_pdf/84/eb/bmjopen-2014-005628.PMC4185336.pdf
"1The data in the WISQARS system are derived from CDC annual mortal- ity data from National Vital Statistics System (NVSS), National Center for Health Statistics (NCHS; http://www.cdc.gov/nchs/) and CDC.",OADS,/arxiv_data1/oa_pdf/84/eb/bmjopen-2014-005628.PMC4185336.pdf
"Retrieved (May 1, 2014)http://www.bradycampaign.org/2013-state-scorecard 10.",Non-OADS,/arxiv_data1/oa_pdf/84/eb/bmjopen-2014-005628.PMC4185336.pdf
"Retrieved (May 1, 2014) http://www.fbi.gov/about-us/cjis/ucr/nibrs/2012 27.",OADS,/arxiv_data1/oa_pdf/84/eb/bmjopen-2014-005628.PMC4185336.pdf
"” Retrieved (May 1, 2014) http://www.tracetheguns.org, 2010.",Non-OADS,/arxiv_data1/oa_pdf/84/eb/bmjopen-2014-005628.PMC4185336.pdf
Secondary EU citizens ’attitudes towards alcohol 2010. http://ec.europa.eu/ health/alcohol/docs/ebs_331_en.pdf 2.,Non-OADS,/arxiv_data1/oa_pdf/b4/85/bmjopen-2014-005462.PMC4185337.pdf
"http://www.sundhedsstyrelsen.dk/ Sundhedogforebyggelse/Alkohol.aspx Jensen TK, et al.BMJ Open 2014; 4:e005462.",Non-OADS,/arxiv_data1/oa_pdf/b4/85/bmjopen-2014-005462.PMC4185337.pdf
To view these files please visit the journal online(http://dx.doi.org/10.1136/ bmjopen-2014-005176).,Non-OADS,/arxiv_data1/oa_pdf/ad/a8/bmjopen-2014-005176.PMC4185338.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/), permitting all non-commercial use, dist ribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Libyan J Med 2014, 9: 25794 - http://dx.doi.org/10.3402/ljm.v9.25794 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/e6/67/LJM-9-25794.PMC4185342.pdf
"2 (page number not for citation purpose)Citation: Libyan J Med 2014, 9: 25794 - http://dx.doi.org/10.3402/ljm.v9.25794",Non-OADS,/arxiv_data1/oa_pdf/e6/67/LJM-9-25794.PMC4185342.pdf
RNA-Seq data reported in this study has been deposited in the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.,OADS,/arxiv_data1/oa_pdf/e5/8e/cr2014120a.PMC4185346.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/Persistence of intrahepatic HBV cccDNA HC Yang and JH Kao 7 Emerging Microbes and Infections",Non-OADS,/arxiv_data1/oa_pdf/98/03/emi201464a.PMC4185362.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Regulatory science and the development of biological products ZL Liang et al 4 Emerging Microbes and Infections",Non-OADS,/arxiv_data1/oa_pdf/68/22/emi201466a.PMC4185363.pdf
",http://omlc.org/spectra/ hemoglobin/ ., (1999) Date of access: 04/05/2013.",Non-OADS,/arxiv_data1/oa_pdf/cc/3a/srep06525.PMC4185377.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/cc/3a/srep06525.PMC4185377.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6521 | DOI: 10.1038/srep06521 5",Non-OADS,/arxiv_data1/oa_pdf/01/c7/srep06521.PMC4185379.pdf
"We analyse comprehensive data from a society, consisting of the players of the massive multiplayer online game (MMOG) Pardus (http://www.pardus.at).",Non-OADS,/arxiv_data1/oa_pdf/bc/63/srep06526.PMC4185380.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6526 | DOI: 10.1038/srep06526 6",Non-OADS,/arxiv_data1/oa_pdf/bc/63/srep06526.PMC4185380.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6524 | DOI: 10.1038/srep06524 7",Non-OADS,/arxiv_data1/oa_pdf/71/77/srep06524.PMC4185381.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/21/77/srep06528.PMC4185386.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6528 | DOI: 10.1038/srep06528 7",Non-OADS,/arxiv_data1/oa_pdf/21/77/srep06528.PMC4185386.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/09/1f/srep06457.PMC4185387.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ef/8f/srep06334.PMC4185388.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/7b/4b/srep06519.PMC4185389.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b4/f1/srep06529.PMC4185410.pdf
"43,44 Although many *Correspondence to: Young-Min Lee; Email: youngmin.lee@usu.edu Submitted: 07/17/2013; Revised: 10/14/2013; Accepted: 10/22/2013;   Published Online: 10/25/2013; http://dx.doi.org/10.4161/hv.26902Japanese encephalitis The virus and vaccines Sang-Im Yun and Young-Min Lee* Department of Animal, Dairy, and Veterinary Sciences; Utah Science Technology and Research; College of Agriculture and Applied Sciences; Utah State University; Logan, UT USA Keywords:  Japanese encephalitis virus, vaccine, immunization, biodefense, prevention, pathogenesis, virulence, flavivirus Japanese encephalitis (J e) is an infectious disease of the  central nervous system caused by Japanese encephalitis virus  (JeV), a zoonotic mosquito-borne flavivirus.",Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
N Engl J Med 2006; 355:869- 71; PMID:16943399 ; http://dx.doi.org/10.1056/ NEJMp058263 2.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol Immunol  2002; 267:11-48;  PMID:12082986 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Emerg Infect Dis 2009 ; 15:1- 7; PMID:19116041 ; http://dx.doi.org/10.3201/ eid1501.080311 7.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol  Immunol  2002 ; 267:49-73; PMID:12083000 ;  http://dx.doi.org/10.1007/978-3-642-59403-8_3 10.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Antiviral Res 2010; 85:328- 45; PMID:19857523 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Annu Rev Entomol  2009 ; 54:17- 35; PMID:19067628 ; http://dx.doi.org/10.1146/ annurev.ento.54.110807.090510,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2000 ; 18(Suppl 2 ):1-25; PMID:10821969 ;  http://dx.doi.org/10.1016/S0264-410X(00)00037-2 14.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Prog Neurobiol  2010 ; 91:108-20; PMID:20132860 ;  http://dx.doi.org/10.1016/j.pneurobio.2010.01.008 15.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol Immunol  2002 ; 267:171-94; PMID:12082989 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol  Immunol  2002 ; 267:105-38; PMID:12082985 ;  http://dx.doi.org/10.1007/978-3-642-59403-8_6 19.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virus Res 2003 ; 96:129- 40; PMID:12951273 ; http://dx.doi.org/10.1016/ S0168-1702(03)00181-3 24.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virus  Res 1996 ; 42:107-17; PMID:8806178 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 2010 ; 91:95-  102; PMID:19776238 ; http://dx.doi.org/10.1099/ vir.0.013631-0 28.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Infect Genet Evol 2011 ; 11:855- 62; PMID:21352956 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol  1990 ; 71:2915 -22; PMID:2273391 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2003 ; 77:3091 -8; PMID:12584335 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virol  J 2011; 8:449; PMID:21943222 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS Negl Trop Dis 2011; 5:e1231; PMID:21750744 ;  http://dx.doi.org/10.1371/journal.pntd.0001231 36.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine 2000;  18(Suppl 2):36-43;  PMID:10821972 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  1995; 13:1713-21;  PMID:8719524 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Annu Rev Microbiol 1986; 40:395-414;  PMID:2877613 ; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Nat Rev Microbiol 2004; 2:789-  801; PMID:15378043 ; http://dx.doi.org/10.1038/ nrmicro1006 45.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
N Engl J Med 2003 ;  348:2196 -203; PMID:12773646 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
N Engl J Med 2003 ;  349:1236 -45; PMID:14500806 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Pediatr Infect Dis J  1996 ; 15:1018 -24; PMID:8933552 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect Dis 2006 ; 43:123-31;  PMID:16779737 ; http://dx.doi.org/10.1086/505121 57.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Mov Disord 2000;  15:1168-72;  PMID:11104201 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Ann Trop Paediatr  2006 ; 26:293-301; PMID:17132294 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Neurol Sci 2007 ; 262:165- 70; PMID:17643451 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Acta Neurol Scand  1997 ; 96:114-7; PMID:9272188 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  1998 ; 351:1094 - 7; PMID:9660579 ; http://dx.doi.org/10.1016/ S0140-6736(97)07509-0 62.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Brain  2002 ; 125:1084 -93;  PMID:11960897 ; http://dx.doi.org/10.1093/brain/ awf116 64.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Neurol Sci 2001 ; 190:57-60; PMID :11574107 ;  http://dx.doi.org/10.1016/S0022-510X(01)00589-5 65.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Adv Virus Res 2003 ; 59:1- 19; PMID:14696325 ; http://dx.doi.org/10.1016/ S0065-3527(03)59001-7 67.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Science  1985 ; 229: 726- 33; PMID:4023707 ; http://dx.doi.org/10.1126/ science.4023707 71.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1987 ;  161:497-510; PMID:3686827 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2003 ; 77:6450 - 65; PMID:12743302 ; http://dx.doi.org/10.1128/ JVI.77.11.6450-6465.2003 74.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2008 ; 82:7846 -62; PMID:18524814 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Nat  Rev Microbiol 2005 ; 3:13-22; PMID:15608696 ;  http://dx.doi.org/10.1038/nrmicro1067 77.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Structure   2004 ; 12:1157-63; PMID:15242592 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Proc Natl Acad Sci U S A  2004 ; 101:3414 -9; PMID:14993605 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Cell 2002 ; 108:717-25;  PMID:11893341 ; http://dx.doi.org/10.1016/ S0092-8674(02)00660-8 80.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Science   2003 ; 302:248; PMID:14551429 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Nat Struct Biol  2003 ; 10:907-12;  PMID:14528291 ; http://dx.doi.org/10.1038/nsb990 82.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Adv Virus Res 2003 ; 59:177- 228; PMID:14696330 ; http://dx.doi.org/10.1016/ S0065-3527(03)59006-6 84.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol Immunol 2002 ;  267:323-51; PMID:12082996 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virus Res  2009 ; 139:230-9; PMID:18703097 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Annu Rev Microbiol 2002 ; 56:371-402;  PMID:12142476 ; http://dx.doi.org/10.1146/ annurev.micro.56.012302.160654 87.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2008 ; 82:3342 - 52; PMID:18199634 ; http://dx.doi.org/10.1128/ JVI.02447-07 88.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2008 ;  82:4731 -41; PMID:18337583 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2003 ; 77:7804 - 13; PMID:12829820 ; http://dx.doi.org/10.1128/ JVI.77.14.7804-7813.2003 90.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2002 ; 76:4773 -84; PMID:11967294 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2006 ;  80:11255 -64; PMID:16971441 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Viruses  2012 ;  4:397-413; PMID:22590678 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Immunol Res   2009 ; 43:172-86; PMID:18841330 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Interferon Cytokine Res 2009 ; 29:521-30;  PMID:19694536 ; http://dx.doi.org/10.1089/ jir.2009.0069 95.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2005 ; 79:1934 -42; PMID:15650219 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Proc Natl Acad Sci U S A  2003 ; 100:14333 -8; PMID:14612562 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2005 ;  79:8004 -13; PMID :15956546 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology   1991 ; 184:707-15; PMID:1716026 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1993 ; 197:265- 73; PMID:8212562 ; http://dx.doi.org/10.1006/ viro.1993.1587 104.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
EMBO J 2002 ; 21:2757 -68;  PMID:12032088 ; http://dx.doi.org/10.1093/ emboj/21.11.2757 106.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
RNA  2009 ; 15:2340 -50; PMID:19850911 ;  http://dx.doi.org/10.1261/rna.1609709 107.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1996 ; 216:317- 25; PMID:8607261 ; http://dx.doi.org/10.1006/ viro.1996.0067 109.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2010 ; 84:1641 - 7; PMID:19906906 ; http://dx.doi.org/10.1128/ JVI.01979-09 110.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virol J 2009 ; 6:14; PMID:19196463 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Nat Med  1997 ; 3:866- 71; PMID:9256277 ; http://dx.doi.org/10.1038/ nm0897-866 112.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2006 ; 80:1290 - 301; PMID :16415006 ; http://dx.doi.org/10.1128/ JVI.80.3.1290-1301.2006 113.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
EMBO Rep 2003 ; 4:723- 8; PMID:12783086 ; http://dx.doi.org/10.1038/ sj.embor.embor866 114.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Cell  2006 ; 124:485-93; PMID:16469696 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Exp Med 2003 ; 197:823- 9; PMID:12682107 ; http://dx.doi.org/10.1084/ jem.20021840 116.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 2008 ; 89:474-84; PMID:18198378 ;  http://dx.doi.org/10.1099/vir.0.83357-0117.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  2006 ; 349:463- 75; PMID:16490225 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2004 ; 78:10543 -55;  PMID :15367621 ; http://dx.doi.org/10.1128/ JVI.78.19.10543-10555.2004 120.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology   2008 ; 378:193-9; PMID:18571214 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
"J Virol 2007 ; 81:12019 - 28; PMID:17728239 ; http://dx.doi.org/10.1128/ JVI.00300-07 122. van der Schaar HM, Rust MJ, Chen  C, van der  Ende-Metselaar  H, Wilschut  J, Zhuang  X, Smit JM.",OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS Pathog   2008 ; 4:e1000244 ; PMID:19096510 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
EMBO J  2004 ; 23:728-38; PMID:14963486 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  2000 ; 269:37- 46; PMID:10725196 ; http://dx.doi.org/10.1006/ viro.1999.0172 126.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2010 ; 84:5730 - 40; PMID:20335260 ; http://dx.doi.org/10.1128/ JVI.00170-10 127.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Nature  2004 ; 427:313- 9; PMID :14737159 ; http://dx.doi.org/10.1038/ nature02165 128.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2009 ; 83:4338 -44; PMID:19244332 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2002 ;  76:3784 -90; PMID:11907218 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS Pathog  2007 ;  3:e20; PMID:17305426 ; http://dx.doi.org/10.1371/ journal.ppat.0030020132.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Adv Virus Res 2003 ; 59:23-61;  PMID:14696326 ; http://dx.doi.org/10.1016/ S0065-3527(03)59002-9 133.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Adv Virus Res 2003 ; 59:99-140; PMID:14696328 ;  http://dx.doi.org/10.1016/S0065-3527(03)59004-2 134.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2010 ; 84:10438 -47;  PMID:20686019 ; http://dx.doi.org/10.1128/ JVI.00986-10 135.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Cell 2010 ; 141:799-811;  PMID:20510927 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Cell Host Microbe  2009 ; 5:365-75; PMID :19380115 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
EMBO J 2003 ; 22:2604 -13;  PMID:12773377 ; http://dx.doi.org/10.1093/emboj/ cdg270 139.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2007 ; 81:6141-5; PMID:17376919 ;  http://dx.doi.org/10.1128/JVI.00037-07 140.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2002 ; 76:5480 - 91; PMID:11991976 ; http://dx.doi.org/10.1128/ JVI.76.11.5480-5491.2002 141.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 1991 ;  72:1323 -9; PMID:1710648 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2009 ; 83:12101 -7; PMID:19759134 ;  http://dx.doi.org/10.1128/JVI.01637-09,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Science  2008 ;  319:1834 -7; PMID:18369148 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Structure   2004 ; 12:1607 -18; PMID:15341726 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2010 ; 84:8353 - 8; PMID:20519400 ; http://dx.doi.org/10.1128/ JVI.00696-10 149.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Antiviral Res  2009 ; 81:6- 15; PMID:18796313 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Opin Drug Discov 2012 ;  7:417-28; PMID:22439769 ; http://dx.doi.org/10.15 17/17460441.2012.673579 151.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Antiviral Res  2010 ; 85:450- 62; PMID:20060421 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Future Med Chem 2009 ; 1:327- 44; PMID:20165556 ; http://dx.doi.org/10.4155/ fmc.09.27 153.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol Immunol  2002 ; 267:139-52; PMID:12082987 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Opin Biol Ther 2008 ;  8:95-106; PMID :18081539 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Opin Infect Dis 2010 ; 23:426-31;  PMID:20581670 ; http://dx.doi.org/10.1097/ QCO.0b013e32833c1d01 156.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Rev Vaccines 2011 ; 10:355-64;  PMID:21434803 ; http://dx.doi.org/10.1586/erv.11.7 157.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS  Negl Trop Dis 2012 ; 6:e1834 ; PMID:23029592 ;  http://dx.doi.org/10.1371/journal.pntd.0001834 158.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ ucm123761.pdf  (accessed 2013).,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  1997 ; 15:1494 - 502; PMID:9330458 ; http://dx.doi.org/10.1016/ S0264-410X(97)00195-3 162.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Rev Vaccines 2008 ;  7:689-93; PMID:18564023 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis 1990 ; 161:878-82; PMID:2324539 ;  http://dx.doi.org/10.1093/infdis/161.5.878 164.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet   1990 ; 335:972-3; PMID:1970043 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2010 ; 28:2436 -41; PMID:20060946 ;  http://dx.doi.org/10.1016/j.vaccine.2009.12.080 169.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect  Dis 1995 ; 171:1074 ; PMID:7706798 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Eur J Neurol 1998 ;  5:479-85; PMID:10210877 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2010 ; 29:58- 64; PMID:20970488 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  1996 ; 348:202- 3; PMID:8684185 ; http://dx.doi.org/10.1016/ S0140-6736(05)66156-9 173.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2000 ; 18:1830 -6; PMID:10699331 ;  http://dx.doi.org/10.1016/S0264-410X(99)00403-X 175.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   1997 ; 15:1239 -43; PMID:9286050 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect Dis 1997 ; 24:265- 6; PMID:9114160 ; http://dx.doi.org/10.1093/ clinids/24.2.265 178.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  1991 ;  337:1044 ; PMID:1673198 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet   1991 ; 338:881-2; PMID:1681228 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Neurol Neurosurg Psychiatry  1995 ; 59:316-7; PMID:7673966 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Pediatr Infect Dis J 2003 ; 22:829-31;  PMID:14506377 ; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Clin Neurosci  2008 ; 15:1315 -22; PMID:18976924 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Top Microbiol  Immunol  2002 ; 267:75-90; PMID:12083001 ;  http://dx.doi.org/10.1007/978-3-642-59403-8_4 184.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2000 ;  18(Suppl 2 ):33-5; PMID:10821971 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2010 ;  28:3635 -41; PMID:20226891 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  1999 ; 17:2259 -64; PMID:10403593 ;  http://dx.doi.org/10.1016/S0264-410X(99)00006-7 194.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis 1998 ; 177:221-3;  PMID:9419193 ; http://dx.doi.org/10.1086/517358 196.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet   1996 ; 347:1583 -6; PMID:8667866 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet   2001 ; 358:791-5; PMID:11564484 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2008 ; 26:1638 - 43; PMID:18294743 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  2005 ; 366:1375 -8; PMID :16226615 ;  http://dx.doi.org/10.1016/S0140-6736(05)67567-8 201.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis  1997 ; 176:1366 -9; PMID:9359740 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect Dis  2010 ; 50:1155 -64; PMID:20218889 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Curr Infect Dis Rep 2010 ; 12:174- 80; PMID:21308526 ; http://dx.doi.org/10.1007/ s11908-010-0098-z 204.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2012 ; 30:2329 -35;  PMID:22306856 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2012 ; 30:5967 - 72; PMID:22841478 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2007 ; 25:3445 - 53; PMID:17241714 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   2001 ; 19:4557 -65; PMID:11483284 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Rev Vaccines 2009 ; 8:1501 - 11; PMID:19863241 ; http://dx.doi.org/10.1586/ erv.09.112 210.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Drugs   2009 ; 69:115-22; PMID:19192940 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect Dis 2000 ; 30(Suppl  3):S266 -70; PMID:10875797 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Immunol Cell Biol  2004 ;  82:497-505; PMID :15479435 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Adv Drug Deliv Rev 1998 ; 32:155- 72; PMID:10837642 ; http://dx.doi.org/10.1016/ S0169-409X(98)00008-8 216.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 2010 ; 91:1407- 17; PMID:20130134 ;  http://dx.doi.org/10.1099/vir.0.019190-0 217.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2008 ; 26:4382 - 6; PMID:18599165 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2009 ; 27:2188 - 93; PMID:19200452 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  2007 ; 370:1847 - 53; PMID:18061060 ; http://dx.doi.org/10.1016/ S0140-6736(07)61780-2 220.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis 2008 ; 198:493-9;  PMID:18588481 ; http://dx.doi.org/10.1086/590116 221.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   2010 ; 28:6463 -9; PMID:20673824 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2011 ; 29:8669 -76;  PMID:21907747 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2010 ; 28:5197 -202; PMID:20541581 ;  http://dx.doi.org/10.1016/j.vaccine.2010.05.069 224.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect Dis  2012 ; 55:825-34; PMID:22696017 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2008 ; 26:6151- 6; PMID:18804132 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2009 ; 27:4483 - 9; PMID:19486955 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Opin Biol Ther  2012 ; 12:1251 -63; PMID:22775524 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Expert Rev Vaccines  2004 ; 3:243-8; PMID :15176941 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   2010 ; 28:632-49; PMID:19808029 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Biologicals  2005 ; 33:131- 44; PMID :15975826 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2000 ; 74:1742 - 51; PMID:10644345 ; http://dx.doi.org/10.1128/ JVI.74.4.1742-1751.2000 236.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  1999 ; 17:1869 - 82; PMID:10217584 ; http://dx.doi.org/10.1016/ S0264-410X(98)00487-3 237.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1999 ; 257:363- 72; PMID:10329547 ; http://dx.doi.org/10.1006/ viro.1999.9695 238.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis  2003 ; 188:1213 -30; PMID:14551893 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2002 ;  20:1004 -18; PMID:11803060 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2010 ; 28:7993 -8000 ;  PMID:20934459 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Hum Vaccin  2010 ; 6:1038 - 46; PMID:21150279 ; http://dx.doi.org/10.4161/ hv.6.12.13057 242.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Pediatr  Infect Dis J 2010 ; 29:1111-7; PMID:20856164 ;  http://dx.doi.org/10.1097/INF.0b013e3181f68e9c 243.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Hum Vaccin  Immunother  2012 ; 8:929-37; PMID:22777096 ;  http://dx.doi.org/10.4161/hv.20071 244.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   2009 ; 27:6905 -9; PMID:19761840 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virus Res  1996 ; 43:91-6; PMID:8822638 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 1989 ;  70:2037 -49; PMID:2549181 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2003 ; 77:3487 - 94; PMID:12610124 ; http://dx.doi.org/10.1128/ JVI.77.6.3487-3494.2003 254.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1989 ;  173:674-82; PMID:2688300 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2000 ; 74:4244 -52;  PMID:10756038 ; http://dx.doi.org/10.1128/ JVI.74.9.4244-4252.2000 257.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  1997 ; 227:353- 60; PMID:9018134 ; http://dx.doi.org/10.1006/ viro.1996.8331 258.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2001 ; 75:2204 - 12; PMID:11160724 ; http://dx.doi.org/10.1128/ JVI.75.5.2204-2212.2001 259.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology   1992 ; 190:454-8; PMID:1326813 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology   1991 ; 180:294-305; PMID:1845826 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   1999 ; 17:261-8; PMID:9987162 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virol J  2012 ; 9:204; PMID:22985466 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2000 ; 19:483-91;  PMID:11027812 ; http://dx.doi.org/10.1016/ S0264-410X(00)00191-2 268.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2008 ;  26:5802 -7; PMID:18786591 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virology  2000 ; 268:49-55;  PMID:10683326 ; http://dx.doi.org/10.1006/ viro.1999.0142 271.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis  2002 ;  185:1-12; PMID:11756975 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Immunol Lett  2010 ; 129:23- 31; PMID:20064558 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS One  2012 ;  7:e34602 ; PMID:22493704 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2009 ; 83:4766 -77; PMID:19264772 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2011 ; 85:9847 -53; PMID:21697481 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Emerg Infect Dis 2010 ; 16:876-8; PMID:20409392 ;  http://dx.doi.org/10.3201/eid1605.091055 280.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Virol J 2010 ; 7:127; PMID:20546562 ;  http://dx.doi.org/10.1186/1743-422X-7-127 281.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol  2004 ; 85:1625 -31; PMID:15166447 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Emerg Infect Dis 2011 ; 17:2354 - 6; PMID:22172307 ; http://dx.doi.org/10.3201/ eid1712.110914 283.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Emerg Infect Dis  2008 ; 14:1762 -5; PMID:18976565 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine   2011 ; 29:2127 -30; PMID:21237278 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2011 ; 29:5925 -31; PMID:21723353 ;  http://dx.doi.org/10.1016/j.vaccine.2011.06.062 287.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Hum Vaccin  2010 ; 6:906-14;  PMID:20864814 ; http://dx.doi.org/10.4161/ hv.6.11.12854288.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
PLoS One   2011 ; 6:e16418 ; PMID:21283590 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Biologicals  2008 ; 36:111-6; PMID:17892945 ;  http://dx.doi.org/10.1016/j.biologicals.2007.07.002 290.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Epidemiol Infect  1997 ; 119:79-83;  PMID:9287947 ; http://dx.doi.org/10.1017/ S095026889700753X 291.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Am J Trop Med Hyg 2010 ; 82:930-6;  PMID:20439978 ; http://dx.doi.org/10.4269/ ajtmh.2010.09-0676 292.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Clin Infect  Dis 2002 ; 35:183-8; PMID:12087525 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Travel Med  2009 ; 16:200-3; PMID:19538582 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Microbes Infect 2011 ; 13:312- 21; PMID:21238600 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Vaccine  2013 ; 31:461- 71; PMID :23153447 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis 1987 ; 155:797- 9; PMID:3029244 ; http://dx.doi.org/10.1093/ infdis/155.4.797 300.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Lancet  2003 ; 361:821- 6; PMID:12642049 ; http://dx.doi.org/10.1016/ S0140-6736(03)12709-2 301.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2002 ; 76:4901 -11;  PMID:11967307 ; http://dx.doi.org/10.1128/ JVI.76.10.4901-4911.2002,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Infect Dis 1985 ; 151:1093 - 9; PMID:2987367 ; http://dx.doi.org/10.1093/ infdis/151.6.1093 303.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
Trans R Soc Trop Med Hyg 2002 ; 96:173-8;  PMID:12055808 ; http://dx.doi.org/10.1016/ S0035-9203(02)90294-4 304.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2008 ; 82:7009 -21; PMID:18480437 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol 2011 ; 85:5446 - 55; PMID:21450826 ; http://dx.doi.org/10.1128/ JVI.02611-10 311.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 2009 ; 90:818-26;  PMID:19264621 ; http://dx.doi.org/10.1099/ vir.0.008045-0 313.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Gen Virol 1996 ; 77:705-14; PMID:8627259 ;  http://dx.doi.org/10.1099/0022-1317-77-4-705 314.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
RNA  2008 ; 14:1791 - 813; PMID:18669441 ; http://dx.doi.org/10.1261/ rna.993608317.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Virol  2009 ; 83:7909 -30; PMID:19494005 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
J Microbiol 2012 ;  50:698-706; PMID:22923123 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/ed/hvi-10-263.PMC4185882.pdf
"4,16 -19 The 13 -valent conjugate vaccine, recently indicated for the  immunization of all the ages, has showed adequate safety and  *Correspondence to: Giorgio Liguori; Email: giorgio.liguori@uniparthenope.it Submitted: 07/31/2013; Revised: 10/09/2013; Accepted: 10/20/2013; Published Online: 11/01/2013http://dx.doi.org/10.4161/hv.26888Adult immunization with 13 -valent pneumococcal  vaccine in Campania region, South Italy An economic evaluation Giorgio Liguori1,*, antonino Parlato2, alessandro s anduzzi Zamparelli3, Patrizia Belfiore1, Francesca Gallé1, Valeria Di Onofrio1,  carla Riganti4, Bruno Zamparelli5, and s ocietà Italiana di Health Horizon s canning ( sIHHs ) 1chair of Hygiene and e pidemiology; Department of s tudies of Institutions and Territorial s ystems; University of Naples “Parthenope”; Naples, Italy; 2complex Operative Unit  “epidemiology and Prevention”; Local Health authority N a2 Nord; Naples, Italy; 3complex Operative Unit of the hospital Monaldi “ second Division of Respiratory Diseases”;  University of Naples Federico II; Naples, Italy; 4General Hospital “Federico II”-Institutional Relationships Hospitals and Local Health authorities of c ampania Region; Naples,  Italy; 5“ss annunziata”-“ santobono-Pausilipon ” Hospital; Naples, Italy Keywords:  pneumococcal diseases, conjugate vaccine, adult immunization, economic evaluation, budget impact analysis Abbreviations:  Spn, Streptococcus pneumoniae ; CAP, community -acquired pneumonia; HR, high risk; COPD, chronic obstructive  pulmonary disease; PCV13, 13 -valent pneumococcal conjugated vaccine; PPV23, 23 -valent pneumococcal polysaccharide vaccine;  FDA, Food and Drugs Administration; EMA, European Medicine Agency; BIA, budget impact analysis; ISTAT, National Institute  for Statistics (Istituto Nazionale di Statistica); SDO, Scheda di Dimissione Ospedaliera Pneumococcal pneumonia has a high clinical burden in terms of morbidity, mortality and hospitalization rate, with  heavy implications for worldwide health systems.",Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Thorax 2012; 67:71 - 9; PMID:20729232 ; http://dx.doi.org/10.1136/ thx.2009.129502 2.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892 .,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Vaccine  2010 ; 28:4955 - 60; PMID:20576535 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
"Which pneumococcal serogroups cause the most  invasive disease: implications for conjugate vaccine  formulation and use, part I. Clin Infect Dis 2000 ;  30:100-21; PMID:10619740 ; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Health Policy  2009 ; 89:225-38;  PMID:18639952 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
J Infect 2003 ; 46:78- 86; PMID:12634068 ; http://dx.doi.org/10.1053/ jinf.2002.11138.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Diabetes Care  2000 ; 23:95-108; PMID:10857977 ;  http://dx.doi.org/10.2337/diacare.23.1.95 10.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Vaccine  2008 ; 26:4947 - 54; PMID:18662735 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Vaccine   2011 ; 29:3398 -412; PMID:21397721 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at: http://www.salute.gov.it/ imgs/C_17_pubblicazioni_1721_allegato.pdf 14.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at: http://www.salute.gov.it/ imgs/C_17_normativa_78_allegato.pdf 15.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available  at: http://www.trovanorme.salute.gov.it/renderNo rmsanPdf?anno=0&codLeg=34861&parte=1%20&serie=16.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
BMC Infect Dis 2010 ; 10:73; PMID:20298596 ;  http://dx.doi.org/10.1186/1471 -2334 -10-73 17.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Clin Infect Dis  2006 ; 43:860 -8; PMID:16941367 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Vaccine  2011 ; 29:5195 -202;  PMID:21619909 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Respirology   2006 ; 11:523-32; PMID:16916323 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Hum  Vaccin Immunother  2013 ; 9; PMID:23295824 ;  http://dx.doi.org/10.4161/hv.2326825.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at: http://www.arsan.campania.it/ 27.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Thorax   2012 ; 67:540 -5; PMID:22374921 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Pediatr Infect Dis J  2002 ; 21:810-5; PMID:12352800 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at: http://demo.istat.it 30.,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
Available at: http://www.agenas.it/index.htm,Non-OADS,/arxiv_data1/oa_pdf/56/6c/hvi-10-492.PMC4185884.pdf
"13 We recently reported  the safety of and immunological and clinical responses to a  *Correspondence to: Shiro Suzuki; Email: shiro-s@med.nagoya-u.ac.jp Submitted: 09/11/2013; Revised: 10/26/2013; Accepted: 11/15/2013; Published Online: 11/21/2013http://dx.doi.org/10.4161/hv.27217Significant clinical response of progressive  recurrent ovarian clear cell carcinoma to glypican- 3-derived peptide vaccine therapy Two case reports shiro s uzuki1,*, Kiyosumi shibata1, Fumitaka Kikkawa1, and t etsuya Nakatsura2 1Department of o bstetrics and Gynecology; Nagoya University Graduate s chool of Medicine; s howa-ku, Nagoya Japan; 2Division of Cancer Immunotherapy;   exploratory o ncology Research and Clinical t rial Center; National Cancer Center; Kashiwa, Chiba Japan Keywords:  Glypican-3, peptide vaccine, refractory disease, ovarian clear cell carcinoma, clinical response Abbreviations:  HLA, human leukocyte antigen; UMIN-CTR, University Hospital Medical Information Network Clinical Trials  Registry; CT, computed tomography; GMP, Good Manufacturing Practice; RECIST, Response Evaluation Criteria in Solid  Tumors; PR, partial response; 18F-FDG PET, Fluorine-18-fluorodeoxyglucose positron emission tomography; IFN- γ, interferon- γ;  PBMC, peripheral blood mononuclear cell Carcinoembryonic antigen glypican-3 (G pC3) is expressed by >40% of ovarian clear cell carcinoma (CCC) and is a  promising immunotherapeutic target.",Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Gynecol Oncol  1989; 32:342-9;  PMID:2920955 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Cancer   2000 ; 88:2584 -9; PMID:10861437 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Gynecol Oncol  2007 ; 105:404-8;  PMID:17292461 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Int J Clin Oncol 2013 ; 18:556-7;  PMID:22552358 ; http://dx.doi.org/10.1007/ s10147-012-0404-x 6.,OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Int J Gynecol Cancer 2012 ; 22:801- 6; PMID:22617480 ; http://dx.doi.org/10.1097/ IGC.0b013e31825401457.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Biochem Biophys Res Commun   2003 ; 306:16-25; PMID:12788060 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Clin Cancer Res 2004 ; 10:6612 -21;  PMID:15475451 ; http://dx.doi.org/10.1158/1078- 0432.CCR-04-0348 9.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Int J Cancer 2000 ; 89:418-22;  PMID:11008203 ; http://dx.doi.org/10.1002/1097- 0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I 10.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
J Pediatr Hematol Oncol  2001 ; 23:496-9; PMID:11878776 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Mod Pathol  2008 ; 21:817-25; PMID:18469798 ;  http://dx.doi.org/10.1038/modpathol.2008.37 12.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Clin Cancer Res 2006 ;  12:2689 -97; PMID:16675560 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
Cancer Sci  2011 ; 102:622-9; PMID:21205085 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
J Clin Oncol 2012 ;  30:2691 -7; PMID:22614989 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/03/35/hvi-10-338.PMC4185885.pdf
"Experts have expressed some con - cern about the use of adjuvant in influenza vaccination due to the recently reported association between adjuvanted influenza Cross-conservation of T-cell epitopes Now even more relevant to (H7N9) influenza vaccine design Anne S De Groot1,2,*, Lenny Moise1,2, Rui Liu1, Andres H Gutierrez1, Frances Terry2, Ousmane A Koita3,4, Ted M Ross5,   and William Martin2 1Institute for Immunology and Informatics; University of Rhode Island; Providence, RI USA; 2EpiVax, Inc.; Providence, RI USA; 3Laboratory of Applied  Molecular Biology; University of Bamako; Bamako, Mali; 4Project SEREFO-NIAID (Centre de Recherche et de Formation sur le VIH/Sida et la Tuberculose- Institut National des Maladies Infectieuses et Allergiques); University of Science, Techniques and Technologies of Bamako; Bamako, Mali; 5Vaccine and Gene  Therapy Institute of Florida; Port St. Lucie, FL USA Keywords:  H7N9, H1N1, avian-origin,  influenza, genome, recombinant protein, hemagglutinin, cell-mediated immunity, T-cell epitope, T cell, CD4+ T cell,  T helper Abbreviations: H7N9, avian origin  influenza A/Anhui/1/2013 and other similar avian-origin strains; HA, hemagglutinin; H7-HA, HA derived from H7N9; H1-HA, HA derived from H1N1; CFR, case fatality rate; IAV, influenza A virus; GISAID, Global Initiative on Sharing Avian Influenza Data *Correspondence to: Anne S De Groot;   Email: AnnieD@EpiVax.com Submitted: 02/01/2014Accepted: 02/06/2014 Published Online: 02/13/2014http://dx.doi.org/10.4161/hv.28135",Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
"Used with permis - sion from http://virologydownunder.blogspot.com/2013/09/h7n9-in-wild-birdsa-review-of-litera - ture.html, accessed 1 February 2014.",Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Hum Vaccin Immunother  2013; 9:950-6;  PMID:23807079 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from: http://www.cdc.gov.tw/eng - lish/info.aspx?treeid=bc2d4e89b154059b&nowtreeid=ee0a2987cfba3222&tid=03ECBB84CD82E4FB .,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
PLoS One 2012; 7:e33723; PMID:22470463 ; http://dx.doi.org/10.1371/jour - nal.pone.00337236.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from: http://platform.gisaid.org 7.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Sci Transl Med  2013; 5:85ra68;  PMID:23677594 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2013; 31:4305-13;  PMID:23891795 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from: http://tinyurl.com/ Dvt-of-Vaccines-Chapt-3 12.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2009; 27:6471-9; PMID:19559119 ;  http://dx.doi.org/10.1016/j.vaccine.2009.06.018 13.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2011; 29:501-11;  PMID:21055490 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2009; 27:5740-7;  PMID:19660593 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Hum Vaccin  2010; 6:161-3;  PMID:20431339 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Virol 2010; 84:3312-9;  PMID :20071564 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Clin Vaccine Immunol 2010;  17:1998-2006;  PMID:20962210 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from: http://www.novartis.com/news - room/media-releases/en/2013/1743124.shtml 21.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
N  Engl J Med 2013; 369:2564-6; PMID:24224560 ;  http://dx.doi.org/10.1056/NEJMc1313186 22.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Emerg Infect Dis 2014;   20:192-200;  PMID:24447423 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2006; 24:1159-  69; PMID:16213065 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
"Available from: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr6207a1.htm 26. de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA.",Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Virol 2005;  79:12401-7;  PMID:16160167 ; http://dx.doi.org/   10.1128/JVI.79.19.12401-12407.2005 27.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2009; 27:1889-97;  PMID:19368768 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
"Atlanta,  Georgia: Centers for Disease Control and Prevention;  2013 Feb 26 [cited 2014 Jan 29] Available from:  http://cdc.gov/vaccinesafety/Concerns/h1n1_narco - lepsy_pandemrix.html 29.",Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from: http://virologydownunder.blogspot.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from from: http://www.who.int/influenza/ human_animal_interface/influenza_h7n9/03_ReportWebH7N9Number.pdf 33.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
N Engl J Med 2014; 370:520- 32; PMID:23614499 ; http://dx.doi.org/10.1056/ NEJMoa1304617 34.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Clin Virol 2013; 58:568-  70; PMID:24091087 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Virol 2014; 88:1502- 12; PMID:24227867 ; http://dx.doi.org/10.1128/ JVI.02959-13 36.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Nature 2013; 501:560- 3; PMID:23925116 ; http://dx.doi.org/10.1038/ nature12476 37.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vet Microbiol 2010; 146:200-  8; PMID:20605691 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
PLoS Pathog  2013; 9:e1003570;  PMID:24009503 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
PLoS Med 2007; 4:e13; PMID:17253899 ;  http://dx.doi.org/10.1371/journal.pmed.0040013 41.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available from:  http://cdc.gov/flu/news/first-human-h5n1-americas.htm 42.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Available  from: http://www.who.int/csr/don/2009_09_18/en/43.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Clin Microbiol Infect  2012; 18:976-81;  PMID:22221838 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Virol 2009; 83:5726- 34; PMID:19321609 ; http://dx.doi.org/10.1128/ JVI.00207-09 46.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
PLoS One 2008; 3:e1501; PMID :18231588 ;  http://dx.doi.org/10.1371/journal.pone.0001501 47.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
J Infect Dis 2010; 202:1011-20; PMID:20715930 ; http://dx.doi.org/10.1086/656188 48.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
BMJ  2009; 339:b3928;  PMID:19808768 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Vaccine 2011; 29:3299-309;  PMID:21349362 ;  http://dx.doi.org/10.1016/j.vaccine.2011.02.019 51.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Hum Vaccin Immunother 2013; 9:1598- 607; PMID:23846304 ; http://dx.doi.org/10.4161/ hv.25598 52.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Hum Vaccin  Immunother 2013; 9:2060-8; PMID:24045788 ;  http://dx.doi.org/10.4161/hv.26511 53.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
Hum Vaccin Immunother 2013; 9:1577-86;  PMID:23584251 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/5b/a3/hvi-10-256.PMC4185886.pdf
"18,19 It is generally observed that the antibody  *Correspondence to: Jun Yao, Email: jyao@cdc.zj.cn; Shichang Xia, Email: shchxia@cdc.zj.cn; Xiaofeng Liang, Email: Liangxf@hotmail.com Submitted: 06/18/2013; Revised: 10/15/2013; Accepted: 10/24/2013; Published Online: 11/05/2013http://dx.doi.org/10.4161/hv.26936The effects of different dosage levels of hepatitis  B vaccine as booster on anti-HBs-negative  children 5–15 y after primary immunization; China,  2009–2010 Yongdi c hen1,†, Huakun Lv1,†, Hua Gu1,†, Fujiang c ui2, Fuzhen Wang2, Jun Yao1,*, shichang Xia1,*, and Xiaofeng Liang2,* 1Zhejiang Provincial c enter for Disease c ontrol and Prevention; Hangzhou, PR c hina; 2chinese National c enter for Disease c ontrol and Prevention; Beijing, PR c hina †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"Hepatitis B virus epidemiology, disease  burden, treatment, and current and emerging pre - vention and control measures.J Viral Hepat2004; 11:97-107;  PMID:14996343 ; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Int J Epidemiol2005; 34:1329-39; PMID:16249217 ;  http://dx.doi.org/10.1093/ije/dyi206 4.,OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"LiangX, BiS, YangW, WangL, CuiG, CuiF, ZhangY, LiuJ, GongX, ChenY, et al.Epidemiological serosur - vey of hepatitis B in China--declining HBV preva - lence due to hepatitis B vaccination.Vaccine2009;  27:6550-7;  PMID:19729084 ; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"LiangX, BiS, YangW, WangL, CuiG, CuiF, ZhangY, LiuJ, GongX, ChenY, et al.Evaluation of the impact of  hepatitis B vaccination among children born during  1992-2005 in China.J Infect Dis2009; 200:39-47;  PMID:19469708 ; http://dx.doi.org/10.1086/599332 6.",OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Management of hepatitis B: 2000--summary of a work - shop.Gastroenterology2001; 120:1828-53;   PMID:11375963 ; http://dx.doi.org/10.1053/ gast.2001.24839 8.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Prevention of hepati - tis B virus infection in the United States: a  pediatric perspective.Pediatr Infect Dis J1992;  11:866-74;  PMID:1408488 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Inactivated hepatitis A vac - cine in Chinese patients with chronic hepati - tis B infection.Aliment PharmacolTher1999; 13:1445-9;  PMID:10571600 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Long-term efficacy of immunization against hepa - titis B virus in infants at high-risk analyzed by  polymerase chain reaction.Vaccine1999; 18:581- 7; PMID :10547415 ; http://dx.doi.org/10.1016/ S0264-410X(99)00320-5 15.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Immune response to hepatitis B vaccine in a group of  health care workers in Sri Lanka.Int J Infect Dis2013; 17:e1078-9;  PMID:23810225 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"ElrashidyH, ElbahrawyA, El-DidamonyG,  MostafaM, GeorgeNM, ElwassifA, Saeid  MohamedAG, ElmestikawyA, MorsyMH, HashimA,  et al.Antibody levels against hepatitis B virus after  hepatitis B vaccination in Egyptian diabetic children and adolescents.Hum VaccinImmunother2013; 9:  (Forthcoming);  PMID:23787761 ; http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Hepatitis B vaccina - tion in infancy in The Gambia: protection against carriage at 9 years of age.Vaccine1999; 17:2946-50; PMID:10462228 ; http://dx.doi.org/10.1016/ S0264-410X(99)00178-4 18.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"HsuHY, ChangMH, LiawSH, NiYH, ChenHL.Changes of hepatitis B surface antigen variants  in carrier children before and after universal vac - cination in Taiwan.Hepatology1999; 30:1312-7;  PMID:10534356 ; http://dx.doi.org/10.1002/ hep.510300511 22.",Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Bivalent inactivated hepatitis A and recom - binant hepatitis B vaccine.Expert Rev Vaccines2007; 6:891-902;  PMID:18377352 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
European Consensus Group  on Hepatitis B Immunity.Lancet2000; 355:561-5; PMID:10683019 ; http://dx.doi.org/10.1016/ S0140-6736(99)07239-6 24.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Long-term persistence of immunity after vaccination of pre-adolescents with low doses of a recombinant  hepatitis B vaccine.Hum VaccinImmunother2013;  9:1685-90;  PMID:23744506 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Long-term anti- HBs antibody persistence following infant vac - cination against hepatitis B and evaluation of  anamnestic response: A 20-year follow-up study in  Thailand.Hum VaccinImmunother2013; 9:1679- 84; PMID:23732904 ; http://dx.doi.org/10.4161/ hv.24844 28.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Immunity to hepatitis B virus (HBV)  infection two decades after implementation of uni - versal infant HBV vaccination: association of detect - able residual antibodies and response to a single HBV  challenge dose.Clin Vaccine Immunol2013; 20:559- 61; PMID:23408522 ; http://dx.doi.org/10.1128/ CVI.00694-12 33.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
The effects of booster vaccination  of hepatitis B vaccine on anti-HBV surface antigen  negative children 11-15 years after primary vaccina - tion.Hum Vaccin2011; 7:1055-9;  PMID:21989290 ;  http://dx.doi.org/10.4161/hv.7.10.15990 35.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"LuCY, NiYH, ChiangBL, ChenPJ, ChangMH, ChangLY, SuIJ, KuoHS, HuangLM, ChenDS, et al.Humoral and cellular immune responses to a  hepatitis B vaccine booster 15-18 years after neona - tal immunization.J Infect Dis2008; 197:1419-26; PMID:18444799 ; http://dx.doi.org/10.1086/587695 36.",OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"Hepatitis  B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in  infancy, 20 years subsequent to national hepa - titis B vaccination.Vaccine2007; 25:8085-90;   PMID:17920732 ; http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Improved anamnestic  response among adolescents boosted with a higher  dose of the hepatitis B vaccine.Vaccine2010; 28:2860- 4; PMID :20153793 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
Booster immuniza - tion of low- and non-responders after a standard  three dose hepatitis B vaccine schedule--results of a  post-marketing surveillance.Vaccine1997; 15:349- 52; PMID:9141203 ; http://dx.doi.org/10.1016/ S0264-410X(96)00205-8,Non-OADS,/arxiv_data1/oa_pdf/a1/5f/hvi-10-498.PMC4185892.pdf
"In contrast to B-cell epitopes, little information is available on specific T-cell epitopes,  *Correspondence to: E Jane Homan; Email: jane_homan@iogenetics.com Submitted: 09/02/2013; Revised: 10/22/2013; Accepted: 11/09/2013; Published Online: 11/25/2013http://dx.doi.org/10.4161/hv.27139Are cases of mumps in vaccinated patients  attributable to mismatches in both vaccine T-cell  and B-cell epitopes?",Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Clin Infect Dis 2008; 47:1458-67;  PMID:18959494 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2011;  204:1413-22;  PMID:21933874 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Vaccine 2009; 27:6186- 95; PMID :19815120 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Emerg Infect Dis 2007; 13:12-7; PMID:17370510 ; http://dx.doi.org/10.3201/ eid1301.060649 7.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
N Engl J Med 2012; 367:1704-13; PMID:23113481 ;  http://dx.doi.org/10.1056/NEJMoa1202865 8.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Pediatr  Infect Dis J 2013; 32:374-80; PMID:23099425 ;  http://dx.doi.org/10.1097/INF.0b013e318279f593 9.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Gen Virol 1993; 74:917-20;  PMID:8492099 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Clin Infect Dis 2007; 45:459-66; PMID:17638194 ; http://dx.doi.org/10.1086/520028 14.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Pediatr Infect Dis J 2013; 32:381- 2; PMID:23552675 ; http://dx.doi.org/10.1097/ INF.0b013e3182809dda 15.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Arch Virol 2005; 150:1903- 9; PMID:15959834 ; http://dx.doi.org/10.1007/ s00705-005-0563-416.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Virology 2007;  359:436-46;  PMID :17081582 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Virus Res 1990;  17:119-29;  PMID:1705373 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Virus Res  2001; 74:133-7;  PMID:11226581 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Vaccine 2006; 24:2662-8;  PMID:16309801 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2008; 198:508-15;  PMID:18558869 ; http://dx.doi.org/10.1086/590115 22.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Virol 2012; 86:615-20; PMID:22072778 ;  http://dx.doi.org/10.1128/JVI.06125-11 23.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Epidemiol Infect 2013;  141:1298-309;  PMID:22954346 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2008; 197:950-6;  PMID:18419470 ; http://dx.doi.org/10.1086/528993 25.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2009; 200:888-99;  PMID:19659440 ; http://dx.doi.org/10.1086/605410 26.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Clin Vaccine Immunol 2011; 18:35- 42; PMID:21047998 ; http://dx.doi.org/10.1128/ CVI.00284-10 27.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2008; 197:1662-8; PMID:18419346 ;  http://dx.doi.org/10.1086/588197 28.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis 2007; 196:861-7; PMID:17703416 ;  http://dx.doi.org/10.1086/52102929.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Infect Dis  2008; 197:1669-75;  PMID:18419345 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
EMBO J 2007; 26:2137- 47; PMID :17396153 ; http://dx.doi.org/10.1038/ sj.emboj.7601660 31.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Cell Mol Life Sci 2011; 68:1491-502;  PMID:21387144 ; http://dx.doi.org/10.1007/ s00018-011-0657-y 34.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
PLoS One  2013; 8:e70115;  PMID:23922927 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
PLoS One 2011; 6:e26711;  PMID:22039539 ; http://dx.doi.org/10.1371/ journal.pone.0026711 37.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
"Biniossek ML, Nägler DK, Becker-Pauly C, Schilling O. Proteomic identification of protease cleavage  sites characterizes prime and non-prime specificity  of cysteine cathepsins B, L, and S. J Proteome Res  2011; 10:5363-73;  PMID:21967108 ; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Glycobiology  2004; 14:1229-46;  PMID :15175256 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Immunome  Res 2009; 5:4; PMID:19778434 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Exp Med  2003; 197:169-79;  PMID:12538657 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Proc Natl Acad Sci U S A 2010; 107:12192-7;  PMID:20547847 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Immunity 2008; 28:847-58; PMID:18549802 ;  http://dx.doi.org/10.1016/j.immuni.2008.04.018 45.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Nat Immunol 2003; 4:431- 2; PMID:12719734 ; http://dx.doi.org/10.1038/ ni0503-431 46.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Nature 2003; 421:852- 6; PMID:12594515 ; http://dx.doi.org/10.1038/ nature01441 47.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Immunol Methods  2006; 317:175-85;  PMID:17055526 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Infect Genet Evol 2008; 8:603-13; PMID :18508415 ;  http://dx.doi.org/10.1016/j.meegid.2008.04.007 51.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Immunome Res 2006; 2:2; PMID:16635264 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Chemom Intell Lab  Syst 2001; 58:109-30; http://dx.doi.org/10.1016/ S0169-7439(01)00155-1 53.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Immunogenetics 2011; 63:325-35;  PMID:21305276 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Mach Learn 1996; 24:123-40; http://dx.doi.org/10.1007/BF00058655 55.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
PLoS  Comput Biol 2008; 4:e1000107; PMID:18604266 ;  http://dx.doi.org/10.1371/journal.pcbi.1000107 56.,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
Biol Chem 2011; 392:961-71; PMID:21972973 ; http://dx.doi.org/10.1515/ BC.2011.162 58.,Non-OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
J Am Stat Assoc 1963; 48:236- 44; http://dx.doi.org/10.1080/01621459.1963.10500 845,OADS,/arxiv_data1/oa_pdf/36/a5/hvi-10-290.PMC4185895.pdf
"2 Every year, observational studies are conducted to assess the  current effectiveness of the seasonal influenza vaccination, and several have analyzed the effectiveness of vaccination during the  *Correspondence to: Rodrigo Jiménez-Garcia; Email: rodrigo.jimenez@urjc.es Submitted: 10/09/2013; Revised: 10/30/2013; Accepted: 11/11/2013; Published Online: 11/26/2013http://dx.doi.org/10.4161/hv.27152Coverage and predictors of vaccination against  2012/13 seasonal influenza in Madrid, Spain Analysis of population-based computerized immunization  registries and clinical records Rodrigo Jiménez-García1,*, María D es teban-Vasallo2, cr istina Rodríguez-Rieiro1, Valentín  her nandez-Barrera1,  Ma  Felicitas Domínguez-Berjón2, Pilar  ca rrasco Garrido1, an a Lopez de  an dres1, Moises  ca meno  he ras3,  Domingo Iniesta Fornies3, and Jenaro  as tray-Mochales2 1Preventive Medicine and Public he alth Department; Rey Juan ca rlos University; Madrid, sp ain; 2Department of ep idemiology;   Directorate of  he alth Promotion and Prevention; Ministry of  he alth;  c ommunity of Madrid; Madrid,  sp ain; 3Department of Prevention and promotion health;   Directorate of  he alth Promotion and Prevention; Ministry of  he alth;  c ommunity of Madrid; Madrid,  sp ain Keywords:  coverage, influenza; predictors, registries, vaccine Abbreviations:  ACM, Autonomous Community of Madrid ; EHSS, European Health Survey for Spain; ICPC, International  Classification for Primary Care; SNHS, Spanish National Health Survey We aim to determine 2012–13 seasonal influenza vaccination coverage.",Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
BMC Public Health 2007; 7:197; PMID:17686175 ;  http://dx.doi.org/10.1186/1471-2458-7-19,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Vaccine 2011; 29:5047-52;  PMID:21620915 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Gac Sanit 2012; 26:325-9; PMID:22284214 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
N Engl J Med 2007; 357:1373-81;  PMID:17914038 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
La  gripe [The flu] Available at: http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe.htm [Accessed 9 October 2013 11.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.msc.es/ciudadanos/proteccionSalud/vacunaciones/docs/recoVacunasAdultos.pdf  [Accessed 9 October 2013 12.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.menacorde.com/wordpress/wp-images/200510/InformeOficialGrip2005.pdf  [Accessed 9 October  2013 13.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t15/p419&file=inebase&L=0  [Accessed 9 October 2013 14.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
J Infect 2008; 57:472-80;  PMID:19010553 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Vaccine 2011; 29:6029-34; PMID:21704109 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Vaccine 2010; 28:6203-9; PMID:20650340 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://apps.who.int/gb/archive/pdf_files/WHA56/ea56r19.pdf  [Accessed 9 October 2013 18.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
COM(2009) 353/final/2.2011Available at: http://ec.europa.eu/health/ph_threats/com/Influenza/docs/seasonflu_rec2009_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
BMC Public Health 2012; 12:938; PMID:23113995 ;  http://dx.doi.org/10.1186/1471-2458-12-93 21.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Presse Med 2012; 41:e568-76; PMID:22795870 ;  http://dx.doi.org/10.1016/j.lpm.2012.05.01 22.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2012.htm  [Accessed 9 October  2013 23.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Expert Rev Vaccines 2009; 8:425-33; PMID:19348558 ; http://dx.doi.org/10.1586/ erv.09.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.cdc.gov/flu/professionals/vaccination/trends-summary.htm   [Accessed 9 October 2013 26.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Vaccine 2011; 29:7075-9; PMID:21777639 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733756886#r5  [Accessed 9  October 2013 28.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.madrid.org/cs/Satellite?c=PTSA_Multimedia_FA&cid=1142705226240&pagename=PortalSalud%2FPTSA_Multimedia_FA%2FPTSA_documentoWebeditpro .,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Infection 2010; 38:52-7; PMID:19904490 ; http://dx.doi.org/10.1007/ s15010-009-9069-30.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Hum Vaccin Immunother 2012; 8:107-18; PMID:22252000 ; http://dx.doi.org/10.4161/ hv.8.1.1827 31.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Winter season 2011/12 Available at: http://webarchive.nationalarchives.gov.uk/20130107105354/https://www.wp.dh.gov.uk/immunisation/files/2012/06/Flu-vaccine-uptake-GP-patients-2011.12.pdf  Accessed 30 October 2013 34.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Vaccine 2011; 29:2840-5; PMID:21334388 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Scand J Infect Dis 2006; 38:506-11; PMID:16798702 ;  http://dx.doi.org/10.1080/0036554050053289 37.,OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Health Serv Res 2005; 40:539-49;  PMID :15762906 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.ine.es/jaxi/menu.do?type=pcaxis&f ile=pcaxis&path=%2Ft20%2Fe245%2Fp04%2F%2Fa2012  [Accessed 9 October 2013 41.,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
Available at: http://www.madrid.org/cs/Satellite?cid=1162295633309&language=es&pagename=PortalSalud%2FPage%2FPTSA_pintarContenidoFinal&vest=1156329829913  [Accessed 9 October 2013,Non-OADS,/arxiv_data1/oa_pdf/db/72/hvi-10-449.PMC4185897.pdf
"9 At 2011 prices, the cost per influenza  *Correspondence to: Gábor Kovács; Email: gabor.kovacs@syreon.eu Submitted: 08/23/2013; Revised: 10/09/2013; Accepted: 10/19/2013; Published Online: 10/28/2013http://dx.doi.org/10.4161/hv.26886Medical and economic burden of influenza   in the elderly population in central   and eastern European countries Gábor Kovács1,*, Zoltán Kaló1, Karina Jahnz-Rozyk2, Jan Kyncl3, agn es cs ohan4, adr iana Pistol5, Mariya Leleka6,   Rafail Kipshakbaev7, Laure Durand8, and Bérengère Macabeo8 1sy reon Research Institute; Budapest, Hungary; 2Military Institute of Medicine; Warsaw, Poland; 3National Institute of Public Health; Department of Infectious Diseases  epi demiology; Prague,  cz ech Republic; 4Bela Johan National ce nter for ep idemiology; Budapest, Hungary; 5National Institute of Public Health; Bucuresti, Romania;   6I.",Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.who.int/ mediacentre/factsheets/2003/fs211/en/ .,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Am J Med 2008; 121:258-64;  PMID:18374680 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.who.int/csr/disease/swineflu/notes/briefing_20091222/en/.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
J Infect Dis 2006; 194(Suppl 2):S82-91; PMID:17163394 ; http://dx.doi.org/10.1086/507558 5.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
JAMA 2003; 289:179-86; PMID:12517228 ; http://dx.doi.org/10.1001/ jama.289.2.179 6.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2007; 25:5086-96;  PMID:17544181 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Clin Drug Investig 2012; 32:73-85;  PMID:22201294 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.euro.who.int/__data/assets/pdf_ file/0004/64966/E92560.pdf16.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Hum Vaccin Immunother 2012; 8:328-35; PMID:22327498 ;  http://dx.doi.org/10.4161/hv.18629 18.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.euro.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF 21.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.euroflu.org/cgi-files/bulletin_v2.cgi?display=1&code=467&bulletin=467 25.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: https://www.isirv.org/cgi-files/bulletin_v2.cgi?display=1&code=442&bulletin=442 26.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://venice.cineca.org/Final_Report_VENICE_Pandemic_Influenza_2009.pdf 27.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.ecdc.europa.eu/en/aboutus/ organisation/director%20speeches/ecdc-director--seasonal-influenza-ivw-2012oct10.pdf 28.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2002; 20:2562-78; PMID:12057614 ; http://dx.doi.org/10.1016/ S0264-410X(02)00154-8 29.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.who.int/influenza/patient_care/clinical/858-WHOGIPReport_A4_WEB_FA.pdf 30.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Anaesthesia 2009; 64:937-41;  PMID:19645759 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
BMC Public Health 2010; 10:650;  PMID:20979640 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
BMC Public Health 2006; 6:242; PMID:17018161 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.bls.gov/opub/ils/pdf/opbils83.pdf 37.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://annazavaritt.blog.ilsole24ore.com/files/making-the-business-case-2.pdf 38.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Hum Vaccin Immunother 2013; 9:144-52; PMID:23143775 ;  http://dx.doi.org/10.4161/hv.22231 42.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2012; 30:5714-20; PMID:22819720 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Int J Epidemiol 2007; 36:1319-26; PMID:17977871 ; http://dx.doi.org/10.1093/ije/ dym208 45.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2003; 21:1749-53; PMID:12686088 ; http://dx.doi.org/10.1016/ S0264-410X(03)00066-5 47.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2006; 24:6812-22; PMID:17034909 ;  http://dx.doi.org/10.1016/j.vaccine.2006.07.042 49.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Croat Med J 2011; 52:126-33; PMID:21495194 ; http://dx.doi.org/10.3325/ cmj.2011.52.126 50.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2012; 30:5222-8; PMID:22721901 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
2012 13:85.e17-23; http://dx.doi.org/10.1016/j.jamda.2011.02.008 52.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Croat Med J 2011; 52:126-33; PMID:21495194 ; http://dx.doi.org/10.3325/ cmj.2011.52.12653.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
BMC Public Health 2006; 6:249; PMID:17034625 ;  http://dx.doi.org/10.1186/1471-2458-6-249 54.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
BMC Infect Dis 2010; 10:99;  PMID:20403201 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Prev Med 2006; 42:240-6; PMID:16480761 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Expert Rev Pharmacoecon Outcomes Res 2006 ; 6 :215-27;  PMID:20528557 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Vaccine 2005; 23:1973-80;  PMID:15734070 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
Available from: http://www.euro.who.int/__data/assets/pdf_ file/0005/186863/Overview-of-SARI-Surveillance-Systems-final.pdf 69.,OADS,/arxiv_data1/oa_pdf/ae/b1/hvi-10-428.PMC4185899.pdf
"Rates of  IMD infection generally decline with age, although disease prevalence rises slightly during the teenage years, presumably due Routine vaccination against MenB Considerations for implementation Patricia Kaaijk1,*, Arie van der Ende2, and Willem Luytjes1 1National Institute for Public Health and the Environment (RIVM); Centre for Immunology of Infectious diseases and Vaccines; Bilthoven, the Netherlands;  2Academic Medical Centre (AMC); Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis; Amsterdam,   the Netherlands Keywords:  MenB, vaccination  strategy, epidemiology, strain variation, immunogenicity, vaccine safety, carriage *Correspondence to: Patricia Kaaijk;  Email: patricia.kaaijk@rivm.nl Submitted: 10/04/2013Accepted: 10/15/2013Published Online: 10/18/2013http://dx.doi.org/10.4161/hv.26816",Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Expert Opin Biol Ther  2011; 11:969-85;  PMID :21615224 ; http://dx.doi.org /10.1517/14712598.2011.585965 3.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Vaccine 2013; 31:2852- 61; PMID:23623866 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Wien Klin Wochenschr 2011; 123(Suppl 1):10- 4; PMID:21935643 ; http://dx.doi.org/10.1007/ s00508-011-0058-0 9.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Boletin epidemiologica semanal 2011;  Available via the Internet: http://revista.isciii.es/  public/journals/1/pdf_92.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Clin Infect Dis 2010; 50(Suppl 2):S54-65; PMID:20144017 ; http://dx.doi.org/10.1086/648966 13.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Clin Infect Dis 2010; 50:184-91;  PMID:20001736 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
BMC Infect Dis  2012; 12:202;  PMID:22928839 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
PLoS One  2012; 7:e50659;  PMID:23209803 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Surveillance report 2012; Available via the  Internet: http://www.surv.esr.cri.nz/PDF_surveil - lance/MeningococcalDisease/2012/2012AnnualRpt.pdf .,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Hum Vaccin Immunother 2012; 8:174-83;  PMID:22426368 ; http://dx.doi.org/10.4161/ hv.18500 20.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Vaccine  2011; 29:7100-6;  PMID:21803101 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Hum Vaccin 2008; 4:158-61; PMID:18388494 ;  http://dx.doi.org/10.4161/hv.4.2.4871 22.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Lancet 1983; 2:355-7; PMID:6135869 ;  http://dx.doi.org/10.1016/S0140-6736(83)90340-9 23.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Clin Vaccine Immunol  2007; 14:1062-9;  PMID:17634513 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
"Vaccine 2000; 18:1456- 66; PMID:10618543 ; http://dx.doi.org/10.1016/ S0264-410X(99)00423-5 26. van den Dobbelsteen GP, van Dijken HH, Pillai S,  van Alphen L. Immunogenicity of a combination  vaccine containing pneumococcal conjugates and  meningococcal PorA OMVs.",Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Vaccine 2007; 25:2491-6; PMID:17023098 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Clin Vaccine Immunol 2009; 16:1113-20; PMID:19553555 ; http://dx.doi.org/10.1128/ CVI.00118-09 29.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Vaccine  2011; 29:1413-20;  PMID:21199704 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Pediatr Infect Dis  J 2013; 32:364-71;  PMID:23114369 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
MBio 2013; 4:e00163-13;  PMID:23760461 ; http://dx.doi.org/10.1128/ mBio.00163-13 32.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Expert Rev Vaccines 2013; 12:505-17; PMID:23659299 ; http://dx.doi.org/10.1586/ erv.13.30 33.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
FEMS Microbiol Rev  2007; 31:89-96;  PMID:17168996 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Int J Med Microbiol 2011; 301:659-62; PMID:21992745 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Genome Biol Evol 2011; 3:1406-18;   PMID:22084315 ; http://dx.doi.org/10.1093/gbe/ evr119 36.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Proc Natl Acad Sci U S A 2010; 107:19490-5; PMID:20962280 ; http://dx.doi.org/10.1073/ pnas.1013758107 37.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
JAMA 2012; 307:573- 82; PMID:22318278 ; http://dx.doi.org/10.1001/ jama.2012.85 39.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Lancet 2012; 379:617- 24; PMID:22260988 ; http://dx.doi.org/10.1016/ S0140-6736(11)61713-3,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
"29th Annual Meeting  of the European Society for Paediatric Infectious  Diseases; The Hague, Netherlands; June 7–11,  2011 Available via internet: http://www.kenes.com/espid2011/cd/PDF/O219.pdf?zoom_highlightsub=p rymula#search= ”prymula 41.",Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Pediatr Infect Dis J 2013; 32:1116- 21; PMID:23958808 ; http://dx.doi.org/10.1097/ INF.0b013e31829cfff2 42.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
J Med Microbiol  2004; 53:821-32;  PMID :15314188 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
FEMS Microbiol  Rev 2007; 31:52-63; PMID:17233635 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Clin Infect Dis 2005; 40:899-902;  PMID :15736029 ; http://dx.doi.org/10.1086/428351 45.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
J Infect Dis  1998; 178:451-9;  PMID:9697726 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Vaccine  2013; 31:2638-46;  PMID:23566946 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
Hum Vaccin Immunother 2013; 9:1129- 38; PMID:23406816 ; http://dx.doi.org/10.4161/ hv.23888,Non-OADS,/arxiv_data1/oa_pdf/e6/b7/hvi-10-310.PMC4185901.pdf
"Furthermore, country-level VC data are internationally collected and compared in order to  *Correspondence to: Thorsten Rieck; Email: RieckT@rki.de Submitted: 08/22/2013; Revised: 10/22/2013; Accepted: 10/29/2013; Published Online: 11/05/2013http://dx.doi.org/10.4161/hv.26986Vaccination coverage among children   in Germany estimated by analysis   of health insurance claims data Thorsten Rieck1,2,*, Marcel Feig3, Tim e ckmanns3, Justus Benzler3, anette s iedler1, and Ole Wichmann1 1Immunization Unit; Robert Koch Institute; Berlin, Germany; 2charité-University Medicine Berlin; Berlin, Germany; 3surveillance Unit; Robert Koch Institute; Berlin, Germany Keywords:  vaccination coverage, vaccines, childhood, Germany, health services research Abbreviations:  ASHIP, Association of Statutory Health Insurance Physicians; CI, confidence interval; DIP, diphtheria vaccine;  HEPB, hepatitis B vaccine; HIB, Haemophilus influenzae type b vaccine; IQR, interquartile range; IPV, polio vaccine; KEE,  kindergarten entrance examinations; MCV, measles vaccine; MENC, meningococcal C vaccine; MMR, measles, mumps, rubella  vaccine; MUM, mumps vaccine; OLAP, online analytical processing technology; PCV, pneumococcal conjugate vaccine; PER,  pertussis vaccine; pp, percentage points; RUB, rubella vaccine; SEE, school entrance examinations; STIKO, Standing Committee  on Vaccination; TET, tetanus vaccine; U7, routine well-child check-up performed at 20-27 months; VAR, varicella vaccine;   VC, vaccination coverage In Germany, the national routine childhood immunization schedule comprises 12 vaccinations.",Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
Gesundheitswesen 2012; 74:49-58; PMID:22006226 ;  http://dx.doi.org/10.1055/s-0031-1276901 4.,Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
Bundesgesundheitsblatt Gesundheitsforschung  Gesundheitsschutz 2009; 11:1019-28; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
BMC Public  Health 2008; 8:82; PMID:18312683 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
BMC Public Health 2010; 10:502; PMID:20723217 ;  http://dx.doi.org/10.1186/1471-2458-10-502 9.,Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
Pediatr Infect Dis J 2007; 26:782- 6; PMID:17721371 ; http://dx.doi.org/10.1097/ INF.0b013e318060aca1 13.,OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
Vaccine 2011; 29:7949- 59; PMID:21872633 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
J Infect  Dis 2011; 204(Suppl 1):S353-65; PMID:21666185 ;  http://dx.doi.org/10.1093/infdis/jir067 21.,OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
Gesundheitswesen 2010; 72:340-6;  PMID:20446216 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/31/0b/hvi-10-476.PMC4185903.pdf
"In the course of the clinical development of RV1, the serum IgA assay has been  *Correspondence to: Brigitte Cheuvart; Email: brigitte.cheuvart@gskbio.com Submitted: 05/21/2013; Revised: 10/30/2013; Accepted: 11/06/2013 ; Published Online: 11/13/2013http://dx.doi.org/10.4161/hv.27097Association of serum anti-rotavirus  immunoglobulin A antibody seropositivity and  protection against severe rotavirus gastroenteritis Analysis of clinical trials of human rotavirus vaccine Brigitte c heuvart1,*, Kathleen M Neuzil2, a Duncan s teele3,†, Nigel c unliffe4, shabir a Madhi5, Naveen Karkada6,  htay h tay h an7, and  carla Vinals1 1Glaxos mithKline Vaccines; Wavre, Belgium; 2Rotavirus Vaccine Program, P aTh; seattle, W a Usa; 3Initiative for Vaccine Research; World h ealth Organization; s eattle, W a Usa;   4Department of c linical Infection; Microbiology & Immunology; Institute of Infection & Global h ealth; University of Liverpool; Liverpool, UK; 5Medical Research c ouncil:  Respiratory and Meningeal Pathogens Research Unit & Department of s cience and Technology/National Research Foundation: Vaccine Preventable Diseases; University of the  Witwatersrand; Johannesburg, s outh a frica; 6Glaxo smithKline Pharmaceuticals Ltd.; Bangalore, India; 7Glaxo smithKline Vaccines; Philadelphia, P a Usa †current affiliation: Bill and Melinda Gates Foundation; s eattle, W a Usa Keywords:  rotavirus, gastroenteritis, RV1, vaccine, correlate of efficacy, meta-analysis Abbreviations:  ATP, according-to-protocol; ELISA, enzyme-linked immunosorbent assay; GE, gastroenteritis; RV, rotavirus;  RVGE, rotavirus gastroenteritis; VE, vaccine efficacy clinical trials of the human rotavirus vaccine Rotarix ™ (RV1) have demonstrated significant reductions in severe  rotavirus gastroenteritis (RVG e) in children worldwide.",Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Infect Dis 2000; 182:1602-9;  PMID:11069230 ; http://dx.doi.org/10.1086/317619 2.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Lancet 1986; 2:417- 21; PMID:2874413 ; http://dx.doi.org/10.1016/ S0140-6736(86)92133-1 3.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Infect Dis 1994; 169:504- 11; PMID :8158022 ; http://dx.doi.org/10.1093/ infdis/169.3.5046.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Curr Opin Virol 2012; 2:419-25; PMID:22677178 ;  http://dx.doi.org/10.1016/j.coviro.2012.05.003 9.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Clin Infect Dis 2002; 34:1351-61;  PMID:11981731 ; http://dx.doi.org/10.1086/340103 10.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Infect Dis 2013; 208:284- 94; PMID:23596320 ; http://dx.doi.org/10.1093/ infdis/jit166 11.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Vaccine  2006; 24:2718-31;  PMID:16446014 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
N Engl J Med 2006; 354:11-22;  PMID:16394298 ; http://dx.doi.org/10.1056/ NEJMoa052434 13.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Pediatr (Rio J) 2007; 83:217- 24; PMID:17380232 ; http://dx.doi.org/10.2223/ JPED.1600 14.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Stat Med  1989; 8:431-40;  PMID:2727467 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Pediatr  Infect Dis J 2009; 28:261-6; PMID:19289978 ;  http://dx.doi.org/10.1097/INF.0b013e3181907177,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Pediatr Infect Dis J  2001; 20:63-75;  PMID:11176570 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
N Engl J Med 2010; 362:289-98;  PMID:20107214 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Scand J Infect Dis 2010; 42:540-4; PMID:20524782 ;  http://dx.doi.org/10.3109/00365541003652556 19.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Clin Infect Dis 2006; 43:312-4;  PMID:16804845 ; http://dx.doi.org/10.1086/505493 20.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Vaccine  2009; 27:5936-41;  PMID:19679216 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Vaccine  2010; 28:5272-9;  PMID:20538094 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Vaccine 2011; 29:6335- 41; PMID:21640780 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Pediatr Infect Dis J 2004; 23:937-43;  PMID :15602194 ; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Pediatr Infect Dis J 2005; 24:807- 16; PMID:16148848 ; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Lancet 2007; 370:1757-63; PMID:18037080 ; http://dx.doi.org/10.1016/ S0140-6736(07)61744-9 28.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Scand J Infect Dis 1990; 22:259-67;  PMID :2371542 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Diagn Microbiol Infect Dis 1987; 8:221-8; PMID:2835201 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Infect Dis  1986; 154:871-80;  PMID:3021869 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
J Infect  Dis 1989; 159:79-88; PMID:2535868 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
Stat Med 1997; 16:1515-27;  PMID:9249922 ; http://dx.doi.org/10.1002/ (SICI)1097-0258(19970715)16 :13<1515::AID- SIM572>3.0.CO;2-1 33.,OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
"Stat Med 2004; 23:685-90,  author reply 891-2;  PMID:14755397 ; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/4b/f7/hvi-10-505.PMC4185910.pdf
"*Correspondence to: Ronald Ellis; Email: rellis@landesbioscience.com Submitted: 1/12/2014; Accepted: 1/12/2014; Published Online: 04/16/2014http://dx.doi.org/10.4161/hv.28446Human Vaccines & Immunotherapeutics  awards  Top Reviewer of the Year ronald Ellis1,* and Eva M r iedmann2 1chief t echnology o fficer; Futu rx, Ltd.; n ess Ziona, i srael; 2Acquisitions Editor; Landes Bioscience; Vienna, Austria Samuel Aballéa Creativ-Ceutical Florence Abravanel CHU Rangueil Nadeem Afzal University of Veterinary &  Animal Sciences Levent Akin Hacettepe University, Faculty of Medicine, Public Health Department Jeff Alexander Paxvax Robert Amato University of Texas Medical School Christopher Ambrose MedImmune, LLCAnnaliesa AndersonPfizer Juana Angel Pontificia Universidad Javeriana Sébastien Anguille Antwerp University Hospital Andrey Anisimov State Research Center for Applied Microbiology and Biotechnology Adriano Arguedas Instituto de Atención Pediátrica Ruth Arnon Weizmann Charles Arntzen Arizona State UniversityAtsushi ArugaJoint Graduate School of Tokyo Women’s Medical University and Waseda University Birgitta Åsjö; Gades Institute, University of  Bergen, Norway Martin Bachmann University of Zurich Susan Baldwin IDRIPamela BarbadoroUniversità Politecnica delle Marche Alan Barrett University of Texas Medical Branch Sandra Bean Oregon State UniversityAngela BechiniUniversity of Florence Rodolfo Bégué Louisiana University Health Sciences Center Luis Bermudez-Humaran INRA Zwi Berneman University of Antwerp Philippe Beutels University of Antwerp Prakash Bhuyan Pfizer Robin Biellik Consultant Joke Bilcke University of AntwerpGeorge BlanckMorsani College of Medicine, USF Mark Blatter Pediatric Alliance Sara Boccalini University of Florence Stefania Boccia University of Rome Rogier Bodewes Erasmus University Medical Center Kalifa Bojang MRC Unit Monika Bokori-Brown University of Exeter Phua Kong Boo KK Women’s and Children’s Hospitaldr Mark J n ewman",Non-OADS,/arxiv_data1/oa_pdf/bb/46/hvi-10-247.PMC4185913.pdf
http://dx.doi.org/10.1016/j.ymgmr.2013.12.001 Contents lists available at ScienceDirect Molecular Genetics and Metabolism Reports journal homepage: http://www.journals.elsevier.com/ molecular-genetics-and-metabolism-reports/,Non-OADS,/arxiv_data1/oa_pdf/03/75/main.PMC4185924.pdf
According to RNAalifold analysis [19] (http://rna.tbi.univie.,OADS,/arxiv_data1/oa_pdf/03/75/main.PMC4185924.pdf
"The RNAfold software [20] (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi ), predicted that this transition may alter the secondary structure of the tRNA.",OADS,/arxiv_data1/oa_pdf/03/75/main.PMC4185924.pdf
mtdb.igp.uu.se/ ) and is reported as pathogenic in MITOMAP ( http://www.mitomap.org/MITOMAP ).,OADS,/arxiv_data1/oa_pdf/03/75/main.PMC4185924.pdf
"References [1] MITOMAP: a human mitochondrial genome database, http://www.mitomap.org.",OADS,/arxiv_data1/oa_pdf/03/75/main.PMC4185924.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"Direct link to deposited data http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60470 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40657http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46944Experimental design, materials and methods Mice Normal C57BL/6 mice and mice containing Foxo1 knock -in (Foxo1tag), Foxp3 -IRES-RFPand birAalleles or Foxp3 -IRES-RFPand birA alleles were previously described [1].",OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
Consent N/A Sample source locationN/A http://dx.doi.org/10.1016/j.gdata.2014.08.006 2213-5960/© 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
Contents lists available at ScienceDirect Genomics Data journal homepage: http://www.journa ls.elsevier.com/genomics-data/,Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
Data analysis Initial quality control of the sequencing was performed using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ ).,OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"After ver- ifying acceptable base calling quality, nucleotide distribution, and adapter contamination, reads were aligned to the mouse mm9 (NCBI, Build 37, July 2007) reference genome obtained through the UCSC Table Browser (http://genome.ucsc.edu/ ) using version 0.12.7 of the Bowtie short read alignment software [3](http://bowtie-bio.sourceforge.net/index.shtml ).",OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"For the CD4+and T regcell-types, MACS [4](version 1.4.1, http://liulab.dfci.",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"For the anal- ysis of the CD8+data, we developed a novel peak-calling algorithm BCP [5](http://rulai.cshl.ed/BCP/ ) ,w h i c he m p l o y saB a y e s i a nH i d d e nM a r k o v model, to perform segmentation of the genome and identify enrichment.",OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"Nature 491 (2012) 554 –559, http://dx.doi.org/10.1038/nature11581 .",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"Immunity 39 (2013) 286 –297, http://dx.doi.org/10.1016/j.immuni.2013.07.013 .",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"10 (2009) R25,http://dx.doi.org/10.1186/gb-2009-10-3-r25 .",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"9 (2008) R137, http://dx.doi.org/ 10.1186/gb-2008-9-9-r137 .",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"8 (2012) e1002613, http://dx.doi.org/10.1371/ journal.pcbi.1002613.t001 .",Non-OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
"Bioinformatics 26 (2010) 841 –842, http://dx.doi.org/10.1093/bioinformat- ics/btq033 .281 W. Liao et al.",OADS,/arxiv_data1/oa_pdf/32/f9/main.PMC4185926.pdf
Although its use has not been implemented in  *Correspondence to: Mustafa Bakir; Email: mbakir@marmara.edu.tr Submitted: 12/17/2013; Revised: 02/02/2014; Accepted: 03/05/2014; Published Online: 03/17/2014; http://dx.doi.org/10.4161/hv.28438Meningococcal serogroup B disease in Turkey A guess or reality?,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from:  http://www.who.int/csr/resources/publications/ meningitis/WHO_EMC_BAC_98_3_EN/en/ .,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Expert Rev Vaccines 2010; 9:285-98; PMID:20218857 ;  http://dx.doi.org/10.1586/erv.10.3 4.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Lancet Infect Dis  2010; 10:317-28;  PMID:20417414 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://ecdc.europa.eu/en/publications/Publications/1111_SUR_Annual_Epidemiological_Report_on_ Communicable_Diseases_in_Europe.pdf .6.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
N Engl J Med  2001; 344:1378-88;  PMID:11333996 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Vaccine 2013;  31:4477-86;  PMID:23933336 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://www.meningitis.org/ menb-vaccine .,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://www.tuik.gov.tr/IcerikGetir.do?istab_id=21 .13.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Emerg Infect Dis  2008; 14:1089-96;  PMID:18598630 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Clin Vaccine Immunol 2013; 20:66-8; PMID:23136117 ; http://dx.doi.org/10.1128/ CVI.00314-12 17.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Drugs  2013; 73:1147-55;  PMID:23839656 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://www.cdc.gov/mmwr/preview/ mmwrhtml/rr6202a1.htm20.,OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://www.cdc.gov/mmwr/pdf/wk/ mm62e0128.pdf 21.,OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Available from: http://w3.kenes-group.,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
Epidemiol Infect 2010; 138:976-8; PMID:19845997 ;  http://dx.doi.org/10.1017/S095026880999104X,Non-OADS,/arxiv_data1/oa_pdf/10/94/hvi-10-1721.PMC4185933.pdf
"13,14  *Correspondence to: Calman A MacLennan; Email: calman.maclennan@novartis.com Submitted: 02/13/2014; Revised: 04/21/2014; Accepted: 04/29/2014 http://dx.doi.org/10.4161/hv.29054Vaccines against invasive Salmonella  disease Current status and future directions Calman A MacLennan1,2,*, Laura B Martin1, and Francesca Micoli1 1Novartis Vaccines Institute for Global Health; Siena, Italy; 2Medical Research Council Centre for Immune Regulation and Clinical Immunology Service; Institute of Biomedical  Research, School of Immunity and Infection; College of Medicine and Dental Sciences; University of Birmingham; Birmingham, UK Keywords:  vaccines, Salmonella , nontyphoidal, typhoid, enteric, global health, glycoconjugate, GMMA Abbreviations:  iNTS, invasive nontyphoidal Salmonella ; NTS, nontyphoidal Salmonella ; CPS, capsular polysaccharide ; Ti2,  T-independent type 2 ; TLR5, toll-like receptor 5 ; rEPA, recombinant Pseudomonas aeruginosa  exoprotein A ; IVI, International  Vaccine Institute ; NVGH, Novartis Vaccines Institute for Global Health ; CVD, Center for Vaccine Development ; EPI, Expanded  Programme on Immunization ; TT, tetanus toxoid ; DT, diphtheria toxoid ; CRM197,nontoxic recombinant form of diphtheria toxin ;  PCMV, protein capsular matrix vaccine ; GMMA, Generalized Modules for Membrane Antigens ; PAMPs, pathogen-associated  molecular patterns ; LAV, live attenuated vaccine Though primarily enteric pathogens, Salmonellae  are  responsible for a considerable yet under-appreciated global  burden of invasive disease.",Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 2013; 382:209-22;  PMID:23680352 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet Infect Dis 2012; 12:480-7;  PMID:22632186 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet Infect Dis 2010; 10:417-32;  PMID:20510282 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Emerg Infect Dis 2005; 11:1764-6; PMID:16318734 ;  http://dx.doi.org/10.3201/eid1111.050168 6.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Pediatr Infect Dis J 2001; 20:521-4;  PMID:11368111 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Emerg Infect Dis 2005; 11:326-9; PMID:15752457 ; http://dx.doi.org/10.3201/ eid1102.040422 9.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 2012; 379:2489-99; PMID:22587967 ;  http://dx.doi.org/10.1016/S0140-6736(11)61752-2 10.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
N Engl J Med 2011; 365:1863-75; PMID:22007715 ;  http://dx.doi.org/10.1056/NEJMoa1102287 11.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Expert Rev Anti Infect Ther 2013; 11:443-6; PMID:23627848 ; http://dx.doi.org/10.1586/ eri.13.27 12.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Nat Genet 2012; 44:1215-21;  PMID:23023330 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
FEMS Immunol Med Microbiol 2002; 33:165-71; PMID:12110478 ; http://dx.doi.org/10.1111/j.1574- 695X.2002.tb00587.x 16.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Med Microbiol 2006; 55:585-91; PMID:16585646 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2007; 25:7848-57;  PMID:17928109 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Expert Rev Vaccines 2010; 9:485-96; PMID:20450323 ;  http://dx.doi.org/10.1586/erv.10.43 20.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Infect Dis 2008; 46:963-9; PMID:18444810 ;  http://dx.doi.org/10.1086/529146 21.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 1987; 155:1319-21; PMID:3553352 ; http://dx.doi.org/10.1093/ infdis/155.6.1319 23.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 2009; 373:267-9; PMID :19150705 ;  http://dx.doi.org/10.1016/S0140-6736(09)60073-8 24.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Immunol 2002; 169:2196-203; PMID:12165550 ;  http://dx.doi.org/10.4049/jimmunol.169.4.2196 26.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Exp Med 2000; 192:237-48; PMID:10899910 ; http://dx.doi.org/10.1084/ jem.192.2.237 28.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Exp Med 2000; 192:227-36; PMID:10899909 ; http://dx.doi.org/10.1084/ jem.192.2.227 29.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Nat Rev Microbiol 2009; 7:73-80;  PMID:19079353 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Exp Med 1966; 124:585-600; PMID:4958757 ;  http://dx.doi.org/10.1084/jem.124.4.585 33.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Exp Med 1966; 124:573-83;  PMID:5922285 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Pediatr 1989; 114:555-60;  PMID:2784499 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 2004; 190:1755-7; PMID :15499529 ; http://dx.doi.org/10.1086/425021 37.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Curr Opin Immunol 2008; 20:39-48;  PMID:18083507 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Medicine (Baltimore) 2013; 92:109-22;  PMID:23429356 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Clin Invest 2008; 118:1553-62; PMID:18357343 ; http://dx.doi.org/10.1172/ JCI33998 40.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Proc Natl Acad Sci U S A 2010; 107:3070-5;  PMID:20133627 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Eur J Immunol 2014; 44:1093-8; PMID:24375424 ;  http://dx.doi.org/10.1002/eji.201343529  42.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
AIDS 2002; 16:1633-41;  PMID:12172085 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
AIDS 2007; 21:2399-408; PMID:18025876 ; http://dx.doi.org/10.1097/ QAD.0b013e3282f25107 45.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Nat Med 2008; 14:421-8; PMID:18376406 ;  http://dx.doi.org/10.1038/nm1743 46.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Infect Dis 2011; 52:341-8; PMID:21217181 ; http://dx.doi.org/10.1093/cid/ ciq10347.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2011; 79:4240-9; PMID:21807909 ; http://dx.doi.org/10.1128/ IAI.05484-11 51.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Microb Pathog 1987; 2:171-83;  PMID:2467161 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Microb Pathog 1996; 21:249-63; PMID:8905614 ; http://dx.doi.org/10.1006/ mpat.1996.0059 54.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Microb Pathog 2013; 63:19-23;  PMID:23756206 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2013; 20:1487-90;  PMID:23904457 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2013; 20:1491-8;  PMID:23803904 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS Pathog 2011; 7:e1002131; PMID:21829346 ; http://dx.doi.org/10.1371/jour- nal.ppat.1002131 58.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
N Engl J Med 2001; 344:1263-9; PMID:11320385 ;  http://dx.doi.org/10.1056/NEJM200104263441701 61.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2011; 18:730-5;  PMID :21411598 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Expert Rev Vaccines 2013; 12:1273-86;  PMID:24156285 ; http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Nat Rev Immunol 2009; 9:213-20;  PMID:19214194 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Semin Immunol 2013; 25:114-23; PMID:23757292 ;  http://dx.doi.org/10.1016/j.smim.2013.05.004 67.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2013; 8:e74850;  PMID:24069357 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Eur J Immunol 2011; 41:1606-18; PMID:21469112 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2013; 8:e64680; PMID:23741368 ;  http://dx.doi.org/10.1371/journal.pone.0064680 70.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Eur J Immunol 2004; 34:2986-95; PMID:15384042 ; http://dx.doi.org/10.1002/ eji.200425403 71.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Immunol 2012; 189:5745-54;  PMID :23152564 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS Negl Trop Dis 2011; 5:e1373; PMID:22069504 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Immunol 2007; 178:6200-7; PMID:17475847 ;  http://dx.doi.org/10.4049/jimmunol.178.10.6200 74.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Proc Natl Acad Sci U S A 2009; 106:9803-8;  PMID:19487686 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Proc Natl Acad Sci U S A 2012; 109:4998-5003; PMID:22331879 ; http://dx.doi.org/10.1073/ pnas.1111413109 76.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Sci Rep 2013; 3:1043; PMID:23304434 ; http://dx.doi.org/10.1038/ srep01043 77.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS Pathog 2012; 8:e1002966;  PMID:23093937 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Infect Dis 2006; 42:1247-53;  PMID:16586383 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Clin Microbiol 2010; 48:2171-6; PMID:20392916 ; http://dx.doi.org/10.1128/ JCM.01983-09 81.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2012; 7:e29119; PMID:22276105 ;  http://dx.doi.org/10.1371/journal.pone.0029119 82.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2012; 7:e31237; PMID:22363591 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Hum Vaccin Immunother 2012; 8:494-8; PMID:22370510 ; http://dx.doi.org/10.4161/ hv.19158 86.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Nat Genet 2008; 40:987-93; PMID:18660809 ; http://dx.doi.org/10.1038/ng.195 87.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Immunity 2010; 33:530-41;  PMID:21029963 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Dtsch Med Wochenschr 1896; 22:3; http://dx.doi.org/10.1055/s-0029-1204734 89.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Br Med J 1900; 1:122-9; PMID:20758818 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Am J Public Health Nations Health 1934; 24:689-709; PMID:18014010 ;  http://dx.doi.org/10.2105/AJPH.24.7.689 91.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 1975; 131:553-8; PMID:1092768 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2013; 8:e60583; PMID:23593253 ; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Rev Infect Dis 1989; 11(Suppl 3):S552-67; PMID:2669099 ; http://dx.doi.org/10.1093/cli - nids/11.Supplement_3.S552,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2011; 29:2761-71; PMID:21300096 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007; 45(Suppl 1):S24-8; PMID:17582564 ;  http://dx.doi.org/10.1086/518141 99.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:6047-53;  PMID:22858557 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2012; 19:825-34; PMID:22492745 ; http://dx.doi.org/10.1128/ CVI.00058-12 101.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:7238-45; PMID:23084770 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
N Engl J Med 2009; 361:335-44;  PMID :19625715 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:5389-95;  PMID:22721899 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 1982; 145:292-5; PMID:7037982 ;  http://dx.doi.org/10.1093/infdis/145.3.292 106.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 1987; 1:1049-52;  PMID:2883393 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 1990; 336:891-4; PMID:1976928 ;  http://dx.doi.org/10.1016/0140-6736(90)92266-K 108.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 1990; 8:81-4;  PMID:2180234 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet 1991; 338:1055-9;  PMID:1681365 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2005; 73:3521-30; PMID :15908381 ; http://dx.doi.org/10.1128/ IAI.73.6.3521-3530.2005 113.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 1984; 150:436-49; PMID:6207249 ; http://dx.doi.org/10.1093/ infdis/150.3.436 114.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 1996; 14:435-8; PMID:8735556 ;  http://dx.doi.org/10.1016/0264-410X(95)00186-5 116.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Available  from: http://biomed.co.in/typh_vaccine.html .,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2011; 6:e25398; PMID:21980445 ; http://dx.doi.org/10.1371/jour- nal.pone.0025398 120.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Lancet Infect Dis 2014; 14:119-29;  PMID:24290843 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2010; 17:73-9;  PMID:19889941 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2011; 29:7618-23; PMID:21843575 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:1023-8;  PMID:22192846 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:3405-12; PMID:22465750 ;  http://dx.doi.org/10.1016/j.vaccine.2012.03.039 125.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Hum Vaccin Immunother 2012; 8:189-93;  PMID:22426380 ;  http://dx.doi.org/10.4161/hv.18350 126.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 2005; 192:360-6;  PMID:15995948 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2006; 24:116-23; PMID:16140433 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2010; 5:e11778; PMID:20668668 ; http://dx.doi.org/10.1371/jour- nal.pone.0011778 131.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2010; 28:3602-8; PMID:20188175 ;  http://dx.doi.org/10.1016/j.vaccine.2010.02.017 132.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2000; 68:4647-52; PMID:10899868 ;  http://dx.doi.org/10.1128/IAI.68.8.4647-4652.2000,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Mucosal Immunol 2008; 1:389-98;  PMID:19079203 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Infect Dis 2007; 45(Suppl 1):S20-3; PMID:17582563 ; http://dx.doi.org/10.1086/518135 136.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Immunol 2011; 138:187-200; PMID:21146460 ;  http://dx.doi.org/10.1016/j.clim.2010.11.006 137.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Infect Dis 1996; 173:1408-14; PMID:8648213 ; http://dx.doi.org/10.1093/ infdis/173.6.1408 138.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Immunology 2006; 117:59-70;  PMID:16423041 ;  http://dx.doi.org/10.1111/j.1365-2567.2005.02263.x 140.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Expert Rev Vaccines 2013; 12:1021-31; PMID:24053396 ;  http://dx.doi.org/10.1586/14760584.2013.825450 144.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Anal Biochem 2013; 434:136-45;  PMID:23142430 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2002; 70:3457-67; PMID:12065485 ; http://dx.doi.org/10.1128/ IAI.70.7.3457-3467.2002 148.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2011; 79:4175-85; PMID:21807911 ; http://dx.doi.org/10.1128/ IAI.05278-11 149.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2010; 28:6436-44;  PMID:20670908 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2011; 6:e16667;  PMID:21347426 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2011; 29:1783-90; PMID:21219981 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2012; 7:e52043; PMID:23284865 ; http://dx.doi.org/10.1371/jour- nal.pone.0052043 153.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Science 1999; 284:967-70; PMID:10320378 ; http://dx.doi.org/10.1126/ science.284.5416.967 154.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2001; 69:6725-30; PMID:11598044 ; http://dx.doi.org/10.1128/ IAI.69.11.6725-6730.2001 155.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Proc Natl Acad Sci U S A 2008; 105:9361-6; PMID:18607005 ; http://dx.doi.org/10.1073/ pnas.0803801105 156.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Infect Immun 2009; 77:1071-82;  PMID:19103774 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Mol Cell Proteomics 2008; 7:473-85; PMID:17982123 ; http://dx.doi.org/10.1074/ mcp.M700295-MCP200 159.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
PLoS One 2012; 7:e35616;  PMID:22701551 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Available from: http://www.ivi.int .,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Available from: http://www.nibr.com/research/developing_world/NVGH/index.shtml .,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Available from: http://medschool.umaryland.edu/cvd/.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Emerg Infect Dis 2010; 16:1448-51; PMID:20735930 ; http://dx.doi.org/10.3201/ eid1609.100125 166.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2012; 30:853-61; PMID:22172503 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2011; 29:712-20; PMID:21115057 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Clin Vaccine Immunol 2011; 18:460-8;  PMID :21248155 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2014; 32:2457-62; PMID:24631090 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Expert Rev Vaccines 2011; 10:1679-82;  PMID:22085171 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Biologicals 2013; 41:224-30;  PMID:23796754 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
Vaccine 2014; 32:2688-95;  PMID:24704334 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
J Biol Chem 1996; 271:12095-102;  PMID:8662613 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/42/hvi-10-1478.PMC4185946.pdf
" Editor's CornEr www.landesbioscience.com Human Vaccines & i mmunotherapeutics 1425Human Vaccines & i mmunotherapeutics 10:6, 1425–1426; June 2014; © 2014 Landes BioscienceEditor's CornEr  Editor's CornEr Dear Reader, *Correspondence to: Ronald Ellis; Email: rellis@landesbioscience.com Submitted: 04/22/2014; Accepted: 04/22/2014http://dx.doi.org/10.4161/hv.29345Letter from the Editor ronald Ellis1,* and Eva M r iedmann2 1senior Vice President r &d and Chief t echnology o fficer; n asVax, Ltd.; n ess Ziona, i srael; 2Acquisitions Editor; Landes Bioscience; Vienna, AustriaEditor's CornEr sPECiAL  FoCus on diArrHEAL  VACCinEs in Human Vaccines & Immunotherapies  we regularly put a special focus on timely and interesting topics in the field  of vaccines and immunotherapies for human use.",Non-OADS,/arxiv_data1/oa_pdf/4e/d5/hvi-10-1425.PMC4185947.pdf
"Origins of Current Crisis in Drug  Development Premodern societies devised systems  of traditional knowledge encompassing medicinal preparations derived from Beyond new chemical entities Advancing drug development based on functional versatility of antibodies Salvador Eugenio C Caoili Department of Biochemistry and Molecular Biology; College of Medicine; University of the Philippines Manila; Manila, Philippines Keywords:  drugs, drug development,  new chemical entities, antibodies, abzymes, antidotes, antibody buffering, deuteration, kinetic isotope effect,  drug repurposing Correspondence to: Salvador Eugenio C Caoili;  Email: badong@post.upm.edu.ph Submitted: 01/30/2014;Accepted: 02/12/2014Published Online: 03/14/2014http://dx.doi.org/10.4161/hv.28192",Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Molecules  2013 ; 18:440- 65; PMID:23282535 ; http://dx.doi.org/10.3390/ molecules18010440 3.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Hum Vaccin Immunother 2013 ; 9:294- 9; PMID:23291934 ; http://dx.doi.org/10.4161/ hv.22858 5.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Biosci  2001 ; 26:135-43;  PMID:11426049 ; http://dx.doi.org/10.1007/ BF02703637 6.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Metabolism  2008 ; 57(Suppl 1 ):S3- 9; PMID:18555851 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Pharmacology   2008 ; 82:171-9; PMID:18679046 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Biosci Biotechnol Biochem  2006 ; 70:1060 -75;  PMID:16717405 ; http://dx.doi.org/10.1271/ bbb.70.1060 10.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
PLoS One  2013 ; 8:e56517 ;  PMID:23457578 ; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
BMC Med Ethics   2012 ; 13:16; PMID:22769234 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Br Med J (Clin Res Ed)   1985 ; 291:130-1; PMID:3926081 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Toxicol  Sci 2010 ; 35:1-8; PMID:20118619 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Toxicol Clin Toxicol   2003 ; 41:309-15; PMID:12807314 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Am Chem Soc   2008 ; 130:5140 -9; PMID:18341277 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Proc Natl Acad Sci U S A   2001 ; 98:8480 -4; PMID:11447282 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Blood   2012 ; 119:2205 -8; PMID:22147890 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Biol Chem 2003 ;  278:20429 -35; PMID:12665517 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
FASEB J  2012 ;  26:1607 -15; PMID:22205784 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Proc Natl Acad Sci U S A 2005 ; 102:40- 4; PMID :15615858 ; http://dx.doi.org/10.1073/ pnas.0405797102 24.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Rev Saude Publica 2007 ; 41:1049 - 53; PMID:17992356 ; http://dx.doi.org/10.1590/ S0034-89102006005000050 25.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Autoimmun  2011 ; 37:144-50;  PMID:21624820 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
BMC Med Ethics  2013 ; 14:55; PMID:24359531 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Br J Clin Pharmacol  2012 ; 74:698-721; PMID:22591598 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Pharmacogenomics  2013 ;  14:1807 -9; PMID:24236479 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Pharmacol Rev  2013 ;  65:779-808; PMID:23476052 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Bioanalysis   2010 ; 2:373-6; PMID:21083245 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Dose Response  2011 ; 9:377-86;  PMID:22013400 ; http://dx.doi.org/10.2203/dose- response.11-026.Maynard 32.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Biochim Biophys Acta  2003 ;  1638 :257-66; PMID:12878327 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Biol Chem 2007 ; 282:1709 - 17; PMID:17135257 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Protein Eng Des Sel 2013 ; 26:489- 501; PMID:23754528 ; http://dx.doi.org/10.1093/ protein/gzt023,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
J Clin Immunol 2013 ; 33(Suppl 1 ):S43-9;  PMID:22941509 ; http://dx.doi.org/10.1007/ s10875-012-9762-4 37.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
N Engl J Med 2013 ; 369:2474 -6; PMID:24369073 ;  http://dx.doi.org/10.1056/NEJMp131147939.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Nat Rev Cancer  2006 ; 6:714-27; PMID:16929325 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
Int J  Environ Res Public Health 2013 ; 10:6096 -105;  PMID:24225646 ; http://dx.doi.org/10.3390/ ijerph10116096,OADS,/arxiv_data1/oa_pdf/39/35/hvi-10-1639.PMC4185958.pdf
"Upregulation of chemokines, *Correspondence to: Jan R Mead; Email: jmead@emory.edu Submitted: 12/13/2013; Revised: 02/26/2014; Accepted: 03/10/2014; Published Online: 03/17/2014; http://dx.doi.org/10.4161/hv.28485Prospects for immunotherapy and vaccines  against Cryptosporidium Jan R Mead1,2,* 1Atlanta v eterans Affairs Medical Center; Decatur, GA USA; 2Department of Pediatrics; e mory University; Atlanta, GA USA Keywords:  Cryptosporidium, vaccine, immunotherapy Cryptosporidium spp  is a ubiquitous parasite that has long  been recognized as a frequent cause of protozoal diarrhea  in humans.",Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Curr Opin Gastroenterol  2001; 17:17-23;  PMID:17031144 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Ann Ist Super Sanita 2012; 48:429- 46; PMID:23247139 ; http://dx.doi.org/10.4415/ ANN_12_04_10 3.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Ann Epidemiol 2004; 14:473-8;   PMID :15310525 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Eur J Clin Microbiol  Infect Dis 1995; 14:677-81; PMID:8565984 ;  http://dx.doi.org/10.1007/BF01690873 6.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin  Infect Dis 2008; 47:915-21; PMID :18715159 ;  http://dx.doi.org/10.1086/591539 7.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect 2001; 42:134- 9; PMID :11531320 ; http://dx.doi.org/10.1053/ jinf.2001.08108.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Pediatr Gastroenterol Nutr 2001; 32:550-4;  PMID :11429515 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Indian J Pediatr 2009; 76:1227-30; PMID:19936657 ;  http://dx.doi.org/10.1007/s12098-009-0258-z 10.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Am J Epidemiol 1998; 148:497-506;  PMID:9737562 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Lancet  2013; 382:209-22;  PMID:23680352 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Gastroenterology 2001; 120:1774- 83; PMID:11375958 ; http://dx.doi.org/10.1053/ gast.2001.24850 16.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Am J Physiol Gastrointest Liver  Physiol 2004; 287:G571-81; PMID :15155179 ;  http://dx.doi.org/10.1152/ajpgi.00413.2003 18.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2004; 72:2772-9; PMID :15102787 ;  http://dx.doi.org/10.1128/IAI.72.5.2772-2779.2004 20.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis  2009; 200:1548-55;  PMID:19821721 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasite Immunol 1994; 16:315-20;  PMID:7970868 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis  2000; 182:1001-4;  PMID:10950807 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J  Infect Dis 2005; 192:1294-302; PMID:16136475 ;  http://dx.doi.org/10.1086/444393 27.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Gastroenterology 2001; 120:99-107;  PMID:11208718 ; http://dx.doi.org/10.1053/ gast.2001.20907 28.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Curr Opin Infect Dis 2002;  15:229-34 ;  PMID:12015455 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis 1991; 163:1297-304; PMID:2037795 ;  http://dx.doi.org/10.1093/infdis/163.6.1297 31.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
"Gastroenterol Clin North Am 2006; 35:291-314,  viii; PMID:16880067 ; http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2005; 73:8425- 8; PMID:16299343 ; http://dx.doi.org/10.1128/ IAI.73.12.8425-8428.2005 34.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Am J Trop Med Hyg 2010; 82:600-7; PMID:20348507 ;  http://dx.doi.org/10.4269/ajtmh.2010.09-0590 35.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Exp Immunol  2006; 145:555-62;  PMID:16907926 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasite Immunol  2005; 27:17-28;  PMID :15813719 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Immunobiology 2009; 214:454- 66; PMID :19155092 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Exp Parasitol  2007; 115:107-13;  PMID:16920103 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis 1986 ; 153:570-8 ;  PMID:3950440 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Eukaryot  Microbiol 2003; 50(Suppl):539-41;  PMID :14736155 ;  http://dx.doi.org/10.1111/j.1550-7408.2003.tb00622.x 45.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Vet Sci 2006; 7:47-51; PMID:16434849 ; http://dx.doi.org/10.4142/ jvs.2006.7.1.47 46.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Microbes Infect 2013; 15:599-606; PMID:23644177 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2004; 72:1306- 10; PMID:14977932 ; http://dx.doi.org/10.1128/ IAI.72.3.1306-1310.2004 49.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasite Immunol  2008; 30:151-61;  PMID:18179628 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Parasitol 2004; 90:1178-80;  PMID:15562625 ; http://dx.doi.org/10.1645/ GE-3333RN 53.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Adv Parasitol 1998; 40:121- 49; PMID:9554072 ; http://dx.doi.org/10.1016/ S0065-308X(08)60119-0 55.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Br Med J (Clin Res Ed) 1986; 293:1276- 7; PMID:3096462 ; http://dx.doi.org/10.1136/ bmj.293.6557.1276 56.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Parasitol  1987; 73:413-5;  PMID:3585635 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
AIDS  1990; 4:581-4;  PMID:2201320 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Scand J Gastroenterol 2006; 41:682-6; PMID:16716966 ;  http://dx.doi.org/10.1080/00365520500380817 60.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Acquir Immune Defic Syndr Hum Retrovirol  1996; 13:348-54;  PMID:8948373 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Infect  Dis 1998; 26:1324-9; PMID:9636857 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vaccine 1999; 17:2453-60; PMID:10392628 ; http://dx.doi.org/10.1016/ S0264-410X(98)00369-764.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vet Parasitol 2011; 175:178- 81; PMID:20951499 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2000; 68:2608-16; PMID:10768951 ;  http://dx.doi.org/10.1128/IAI.68.5.2608-2616.2000 71.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Immunol  2012 ; 143:152-61;  PMID:22459705 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Antimicrob Agents Chemother  2010; 54:1385-92;  PMID:20086143 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Br J Clin Pharmacol  2007; 63:387-93;  PMID:17335543 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Microbes Infect 2002; 4:1059-66; PMID:12191656 ;  http://dx.doi.org/10.1016/S1286-4579(02)01630-1 75.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Immunol Rev 2011; 239:125-48;  PMID:21198669 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasitology 2009; 136:1477-89; PMID:19523251 ; http://dx.doi.org/10.1017/ S0031182009006349 77.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Am J Trop Med Hyg 2012; 86:214- 22; PMID:22302851 ; http://dx.doi.org/10.4269/ ajtmh.2012.11-0273 79.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis 2012;  205:1019-23;  PMID:22279124 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
JAMA 2011;  306:1701-2;  PMID:22009102 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Microbiol Infect 2012; 18(Suppl 5):57-63;  PMID:22882248 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Parasitol  2003; 89:639-42;  PMID:12880278 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Biotechnol Adv 2007;  25:13-44;  PMID:17055210 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2007; 75:184- 92; PMID:17043102 ; http://dx.doi.org/10.1128/ IAI.00944-06 85.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Mol Biochem Parasitol 2007; 156:80-3; PMID:17719100 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Mol Biochem Parasitol 2001; 113:117-26;  PMID:11254960 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Parasitol 1991; 77:315-7; PMID:2010865 ;  http://dx.doi.org/10.2307/3283104 89.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Mol Biochem Parasitol  1996; 80:137-47;  PMID:8892291 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Nature  2005; 433:164-7;  PMID :15580261 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Nanosci Nanotechnol  2005; 5:1292-6;  PMID:16193995 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vaccine 1995; 13:1658-64; PMID:8719516 ;  http://dx.doi.org/10.1016/0264-410X(95)00121-G 94.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vaccine 1999; 17:2346-55; PMID:10392616 ; http://dx.doi.org/10.1016/ S0264-410X(99)00041-9 95.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasite Immunol  1999; 21:507-16;  PMID:10587377 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
DNA Cell Biol 2004; 23:335-9;  PMID :15169612 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Parasitol Res 2007;  101:943-50;  PMID:17487508 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vaccine  2010; 29:323-8;  PMID:21029808 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Vaccine  Immunol 2010; 17:954-65;  PMID:20410328 ;  http://dx.doi.org/10.1128/CVI.00073-10 101.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Lett Appl Microbiol  2002; 34:62-6; PMID:11849495 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2008; 76:5745- 53; PMID:18809658 ; http://dx.doi.org/10.1128/ IAI.00897-08 104.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Vaccine Immunol  2009; 16:1272-8;  PMID:19605593 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Clin Vaccine Immunol 2011; 18:1796-802;  PMID:21918117 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Vaccine  2013; 31:912-8;  PMID:23246541 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Infect Immun 2003; 71:6027- 34; PMID:14500524 ; http://dx.doi.org/10.1128/ IAI.71.10.6027-6034.2003 111.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Parasitol 2005; 91:476-9; PMID:15986633 ;  http://dx.doi.org/10.1645/GE-364R1 112.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Curr Microbiol 2011; 62:1573-80; PMID:21336991 ; http://dx.doi.org/10.1007/ s00284-011-9894-4 114.,Non-OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
Int J Med Microbiol  2008; 298:39-44;  PMID:17716944 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
J Infect Dis 2006; 193:1400-7;  PMID:16619188 ; http://dx.doi.org/10.1086/503748,OADS,/arxiv_data1/oa_pdf/50/79/hvi-10-1505.PMC4185963.pdf
"Results Individual replicon vaccine for TeNT The immunogenicity and protective ability of replicon  DNA or VRP vaccine against TeNT were investigated and  *Correspondence to: Yun-Zhou Yu, Email: yunzhouyu@163.com; Zhi-Wei Sun, Email: szwyhhh@rliyun.com Submitted: 02/12/2014; Revised: 04/08/2014; Accepted: 04/16/2014; Published Online: 05/01/2014http://dx.doi.org/10.4161/hv.28937Pentavalent replicon vaccines against botulinum  neurotoxins and tetanus toxin using DNA-based  Semliki Forest virus replicon vectors Yun-Zhou Yu*, s i Liu, Yao Ma, Zheng-Wei Gong, s huang Wang, and Zhi-Wei s un* Beijing Institute of Biotechnology; Beijing, PR c hina Keywords:  botulinum neurotoxin, tetanus neurotoxin, multivalent vaccine, replicon vector, immunogenicity The clostridial neurotoxin ( cNT) family includes botulinum neurotoxin (BoNT), serotypes a , B, e , and F of which can cause  human botulism, and tetanus neurotoxin (TeNT), which is the causative agent of tetanus.",Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Trends Biochem Sci 2002; 27:552- 8; PMID:12417130 ; http://dx.doi.org/10.1016/ S0968-0004(02)02177-1 2.,OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Disaster  Med Public Health Prep 2007 ; 1:122-34;  PMID:18388640 ; http://dx.doi.org/10.1097/ DMP.0b013e318158c5fd 4.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
JAMA   2001 ; 285:1059 -70; PMID:11209178 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Adv Drug Deliv Rev 2005 ; 57:1415 - 23; PMID :15896873 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Crit Rev Immunol  2007 ; 27:303-18; PMID:18197811 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2009 ; 27(Suppl 4 ):D33-9; PMID:19837283 ;  http://dx.doi.org/10.1016/j.vaccine.2009.08.059 9.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Toxicon  1998 ; 36:1539 - 48; PMID:9792170 ; http://dx.doi.org/10.1016/ S0041-0101(98)00146-9 12.,OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Infect Immun  2007 ; 75:3043 - 54; PMID:17371853 ; http://dx.doi.org/10.1128/ IAI.01893-06 13.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine   2009 ; 27:2816 -22; PMID:19428892 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2011 ; 29:5978 - 85; PMID:21718736 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2000 ; 18:1855 - 62; PMID:10699334 ; http://dx.doi.org/10.1016/ S0264-410X(99)00253-4 17.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2000 ; 19:810-5; PMID:11115703 ;  http://dx.doi.org/10.1016/S0264-410X(00)00246-2 18.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2001 ; 20:516-25; PMID:11672917 ;  http://dx.doi.org/10.1016/S0264-410X(01)00325-5 19.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
DNA  vaccination protects against botulinum neurotoxin  type F.  Vaccine  2003 ; 21:3110 -7; PMID:12804837 ;  http://dx.doi.org/10.1016/S0264-410X(03)00260-320.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Infect Immun  2001 ; 69:5709 -15; PMID:11500447 ;  http://dx.doi.org/10.1128/IAI.69.9.5709-5715.2001 21.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2006 ;  24:6886 -92; PMID:16828936 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2007 ; 25 :8843 -50; PMID:18022294 ;  http://dx.doi.org/10.1016/j.vaccine.2007.10.016 23.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2009 ; 27:6148 -53;  PMID:19712769 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine  2013 ; 31:2427 - 32; PMID:23583890 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
J Virol 2001 ; 75:11677 - 85; PMID:11689649 ; http://dx.doi.org/10.1128/ JVI.75.23.11677-11685.2001 26.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Proc Natl Acad Sci U S A  2010 ; 107:18091 -6; PMID:20921397 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Vaccine   2010 ; 28:7529 -35; PMID:20854897 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
Eur  J Immunol  2013 ; 43:228-39; PMID:23037552 ;  http://dx.doi.org/10.1002/eji.201242690,Non-OADS,/arxiv_data1/oa_pdf/47/26/hvi-10-1874.PMC4186014.pdf
"9 However, an increase in injection site and general  adverse events (AEs) after the second compared with the first dose of AS03 B-adjuvanted A(H1N1)pdm09 vaccine was  observed, including an increase in the rate of fever ( ≥38 °C).12,13  *Correspondence to: Jeanne-Marie Devaster; Email: jeanne-marie.devaster@gsk.com Submitted: 01/30/2014; Revised: 03/21/2014; Accepted: 04/02/2014; Published Online: 04/30/2014http://dx.doi.org/10.4161/hv.28743A phase 1, open-label safety and immunogenicity  study of an AS03-adjuvanted trivalent inactivated  influenza vaccine in children aged 6 to 35 months alfonso c armona Martinez1, Ignacio s alamanca de la c ueva1, Philippe Boutet2, carline Vanden abeele2, Igor s molenov3,   and Jeanne-Marie Devaster2,* 1Instituto h ispalense de Pediatría; s evilla, s pain; 2Glaxos mithKline Vaccines; Rixensart, Belgium; 3Glaxos mithKline Vaccines; Rixensart, Belgium ( current: Novartis Vaccines and  Diagnostics; a msterdam, The Netherlands) Keywords:  AS03, seasonal influenza vaccine, children Background : There is a need for better vaccines and vaccine strategies to reduce the burden of influenza in very  young children.",Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Lancet 2011;  378:1917-30;  PMID:22078723 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
N Engl J Med 2000 ; 342:225- 31; PMID:10648763 ; http://dx.doi.org/10.1056/ NEJM200001273420401 4.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
N  Engl J Med 2005 ; 353:2559 -67; PMID:16354892 ;  http://dx.doi.org/10.1056/NEJMoa051721 5.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
N Engl J Med 2011 ; 365:1406 - 16; PMID:21995388 ; http://dx.doi.org/10.1056/ NEJMoa10103318.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
BioDrugs  2008 ;  22:279-92; PMID:18778110 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Expert Rev Vaccines  2012 ; 11:349-66; PMID:22380826 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Vaccine  2011 ; 29:4353 - 61; PMID:21504774 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Vaccine   2011 ; 30:35-41; PMID:22063386 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Vaccine  2008 ; 26:2378 -88;  PMID:18407382 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Vaccine  2011 ; 29:4353 - 61; PMID:21504774 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
N Engl J Med 2006 ; 354:1343 -51; PMID:16571878 ;  http://dx.doi.org/10.1056/NEJMoa055778 20.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Clin Drug Investig 2002 ; 22:751-69; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/60/e9/hvi-10-1959.PMC4186022.pdf
"*Correspondence to: Masanari Shiramoto; Email: masanari-shiramoto@lta-med.com Submitted: 11/05/2013; Revised: 03/16/2014; Accepted: 03/24/2014; Published Online: 04/28/2014http://dx.doi.org/10.4161/hv.28633Immunogenicity and safety of 13-valent  pneumococcal conjugate vaccine when  administered to healthy Japanese adults   aged ≥ 50 years An open-label trial Masanari  sh iramoto1,*, sh in Irie2, ch ristine Juergens3, Masako Yamaji4, sa toshi Tamai4, Masakazu  aiz awa4, Todd Belanger5,  William  c  Gruber5, Daniel  a sc ott5, and Beate  sc hmoele-Thoma3 1Medical co. LT a  Ps  cl inic; Fukuoka, Japan; 2Medical co .",Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
J Infect Chemother 2006; 12:63-9; PMID:16648944 ; http://dx.doi.org/10.1007/ s10156-005-0425-8 4.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
J Med Microbiol 2008; 57:820-6;  PMID:18566139 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Epidemiol Infect 2010; 138:61-8;  PMID:19538821 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
N Engl J Med  2001; 345:1042-53;  PMID:11586958 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
J Infect Dis 2012; 205:1408-16; PMID:22457293 ; http://dx.doi.org/10.1093/ infdis/jis212 9.,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Vaccine 2013; 31:3594-602; PMID:23688525 ;  http://dx.doi.org/10.1016/j.vaccine.2013.04.084 10.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Vaccine 2011; 29:5195-202;  PMID:21619909 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Available at: http://www.clinicaltrials.gov/ct2/show/NCT00562354 .,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Vaccine 2003; 21:2190-6;  PMID:12706710 ;  http://dx.doi.org/10.1016/S0264-410X(03)00025-2 13.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
J Infect Dis 2010; 201:32-41;  PMID:19947881 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Expert Rev Vaccines 2011; 10:951-80; PMID:21806394 ; http://dx.doi.org/10.1586/ erv.11.76 18.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Scand J Infect Dis 2001; 33:542-4;  PMID :11515767 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Clin Exp Immunol 2005; 140:507-16; PMID:15932512 ;  http://dx.doi.org/10.1111/j.1365-2249.2005.02791.x 23.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Available at: http://idsc.nih.go.jp/iasr/19/224/inx224.html .,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Eur J Clin Nutr 2002; 56(Suppl 3):S14-9;  PMID:12142955 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Nat Rev Immunol 2009; 9:185-94;  PMID:19240757 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Vaccine 2008; 26:3551-5; PMID:18524433 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Nat Rev Immunol 2009; 9:377-84; PMID:19330016 ; http://dx.doi.org/10.1038/ nri2530 30.,Non-OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
Stat Med 1985; 4:213-26; PMID:4023479 ;  http://dx.doi.org/10.1002/sim.4780040211,OADS,/arxiv_data1/oa_pdf/55/93/hvi-10-1850.PMC4186023.pdf
"7 Inflexal  *Correspondence to: Maria Teresa Infante; Email: infante.mariateresa@gmail.com Submitted: 03/20/2014; Revised: 04/10/2014; Accepted: 04/21/2014; Published Online: 05/01/2014http://dx.doi.org/10.4161/hv.28961Acute disseminated encephalomyelitis with  severe neurological outcomes following virosomal  seasonal influenza vaccine Cristiano  alicino1,2, Maria t eresa Infante2,3,*, Ilaria Gandoglia2,3, Nadia Miolo4, Gian Luigi Mancardi2,3, simona Zappettini5,  elisabetta Capello2,3, andrea o rsi1,2, tiziano t amburini2,3, and Marina Grandis2,3 1Department of Health s ciences; Vaccines and Clinical t rials Unit; University of Genoa; Genoa Italy; 2I.R.C.C.",Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Available  from http://www.who.int/mediacentre/factsheets/ fs211 .,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Vaccine 2006; 24:1159-69;  PMID:16213065 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Vaccine 2007; 25:5771- 92; PMID:17570566 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
J  Child Neurol 2012; 27:1408-25; PMID:22914374 ;  http://dx.doi.org/10.1177/0883073812455104 11.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
J Neurol  Neurosurg Psychiatry 2004; 75(Suppl 1):i22- 8; PMID:14978147 ; http://dx.doi.org/10.1136/ jnnp.2003.034256 13.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Clin Vaccine Immunol 2013; 20:1485- 6; PMID:23885031 ; http://dx.doi.org/10.1128/ CVI.00307-13 15.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Vaccine 2007; 25:570- 6; PMID:16945455 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
N Engl J Med 2011; 364:638- 47; PMID:21288090 ; http://dx.doi.org/10.1056/ NEJMoa1008553 17.,OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Vaccine 2011; 29:8302- 8; PMID:21893148 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
Curr Treat Options Neurol  2012; 14:264-75;  PMID:22476745 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/41/3f/hvi-10-1969.PMC4186031.pdf
"5-7 The HPV-16/18 AS04-adjuvanted vaccine ( Cervarix®,  GlaxoSmithKline Vaccines) is currently registered in more than  *Correspondence to: Junzhi Wang; Email: wangjz@nicpbp.org.cn Submitted: 12/29/2013; Revised: 03/19/2014; Accepted: 03/29/2014; Published Online: 04/29/2014http://dx.doi.org/10.4161/hv.28702Immunogenicity and safety of the HPV-16/18  AS04-adjuvanted vaccine in healthy Chinese girls  and women aged 9 to 45 years Results from 2 randomized controlled trials Fengcai Zhu1,†, Juan Li2,†, Yuemei hu1, Xiang Zhang3, Xiaoping Yang4, hui  Zhao2, Junzhi Wang2,*, Jianguo Yang3, Guodong Xia4,  Qinyong Dai5, ha iwen Tang6, Pemmaraju su ryakiran7, sa njoy K Datta8, Dominique Descamps8, Dan Bi8, and Frank st ruyf8 1ce nter for Disease Prevention and c ontrol; Nanjing ci ty, Jiangsu Province, PR ch ina; 2National Institute for Food and Drug control; Beijing, PR ch ina; 3ce nter for Disease  Prevention and  co ntrol; Taizhou  ci ty, Jiangsu Province, PR  ch ina; 4ce nter for Disease c ontrol and Prevention; Jintan ci ty, Jiangsu Province, PR ch ina; 5Roche ho ng Kong Ltd;  ho ng Kong, PR  ch ina; 6Glaxo sm ithKline Vaccines; sh anghai, PR ch ina; 7Glaxo sm ithKline Vaccines; Bangalore, India; 8Glaxo sm ithKline Vaccines; Wavre, Belgium;  †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Do not distribute.1804  h uman Vaccines & Immunotherapeutics  V olume 10 Issue 7Disclosure of Potential Conflicts of Interest All authors have completed the Unified Competing Interest  form at http://www.icmje.org/coi_disclosure.pdf and declare the  following potential conflicts of interest.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Available from: http://globocan.iarc.fr .,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Cancer 2012; 130:641-52; PMID:21387308 ;  http://dx.doi.org/10.1002/ijc.26042 3.  z ur Hausen H. Human papillomaviruses in the  pathogenesis of anogenital cancer.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Virology 1991; 184:9-13;  PMID:1651607 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Pathol 1999; 189:12-9;   PMID:10451482 ; http://dx.doi.org/10.1002/ (SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 5.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J STD AIDS 2008; 19:106-11;  PMID:18334063 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Cancer Causes Control 2009; 20:1705-13; PMID:19705288 ; http://dx.doi.org/10.1007/ s10552-009-9422-z 7.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Cancer 2011; 128:927-35; PMID:20473886 ; http://dx.doi.org/10.1002/ ijc.25396 8.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Cancer 2014; (Forthcoming);   PMID:24740596 ; http://dx.doi.org/10.1002/ ijc.28897 9.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Lancet 2004; 364:1757-65;  PMID :15541448 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Lancet 2007; 369:2161-70;  PMID:17602732 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Vaccine 2009; 27:581-7;  PMID:19022320 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Adolesc Health 2007; 40:564-71; PMID:17531764 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Hum Vaccin 2009; 5:332-40;   PMID :19221517 ; http://dx.doi.org/10.4161/ hv.5.5.7211 15.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Cell Host Microbe 2010; 8:260-70; PMID:20833377 ;  http://dx.doi.org/10.1016/j.chom.2010.08.003 17.,OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Hum Vaccin 2008; 4:425-34; PMID:18948732 ;  http://dx.doi.org/10.4161/hv.4.6.6912 18.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Hum Vaccin 2010; 6:1054-61; PMID :21157180 ;  http://dx.doi.org/10.4161/hv.6.12.13399 19.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
PLoS One 2013; 8:e61825; PMID:23650505 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Lancet 2009; 374:301-14;  PMID:19586656 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Lancet Oncol 2012; 13:89-99; PMID:22075171 ;  http://dx.doi.org/10.1016/S1470-2045(11)70286-822.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Lancet 2006; 367:1247-55; PMID:16631880 ; http://dx.doi.org/10.1016/ S0140-6736(06)68439-0 23.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Vaccine 2010; 28:6247-55; PMID:20643092 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Hum Vaccin Immunother 2012; 8:390-7;  PMID:22327492 ; http://dx.doi.org/10.4161/ hv.18865 26.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Gynecol Cancer 2010; 20:847-55;  PMID:20606533 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Gynecol Cancer 2009; 19:905-11; PMID:19574783 ; http://dx.doi.org/10.1111/ IGC.0b013e3181a23c0e 28.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Gynecol Cancer 2010; 20:404-10;  PMID:20375805 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Available from: http://www.clinicaltrials.gov/show/NCT00294047 .,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Obstet Gynaecol Res 2010; 36:123-32; PMID:20178538 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Cancer 2011; 129:2147-57;  PMID:21190190 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Adolesc Health 2010; 46:414-21; PMID:20413076 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Adolesc Health 2012; 50:187-94; PMID:22265115 ;  http://dx.doi.org/10.1016/j.jadohealth.2011.11.004 35.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Gynecol Oncol 2009; 115(Suppl):S1-6; PMID:19217149 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Hum Vaccin 2011; 7:958-65; PMID:21892005 ; http://dx.doi.org/10.4161/ hv.7.9.1599937.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Sex Transm Dis 2010; 37:706-14;  PMID:20661178 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Infect Dis 1996; 174:927-36; PMID:8896492 ;  http://dx.doi.org/10.1093/infdis/174.5.927 39.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Asian Pac J Cancer Prev 2013; 14:4015-23; PMID:23991946 ;  http://dx.doi.org/10.7314/APJCP.2013.14.7.4015 41.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Int J Cancer 2012; 131:106-16; PMID:21858807 ; http://dx.doi.org/10.1002/ ijc.2636242.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
J Korean Med Sci 2010; 25:1197-204; PMID:20676333 ; http://dx.doi.org/10.3346/ jkms.2010.25.8.1197 43.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
Cancer Epidemiol Biomarkers Prev 2010; 19:2379-88; PMID:20826835 ; http://dx.doi.org/10.1158/1055- 9965.EPI-10-0336 45.,Non-OADS,/arxiv_data1/oa_pdf/e7/5e/hvi-10-1795.PMC4186032.pdf
"A recom - binant vaccine that targets one of the biochemical pathways nec - essary for the survival of the parasite within the host is under  development by the Sabin Vaccine Institute and Texas Children’s  Hospital Center for Vaccine Development, a non-profit product  development partnership (PDP).2 *Correspondence to: Maria Elena Bottazzi; Email: bottazzi@bcm.edu Submitted: 01/31/2014; Revised: 03/31/2014; Accepted: 04/13/2014; Published Online: 04/30/2014 http://dx.doi.org/10.4161/hv.28872Optimization and revision of the production  process of the Necator americanus  glutathione  s-transferase 1 ( Na-GST-1), the lead hookworm  vaccine recombinant protein candidate elena c urti1,2,‡, christopher a s eid1,2,‡, elissa Hudspeth1,2, Lori c enter1,2, Wanderson Rezende1,2, Jeroen Pollet1,2, cliff Kwityn1,†  Molly Hammond1,2, Rise K Matsunami3, David a e ngler3, Peter J Hotez1,2, and Maria e lena Bottazzi1,2,* 1Departments of Pediatrics and Molecular Virology and Microbiology; National s chool of Tropical Medicine; Baylor college of Medicine, Houston, TX U sa; 2sabin Vaccine  Institute and Texas c hildren’s Hospital c enter for Vaccine Development; Houston, TX U sa; 3Proteomics Programmatic c ore Laboratory at Houston Methodist Hospital  Research Institute, Houston, TX U sa †current affiliation: Beckman c oulter Inc., c haska, MN, U sa ‡authors contributed equally to the manuscript.",Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Vaccine 2011; 29(Suppl 4):D104-10;  PMID:22188933 ;  http://dx.doi.org/10.1016/j.vaccine.2011.06.024 2.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Vaccine 2013; 31(Suppl 2):B227-32;  PMID:23598487 ;  http://dx.doi.org/10.1016/j.vaccine.2012.11.034 3.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Protein Expr Purif 2012; 83:145-51;  PMID:22503665 ;  http://dx.doi.org/10.1016/j.pep.2012.03.0134.,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Vaccine 2013; 31(Suppl 2):B227-32;  PMID:23598487 ;  http://dx.doi.org/10.1016/j.vaccine.2012.11.034 5.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
BMC Struct Biol 2007; 7:42;  PMID:17594497 ;  http://dx.doi.org/10.1186/1472-6807-7-42,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Infect Immun 2005; 73:6903- 11; PMID:16177370 ; http://dx.doi.org/10.1128/ IAI.73.10.6903-6911.2005 10.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Exp Parasitol  2008; 118:32-40;  PMID:17645877 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Infect Immun 2010; 78:1552- 63; PMID:20145100 ; http://dx.doi.org/10.1128/ IAI.00848-09 12.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Hum Vaccin Immunother 2012; 8:765-76;   PMID :22495115 ; http://dx.doi.org/10.4161/hv.1972613.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Health Aff (Millwood) 2011; 30:1080- 7; PMID:21653960 ; http://dx.doi.org/10.1377/ hlthaff.2011.0317 15.,Non-OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Yeast  2009; 26:473-84;  PMID:19575480 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
J Biotechnol  2007; 131:57-66;  PMID :17614154 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
J Biotechnol  2007; 130:39-46;  PMID:17399833 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
Nat Protoc 2006; 1:2856- 60; PMID:17406544 ; http://dx.doi.org/10.1038/ nprot.2006.468,OADS,/arxiv_data1/oa_pdf/61/5c/hvi-10-1914.PMC4186034.pdf
"11 Two live attenuated oral RV vaccines, the pentavalent  human bovine (WC3) reassortant rotavirus vaccine (RotaTeq®, Merck) and the monovalent G1P1A[8] human rotavirus vaccine (Rotarix®, GlaxoSmithKline) were licensed in 2006 and are now used extensively, but the mechanisms or effectors of protection  *Correspondence to: Suvi Lappalainen; E-mail: suvi.lappalainen@uta.fi Submitted: 01/13/2014; Revised: 04/03/2014; Accepted: 04/11/2014; Published Online: 04/29/2014http://dx.doi.org/10.4161/hv.28858Immune responses elicited against rotavirus  middle layer protein VP6 inhibit viral replication in  vitro and in vivo su vi Lappalainen1,*, an a Ruth Pastor2, Kirsi Tamminen1, Vanessa López-Guerrero3, Fernando  es quivel-Guadarrama3,   Laura  a  Palomares2, Timo Vesikari1, and Vesna Blazevic1 1Vaccine Research ce nter; sc hool of Medicine; University of Tampere; Tampere, Finland; 2Instituto de Biotecnología; Universidad Nacional au tónoma de México; cue rnavaca,  Morelos, México; 3Facultad de Medicina; Universidad au tónoma del es tado de Morelos; cue rnavaca, Morelos, México Keywords:  rotavirus, VP6, neutralization, mucosal IgA, intranasal immunization Abbreviations:  dl, double-layered; ELISA, enzyme-linked immunosorbent assay; FFU, focus forming units; GE, gastroenteritis;  HRP, horseradish peroxidase; IM, intramuscular; IN, intranasal; NAbs, neutralizing antibodies; NELISA, ELISA-based antigen  reduction neutralization assay; NoV, norovirus; OD, optical density; OPD, o -phenylenediamine dihydrochloride; PFU, plaque- forming units; pIgA, polymeric IgA; RV, rotavirus; rVP6, recombinant VP6; SDS-PAGE, sodium dodecyl sulphate polyacrylamide  gel electrophoresis; SG, subgroup; SIgA, secretory IgA; VLP, virus-like particle; VW, vaginal wash Rotavirus (RV) is a common cause of severe gastroenteritis (G e) i n children worldwide.",Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Infect Dis 2011; 203:188-95; PMID:21288818 ; http://dx.doi.org/10.1093/ infdis/jiq031 2.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol 2003; 77:9969-78; PMID:12941907 ; http://dx.doi.org/10.1128/ JVI.77.18.9969-9978.2003 5.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Arch Virol 2012; 157:1177-82; PMID:22430951 ;  http://dx.doi.org/10.1007/s00705-012-1273-3 6.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Virology 1997; 237:89-96; PMID:9344910 ;  http://dx.doi.org/10.1006/viro.1997.8762 7.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Gen Virol 1987; 68:643-51; PMID:3029295 ;  http://dx.doi.org/10.1099/0022-1317-68-3-643 9.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Gen Virol 1987; 68:1993-9; PMID:3037019 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2006; 24:2718-31;  PMID:16446014 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
N Engl J Med 2006 ; 354:11-22;  PMID:16394298 ; http://dx.doi.org/10.1056/ NEJMoa052434 14.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
N Engl J Med 2006 ; 354:23- 33; PMID:16394299 ; http://dx.doi.org/10.1056/ NEJMoa052664 15.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Clin Microbiol Infect 2012; 18(Suppl 5):57-63;  PMID:22882248 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Virology 1998 ; 243:158-66 ;  PMID:9527925 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2003; 21:3885-900; PMID:12922123 ;  http://dx.doi.org/10.1016/S0264-410X(03)00308-6 22.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2002; 20:3310-21;  PMID:12213401 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Infect Dis 1996; 174(Suppl 1):S93-7; PMID:8752297 ; http://dx.doi.org/10.1093/ infdis/174.Supplement_1.S93 25.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol 2000; 74:8843-53; PMID:10982326 ; http://dx.doi.org/10.1128/ JVI.74.19.8843-8853.2000 27.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Clin Vaccine Immunol 2010; 17:1647-55;  PMID:20810679 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Virol J 2011; 8:3; http://dx.doi.org/10.1186/1743-422X-8-3 ; PMID:21205330,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Science 1996; 272:104-7; PMID:8600516 ; http://dx.doi.org/10.1126/ science.272.5258.104 30.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Clin Invest 2002; 109:1203-13; PMID:11994409 ; http://dx.doi.org/10.1172/ JCI14397 32.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol 2006; 80:10692-9; PMID:16956954 ; http://dx.doi.org/10.1128/ JVI.00927-06 33.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
PLoS One 2013; 8:e61101; http://dx.doi.org/10.1371/jour-nal.pone.0061101 ; PMID :23671563 34.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Arch Virol 2007; 152:2183-96 ;  PMID:17876681 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol 2008; 82:9753-64; PMID:18632867 ; http://dx.doi.org/10.1128/ JVI.00436-08 36.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
PLoS One 2012; 7:e32949; http://dx.doi.org/10.1371/jour-nal.pone.0032949 ; PMID:22403728 37.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
PLoS Pathog 2013; 9:e1003334; http://dx.doi.org/10.1371/jour-nal.ppat.1003334 ; PMID:23658521 38.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol Methods 1991; 33:127-34;  PMID:1658027 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2011; 29:8126-33; PMID:21854823 ;  http://dx.doi.org/10.1016/j.vaccine.2011.08.026 42.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
PLoS One 2013; 8:e70409; http://dx.doi.org/10.1371/journal.pone.0070409 ;  PMID:23922988 44.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol 2001; 75:9713-22; PMID:11559804 ; http://dx.doi.org/10.1128/ JVI.75.20.9713-9722.2001 45.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2011; 29:4778-84; PMID:21565244 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Hum Vaccin Immunother 2013; 9:1991-2001; http://dx.doi.org/10.4161/hv.25249 ; PMID:23777748 47.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Curr Opin Virol 2012; 2:419-25; PMID:22677178 ;  http://dx.doi.org/10.1016/j.coviro.2012.05.003 48.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Infect Dis 2013; 208:284-94; PMID:23596320 ; http://dx.doi.org/10.1093/ infdis/jit166 49.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Front Immunol 2013; 4:402; http://dx.doi.org/10.3389/fimmu.2013.00402 ;  PMID:24348474 50.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Hum Vaccin Immunother 2013; 10:58-64; http://dx.doi.org/10.4161/hv.27097 ; PMID:2424006851.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Proc Natl Acad Sci U S A 1992; 89:6901-5; PMID:1323121 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Virology 1994; 204:8-16; PMID:7522377 ;  http://dx.doi.org/10.1006/viro.1994.1505 53.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Vaccine 2014;In press: http://dx.doi.org/10.1016/j.vaccine.2014.02.018 ;  PMID:24583002 55.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Virology 2006; 346:338-47; PMID:16375942 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Immunology 2012; 135:89-99;  PMID:22044070 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Virol Methods 1995; 55:199-208;  PMID:8537458 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Clin Virol 1999; 13:9-16; PMID:10405887 ; http://dx.doi.org/10.1016/ S1386-6532(98)00013-4 59.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
J Infect Dis 1989; 159:79-88; PMID:2535868 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
Arch Virol 2000; 145:813-25;  PMID :10893159 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/15/95/hvi-10-2039.PMC4186038.pdf
"We began  Portrait of Dr Michael G. Hanna, Jr. A pioneer in active specific immunotherapy of cancer Michael G Hanna, Jr Founder and Chairman Emeritus; Vaccinogen, Inc.; Frederick, MD USA Keywords:  Cancer Vaccines, Lymphatic  Tissue, Germinal Centers, Mechanism of Humoral Immunity, Bacillus Calmette Guerin (BCG), Bladder Cancer, Cancer Genomic Heterogeneity, Cancer Diversity, Active Specific Immunotherapy, Tumor Antigens, Autologous Tumor Cells, OncoVAX Correspondence to: Michael G Hanna, Jr;   Email: mghannajr@vaccinogeninc.com Submitted: 05/01/2014Accepted: 05/01/2014http://dx.doi.org/10.4161/hv.32094",Non-OADS,/arxiv_data1/oa_pdf/c1/98/hvi-10-1778.PMC4186039.pdf
" ReseaR ch PaPeR www.landesbioscience.com human Vaccines & Immunotherapeutics 1781human Vaccines & Immunotherapeutics 10:7, 1781–1794; July 2014; © 2014 Landes BioscienceReseaR ch PaPeR Introduction In terms of incidence rates, cervical cancer is the third most  common cancer in women worldwide and the eighth most common cancer in Japanese women, ranking second for women  aged 15–44 y.1,2 According to 2008 estimates, in a population of  56.69 million women aged 15 y and over in Japan, 8894 women are diagnosed with cervical cancer and 3350 die from the disease  *Correspondence to: Ryo Konno; Email: kryo772007@yahoo.co.jp Submitted: 12/18/2013; Revised: 03/18/2014; Accepted: 03/31/2014; Published Online: 04/24/2014 http://dx.doi.org/10.4161/hv.28712Efficacy of the human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical  intraepithelial neoplasia and cervical infection in  young Japanese women Open follow-up of a randomized clinical trial up to 4 years  post-vaccination Ryo Konno1,†,*, hiroyuki Yoshikawa2,†, Marie Okutani3,‡, Wim Quint4, Pemmaraju V s uryakiran5, Lan Lin6, and Frank s truyf7 1Department of Obstetrics and Gynaecology; Jichi Medical University; s aitama Medical c enter; s aitama, Japan; 2Department of Obstetrics and Gynecology; Graduate  school of comprehensive h uman s ciences; University of Tsukuba; Ibaraki, Japan; 3Glaxos mithKline KK; Tokyo, Japan; 4DDL Diagnostic Laboratory; Rijswijk, The Netherlands;  5Glaxos mithKline; Bangalore, India; 6XPe Pharma & s cience on behalf of Glaxos mithKline Vaccines; Wavre, Belgium7Glaxos mithKline Vaccines; Wavre, Belgium;  †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
"Gardasil  is a registered trade mark of Merck and Co., Inc. Aimmugen  is a trade mark of Kaketsuken (Chemo-Sero- Therapeutic Research Institute) Disclosure of Potential Conflicts of Interest All authors have completed the Unified Competing Interest  form at http://www.icmje.org/coi_disclosure.pdf and declare: R.K. received from the GlaxoSmithKline group of companies support for travel to the investigator meeting for the study; fee for participation at the investigator meeting; financial support",Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
J Pathol 1999; 189:12-9; PMID:10451482 ;  http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F4.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Vaccine 2008;  26(Suppl 10):K1-16;  PMID:18847553 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
N Engl J Med  2003; 348:518-27;  PMID:12571259 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Int J Cancer  2007; 121:621-32;  PMID:17405118 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Cancer Sci 2009;  100:1312-6;  PMID:19432906 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Available at: http://www.iarc.fr/en/publications/pdfs-online/prev/hand- book10/HANDBOOK10.pdf  [Accessed: 16 Aug.  2013].,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
BMC Infect  Dis 2011; 11:13;  PMID:21226933 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
J Adolesc Health 2007; 40:564-71; PMID:17531764 ;  http://dx.doi.org/10.1016/j.jadohealth.2007.02.015 13.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Hum Vaccin 2009; 5:332-40; PMID :19221517 ;  http://dx.doi.org/10.4161/hv.5.5.7211 14.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Vaccine 2009;  27:581-7;  PMID:19022320 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Vaccine 2006; 24:5571-83; PMID:16753240 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet 2006; 367:1247-55; PMID:16631880 ;  http://dx.doi.org/10.1016/S0140-6736(06)68439-0 18.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Hum Vaccin Immunother 2012; 8:390-7;   PMID:22327492 ; http://dx.doi.org/10.4161/hv.18865 20.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet 2009; 374:1975-85;  PMID:19962185 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet Oncol 2012;  13:89-99;  PMID:22075171 ; http://dx.doi.org/10.1016/ S1470-2045(11)70286-8 23.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet Oncol 2012; 13:100- 10; PMID:22075170 ; http://dx.doi.org/10.1016/ S1470-2045(11)70287-X 24.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet 2007; 369:2161- 70; PMID:17602732 ; http://dx.doi.org/10.1016/ S0140-6736(07)60946-5 25.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Lancet 2009; 374:301-14; PMID:19586656 ;  http://dx.doi.org/10.1016/S0140-6736(09)61248-4 26.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Available from http://www.jase.faje.or.jp/jigyo/journal/seikyoiku_journal_201208.pdf  [Accessed: 2 Mar.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Int J Gynecol Cancer 2010; 20:847- 55; PMID:20606533 ; http://dx.doi.org/10.1111/ IGC.0b013e3181da2128 28.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Int J Gynecol Cancer  2010; 20:404-10;  PMID:20375805 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Int  J Gynecol Cancer 2009; 19:905-11; PMID:19574783 ;  http://dx.doi.org/10.1111/IGC.0b013e3181a23c0e 30.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Cancer Sci  2011; 102:877-82;  PMID:21251162 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Cancer Discov 2011; 1:408-19; PMID:22586631 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Am J Epidemiol 2008; 168:123-37; PMID:18483125 ;  http://dx.doi.org/10.1093/aje/kwn036 33.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
BMJ 2009; 339:b2569;  PMID:19638649 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
J Infect Dis  2009; 199:926-35;  PMID:19236279 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Hum Vaccin 2011; 7:1343- 58; PMID:22048173 ; http://dx.doi.org/10.4161/ hv.7.12.18281 36.,Non-OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
J Clin Microbiol  2006; 44:3292-8;  PMID:16954263 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
Am J Pathol 1998; 153:1731-9; PMID:9846964 ;  http://dx.doi.org/10.1016/S0002-9440(10)65688-X 41.,OADS,/arxiv_data1/oa_pdf/9f/db/hvi-10-1781.PMC4186043.pdf
"With the Accelerated 1st/2nd/3rd Dose Schedule, corre - sponding expected reductions would be 14%, 13%, and 13%  *Correspondence to: Derek Weycker; Email: dweycker@pai2.com Submitted: 01/21/2014; Revised: 02/28/2014; Accepted: 03/27/2014; Published Online: 04/29/2014 http://dx.doi.org/10.4161/hv.28689Public health impact of accelerated immunization  against rotavirus infection among children aged  less than 6 months in the United States Derek Weycker1,*, Mark a ndrew a twood1, Baudouin  standaert2, and Girishanthy Krishnarajah3 1Policy a nalysis Inc. (P aI); Four Davis c ourt; Brookline, M a Usa; 2Glaxos mithKline Vaccines; Wavre, Belgium; 3Glaxos mithKline U sHO Vaccines; King of Prussia, P a Usa Keywords:  emergency department, gastroenteritis, hospitalization, outpatient, rotavirus, rotavirus vaccine; communicable diseases Abbreviations:  ACIP, Advisory Committee on Immunization Practice; ED, emergency department;    RV, rotavirus; RVGE, rotavirus gastroenteritis We developed a cohort model to evaluate the expected public health impact of accelerated regimens for immuniza - tion against rotavirus gastroenteritis (RVG e).",Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
N Engl J Med 2006; 354:23- 33; PMID:16394299; http://dx.doi.org/10.1056/ NEJMoa052664 3.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
N Engl J Med 2006; 354:11-22;  PMID:16394298; http://dx.doi.org/10.1056/ NEJMoa052434 4.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Lancet 2007; 370:1757- 63; PMID:18037080; http://dx.doi.org/10.1016/ S0140-6736(07)61744-9 5.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
N Engl J Med 2011; 365:1108-17; PMID:21992123;  http://dx.doi.org/10.1056/NEJMoa10004466.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Available at: http://us.gsk.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Vaccine 2012; 30:2738- 41; PMID:22374373; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Pediatr Infect Dis J  2010; 29:1083-6; PMID:21155173; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Pediatrics 2008;  122:1235-43; PMID:19047240; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Vaccine 2010; 28:7457- 9; PMID:20846529; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Clin Infect Dis 2013; 57:13-20; PMID:23487388;  http://dx.doi.org/10.1093/cid/cit164 13.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
J Infect Dis  2007; 195:1117-25; PMID:17357047; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Available from:  http://www.census.gov/popest/data/index.html.,OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
Hum Vaccin Immunother  2013; 9:389-97; PMID:23291933; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9e/26/hvi-10-2032.PMC4186049.pdf
"Whereas the serotypes in PCV7 account for only 39% to 53% of disease-causing serotypes in Africa, Asia, Latin America, and the Caribbean, the 13-valent version (PCV13) con - tains additional polysaccharides from serotypes more common  *Correspondence to: Pope Kosalaraksa; Email: pkosalaraksa@yahoo.com Submitted: 11/14/2013; Revised: 03/10/2014; Accepted: 03/25/2014; Published Online: 04/23/2014http://dx.doi.org/10.4161/hv.28642Immunogenicity and safety of 23-valent  pneumococcal polysaccharide vaccine    as a booster dose in 12- to 18-month-old children  primed with 3 doses of 7-valent pneumococcal  conjugate vaccine Usa Thisyakorn1, Kulkanya c hokephaibulkit2, Pope Kosalaraksa3,*, suwat Benjaponpitak4, chitsanu Pancharoen1,  and  sunate  chuenkitmongkol5 1Department of Pediatrics; Faculty of Medicine; c hulalongkorn University; Bangkok, Thailand; 2Department of Pediatrics; Faculty of Medicine; s iriraj h ospital;   Mahidol University; Bangkok, Thailand; 3srinagarind h ospital; Faculty of Medicine; Khon Kaen University; Khon Kaen, Thailand; 4Department of Pediatrics; Faculty of Medicine;  Ramathibodi h ospital; Mahidol University; Bangkok, Thailand; 5sanofi Pasteur Thailand; Bangkok, Thailand Keywords:  23-valent pneumococcal capsular polysaccharide vaccine; heptavalent pneumococcal conjugate vaccine;   pneumococcal vaccines; infant; clinical trial, phase III; immunization; booster Abbreviations:  AE, adverse event; ELISA, enzyme-linked immunoassay; GMC, geometric mean antibody concentration;  MOPA, multiplex opsonophagocytosis assay; OI, opsonization index; PCV, pneumococcal conjugate vaccine; PCV7, heptavalent  pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent unconjugated  pneumococcal vaccine The current study examined the safety and immunogenicity of 23-valent pneumococcal capsular polysaccharide  vaccine (Pneumo23® [PPV23], sanofi Pasteur) as a booster dose in 12- to 18-month-old children primed with heptavalent  pneumococcal vaccine (P cV7; Prevnar®, Pfizer).",Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Lancet 2010; 375:1969-87; PMID:20466419 ; http://dx.doi.org/10.1016/ S0140-6736(10)60549-1 2.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Lancet 2009;  374:893-902;  PMID:19748398 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
All-Party Parliamentary Group on  Pneumococcal Disease Prevention in the Developing  World; 2008.Available from http://www.path.org/vaccineresources/details.php?i=6926.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Lancet 2011; 378:1962-73; PMID:21492929 ;  http://dx.doi.org/10.1016/S0140-6736(10)62225-8 8.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2000; 18:2359-67;  PMID:10738092 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Pediatr Infect Dis  J 1997; 16:1053-9; PMID:9384339 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2011; 29:535-44; PMID:21044669 ;  http://dx.doi.org/10.1016/j.vaccine.2010.10.046 12.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2010; 28:3086- 94; PMID:20199764 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Available from: http://www.cdc.gov/ vaccines/programs/vfc/downloads/resolutions/02-13- 1-pneumo.pdf 14.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Pediatr Infect Dis  J 1998; 17:211-6; PMID:9535248 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Pediatr Infect Dis J 2006; 25:312-9;  PMID:16567982 ; http://dx.doi.org/10.1097/01.,OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine  2004; 22:2696-700;  PMID :15246599 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Infect Dis 2003; 37:1155-64;  PMID:14557958 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2004; 22:2209-20;  PMID :15149779 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Vaccine Immunol 2011; 18:2161- 7; PMID:21994351 ; http://dx.doi.org/10.1128/ CVI.05313-11 21.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Vaccine Immunol 2006; 13:165-9; PMID:16467321 ; http://dx.doi.org/10.1128/ CVI.13.2.165-169.2006 22.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Vaccine Immunol 2009; 16:376-81; PMID:19144787 ; http://dx.doi.org/10.1128/ CVI.00344-08 23.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
BMC Pediatr  2010; 10:4;  PMID:20122261 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine  2007; 25:1275-80;  PMID:17092618 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Infect Dis 2006; 42:907-14; PMID:16511752 ;  http://dx.doi.org/10.1086/50094126.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Infect Dis 2008; 46:174-82; PMID:18171247 ;  http://dx.doi.org/10.1086/524660 27.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine  2010; 28:3440-4;  PMID:20199759 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Clin Vaccine Immunol 2010; 17:134-42; PMID:19889940 ; http://dx.doi.org/10.1128/ CVI.00289-09 30.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2007; 25:3816-26; PMID:17368878 ;  http://dx.doi.org/10.1016/j.vaccine.2007.01.119 31.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Int J Infect Dis 2011; 15:e249-56; PMID:21334243 ;  http://dx.doi.org/10.1016/j.ijid.2010.12.004 32.,OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
Vaccine 2012; 30:4717-8;  PMID:22621828 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/20/57/hvi-10-1859.PMC4186054.pdf
"Keywords Undocumented migrants, health, access to care, European Union, reviewThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/03/czt061.PMC4186209.pdf
"http://europa.eu/about-eu/ countries/index_en.htm, accessed 5 January 2012.",Non-OADS,/arxiv_data1/oa_pdf/dc/03/czt061.PMC4186209.pdf
"http://ec.europa.eu/ employment_social/social_situation/docs/rn_migration_health.pdf,accessed on 5 May 2012.",Non-OADS,/arxiv_data1/oa_pdf/dc/03/czt061.PMC4186209.pdf
"Possible integrated strategies for strengthening universities’ capacity include: refining HPSR þAThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by- nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/53/92/czt065.PMC4186210.pdf
http://www.undp.org/cpr/iasc/content/ docs/UNDP_Capacity_Development.pdf.,Non-OADS,/arxiv_data1/oa_pdf/53/92/czt065.PMC4186210.pdf
"Static optimization modelling is less operationally applicable in low capacity and high uncertainty settings.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://allafrica.com/stories/200709200095.html, accessed September 2013.890 HEALTH POLICY AND PLANNING",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.malecircumcision.org/programs/documents/Rwanda11209.pdf accessed September 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://pdf.usaid.gov/pdf_docs/PNADR404.pdf accessed September 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://www.theatlantic.com/health/archive/2013/ 02/rwandas-historic-health-recovery-what-the-us-might-learn/273226/, accessed 20 July 2013.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.malecircumcision.org/programs/DMPPT.html accessed July 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://globalhealth.kff.org/Daily- Reports/2011/December/02/GH-120211-Obama-AIDS-Day.aspx, ac-cessed December 2011.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://www.msh.org/resource center/publications/upload/Rwanda-EOP-11-10-09_spreads.pdf, accessed September 2012.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://www.nytimes.com/2010/06/15/health/policy/15rwanda.html, accessed September 2012.Ministry of Health Republic of Rwanda.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.moh.gov.rw/fileadmin/templates/MOH-Reports/Final- MoH-annual-report-2008.pdf accessed September 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.populationmedia.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://statistics.gov.rw/publications/national- population-projection-2007-2022 accessed September 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.measuredhs.com/pubs/pdf/FR183/FR183.pdf accessed September 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
Final version available: http://www.measuredhs.com/pubs/pdf/FR214/FR214.pdf accessedSeptember 2013.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"http://opinionator.blogs.nytimes.com/ 2012/07/03/rwandas-health-care-miracle/, accessed September2012.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
http://hdl.handle.net/10101/npre.,Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"Geneva, Switzerland http://www.malecircumcision.",Non-OADS,/arxiv_data1/oa_pdf/5c/f3/czt069.PMC4186211.pdf
"• Latissimus Dorsi Flap Invasion by Ductal Breast Carcinoma Currently, our unit is performing a controlled and  randomized multicenter prospective study in France  [Adipose Tissue Transfer for Moderate Breast Can- cer Conservative Treatment Sequella (GRATSEC);  http://clinicaltrials.gov/show/NCT01035268].",Non-OADS,/arxiv_data1/oa_pdf/87/f4/gox-1-e68.PMC4186293.pdf
2012 Plastic Surgery  Statistics Report Available at: http://www.plasticsurgery.,Non-OADS,/arxiv_data1/oa_pdf/fb/6e/gox-1-e77.PMC4186295.pdf
"High-magnifi-cation view of area in the rectangular frame, http://links.lww.com/PRSGO/A14).",Non-OADS,/arxiv_data1/oa_pdf/cb/21/gox-1-e70.PMC4186297.pdf
"ETK is an extracellular-type solution, whereas UW is an intracellular-type solution (Supplemental Table 1,  Supplemental Digital Content 1, http://links.lww.",Non-OADS,/arxiv_data1/oa_pdf/cb/21/gox-1-e70.PMC4186297.pdf
Available at: http://www.handreg-istry.com.,Non-OADS,/arxiv_data1/oa_pdf/cb/21/gox-1-e70.PMC4186297.pdf
"To conserve article space, the complete data for all 87 articles are given in Supplemental Table ( Supplemen- tal Digital Content 1, which shows the publications in cosmetic surgery, 2011–2013, and quality of evidence criteria, http://links.lww.com/PRSGO/A12).",Non-OADS,/arxiv_data1/oa_pdf/a9/43/gox-1-e66.PMC4186301.pdf
"89 Discussion of Limitations All studies had limitations (Supplemental Table,  Supplemental Digital Content 1, which shows the  publications in cosmetic surgery, 2011–2013, and  quality of evidence criteria, http://links.lww.com/PRS- GO/A12).",Non-OADS,/arxiv_data1/oa_pdf/a9/43/gox-1-e66.PMC4186301.pdf
"See Supplemental Table,  Supplemental Digital Content 1, which shows publi-cations in cosmetic surgery, 2011–2013, and quality of  evidence criteria, http://links.lww.com/PRSGO/A12.",Non-OADS,/arxiv_data1/oa_pdf/a9/43/gox-1-e66.PMC4186301.pdf
Available at: http://www.cebm.net/index.,Non-OADS,/arxiv_data1/oa_pdf/a9/43/gox-1-e66.PMC4186301.pdf
"1)  (See Video 1, Supplemental Digital Content 1, which  displays neurotization with the nerve conduit, avail-able in the “Related Videos” section of the full-text  article at http://www.PRSGO.com or, for Ovid users, http://links.lww.com/PRSGO/A13).",Non-OADS,/arxiv_data1/oa_pdf/06/e9/gox-1-e72.PMC4186303.pdf
"PrSgO.com or, for Ovid users, http://links.lww.com/ PRSGO/A13.",Non-OADS,/arxiv_data1/oa_pdf/06/e9/gox-1-e72.PMC4186303.pdf
"As seen  in Video 1 (Supplemental Digital Content 1, which  displays neurotization with the nerve conduit, avail- able in the “Related Videos” section of the full-text  article at http://www.PRSGO.com or, for Ovid users, http://links.lww.com/PRSGO/A13), this technique Table 4.",Non-OADS,/arxiv_data1/oa_pdf/06/e9/gox-1-e72.PMC4186303.pdf
"With its con- veniently located position within the microsurgical field, the nerve is easily incorporated into the flap inset, as seen in Video 1 (Supplemental Digital Con- tent 1, which displays neurotization with the nerve  conduit, available in the “Related Videos” section of the full-text article at http://www.PRSGO.com or, for Ovid users, http://links.lww.com/PRSGO/A13).",Non-OADS,/arxiv_data1/oa_pdf/06/e9/gox-1-e72.PMC4186303.pdf
"), Biological & Materials Sciences Department, University of Michigan School of Dentistry 2Michigan Center for Oral Health Research (MCOHR), University of Michigan School of Dentistry 3Translational Neuroimaging Laboratory, Molecular & Behavioral Neuroscience Institute, University of Michigan 4PET Physics Section, Division of Nuclear Medicine, Radiology Department, University of Michigan 53DLab, University of Michigan 6Department of Obstetrics and Gynecology, University of Michigan *These authors contributed equally Correspondence to: Alexandre F. DaSilva at adasilva@umich.edu URL: http://www.jove.com/video/50682 DOI: doi:10.3791/50682 Keywords: Medicine, Issue 88, μ-opioid, opiate, migraine, headache, pain, Positron Emission Tomography, molecular neuroimaging, 3D, neuronavigation Date Published: 6/2/2014 Citation: DaSilva, A.F., Nascimento, T.D., Love, T., DosSantos, M.F., Martikainen, I.K., Cummiford, C.M., DeBoer, M., Lucas, S.R., Bender, M.A., Koeppe, R.A., Hall, T., Petty, S., Maslowski, E., Smith, Y.R., Zubieta, J.K. 3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache.",Non-OADS,/arxiv_data1/oa_pdf/bc/bc/jove-88-50682.PMC4186390.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/50682/ Introduction Migraine is a chronic trigeminal pain disorder that affects nearly 16% of women and 6% of men in the United States and worldwide1-3.,Non-OADS,/arxiv_data1/oa_pdf/bc/bc/jove-88-50682.PMC4186390.pdf
Available at http://globocan.iarc.fr (accessed 30 December 2013).,Non-OADS,/arxiv_data1/oa_pdf/87/0c/prp20002-e00047.PMC4186415.pdf
Available at http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/002434/WC500130815.pdf (accessed 26 March 2014).,Non-OADS,/arxiv_data1/oa_pdf/7b/9f/prp20002-e00063.PMC4186423.pdf
Available at http://www.accessdata.fda.gov/ drugsatfda_docs/label/2012/202834lbl.pdf (accessed 26 March 2014).,Non-OADS,/arxiv_data1/oa_pdf/7b/9f/prp20002-e00063.PMC4186423.pdf
The sequence (UGAGGUAGUAGGUUGUAUGGUU) was obtained from miRBase (http://www.mirbase.org/).,OADS,/arxiv_data1/oa_pdf/7c/93/prp20002-e00056.PMC4186442.pdf
Available at http://www.literacytrust.org.uk/ adult_literacy/illiterate_adults_in_england (accessed 1 April 2014).,Non-OADS,/arxiv_data1/oa_pdf/fa/fe/prp20002-e00075.PMC4186451.pdf
Available at http://www.snip-newsle tter.co.uk/pdfs/downloads/readability_brieﬁng.pdf (accessed 1 April 2014).,Non-OADS,/arxiv_data1/oa_pdf/fa/fe/prp20002-e00075.PMC4186451.pdf
1997) and the banning of NDGA from food in the United States more than 40 years ago (http://www.accessdata.fda.gov).,Non-OADS,/arxiv_data1/oa_pdf/64/9f/prp20002-e00079.PMC4186454.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2014:5 339–345Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  339OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S6824 1An international validation study of two  achievement goal measures in a pharmacy  education context saleh Alrakaf1 Ahmed Abdelmageed2 Mary Kiersma2 sion A coulman3 Dai n John3 June T ordoff4 claire Anderson5 Ayman noreddin6 Erica sainsbury1 grenville rose7 lorraine smith1 1Faculty of Pharmacy, University  of sydney, sydney, nsW, Australia;   2Faculty of Pharmacy, Manchester  University, Fort Wayne, in,   UsA; 3school of Pharmacy and  Pharmaceutical sciences, cardiff  University, cardiff, UK; 4school  of Pharmacy, University of Otago,   Dunedin, nZ; 5school of Pharmacy,   University of nottingham,   nottingham, UK; 6school of Pharmacy,   hampton University, hampton,   VA, UsA; 7Aftercare, sydney, nsW,   Australia correspondence: saleh Alrakaf   Faculty of Pharmacy, room s114,  Pharmacy and Bank Building A15,  University of sydney, sydney, nsW 2006,  Australia   Tel +61 2 9351 5544   Fax +61 2 9351 4451   Email salr4982@uni.sydney.edu.a uBackground:  Achievement goal theory helps us understand what motivates students to   participate in educational activities.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Available from: http://sydney.edu.au/courses/Bachelor-of- Pharmac y. Accessed August 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Available from: http://cardiff.ac.uk/for/ prospective/international/english-foundation-courses/english-language- programmes/ielts.htm l. Accessed August 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Available  from: http://www.otago.ac.nz/international/undergraduate/index.htm l.  Accessed August 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
"Available from: http://www.nottingham.ac.uk/ pharmacy/prospectivestudents/undergraduates/entryreqs-ugs.asp x.  Accessed August 11, 2014.",Non-OADS,/arxiv_data1/oa_pdf/9e/57/amep-5-339.PMC4186489.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 1781–1791Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1781Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S6413 6Kevin Nugent1  wallace Smart2,3 1Kinark Child and Family Services,   Trent University and Sir Sanford  Fleming College, Peterborough, ON,   Canada; 2Department of Psychiatry,   Faculty of Medicine and Dentistry,   University of Alberta, edmonton, AB,   Canada; 3University of Lethbridge  Health Centre, Lethbridge, AB, Canada Correspondence: wallace Smart 907–400 4th Avenue South, Lethbridge,  AB T1J 4e1, Canada Tel +1 403 394 2292 Fax +1 403 394 2296 email wallacesmart@gmail.co m Attention-deficit/hyperactivity disorder  in postsecondary students Abstract:  A PubMed review was conducted for papers reporting on attention-deficit/   hyperactivity disorder (ADHD) in postsecondary students.",Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
We also consider how this condition can  be most appropriately managed in the postsecondary setting and examine concerns  regarding nonprescribed use of stimulant medication.Journal name: Neuropsychiatric Disease and Treatment Journal Designation: Review Y ear: 2014 Volume: 10 Running head verso: Nugent and Smart Running head recto: Attention-deficit/hyperactivity disorder in postsecondary students DOI: http://dx.doi.org/10.2147/NDT.S64136,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
Available  from: http://www.naceonline.com/AdultADHDtoolkit/assessmenttools/ quickscreen.pdf.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
Available from: http://naceonline.com/screening_tools/Weiss_ Functional_Impairment_Rating_Scale_Self-Report_WFIRS-S.pdf.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
Available from: http://www.caddra.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
Available from  http://www.nice.org.uk/Guidance/cg7.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.Dove pres s Neuropsychiatric Disease and Treatment 2014:10submit your manuscript | www.dovepress.co m Dove press Dove press 1791Attention-deficit/hyperactivity disorder in postsecondary students 121.,Non-OADS,/arxiv_data1/oa_pdf/05/d5/ndt-10-1781.PMC4186490.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9b/0e/ijn-9-4597.PMC4186491.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 4597–4608International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  4597OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S6957 2TNYl peptide functional chitosan-g-stearate  conjugate micelles for tumor specific targeting Feng-Ying chen1 Jing-Jing Yan1 han-Xi Yi2 Fu-Qiang hu2 Y ong-Zhong Du2 hong Yuan2 Jian Y ou2 Meng-Dan Zhao1 1Women’s hospital, school of  Medicine, Zhejiang University,   hangzhou, People’s republic of china;   2college of Pharmaceutical science,   Zhejiang University, hangzhou,   People’s republic of chinaAbstract:  Nowadays, a real challenge in cancer therapy is to design drug delivery systems  that can achieve high concentrations of drugs at the target site for improved therapeutic effect  with reduced side effects.",Non-OADS,/arxiv_data1/oa_pdf/9b/0e/ijn-9-4597.PMC4186491.pdf
"High entrapment efficiency  can be achieved by optimizing the formulation.9 The physicochemical parameters can be  accommodated to allow drug-loaded micelles to achieve tumor passive transport via the  leakage vasculature surrounding the tumors through enhancing permeability and reten - tion effects.1,10 However, the passive transportation of drugs in the tumor tissues does correspondence:  Meng-Dan Zhao Women’s hospital, school of Medicine,  Zhejiang University, 2 Xueshi road,  hangzhou, People’s republic of china Tel +86 0571 8999 1148 email dreamdan2003@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2014 Volume: 9 Running head verso: Chen et al Running head recto: Functional micelles for tumor specific targeting DOI: http://dx.doi.org/10.2147/IJN.S69572",Non-OADS,/arxiv_data1/oa_pdf/9b/0e/ijn-9-4597.PMC4186491.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/9b/0e/ijn-9-4597.PMC4186491.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9b/0e/ijn-9-4597.PMC4186491.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b1/01/amep-5-331.PMC4186492.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdvances in Medical Education and Practice 2014:5 331–337Advances in Medical Education and Practice Dove press submit your manuscript | www.dovepress.co m Dove press  331OriginAl rEsEArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S7077 6Utility of a dermatology interest group blog:   the impact of medical student interest groups   and Web  2.0 tools as educational resources sheila Z Jalalat richard F Wagner Jr Department of Dermatology,   University of T exas Medical Branch,   galveston, TX, UsA correspondence: richard F Wagner Jr   UTMB Dermatology,  301 University Blvd,   galveston, TX  77555-0783, UsA   Email rfwagner@utmb.ed uAbstract:  The open access University of Texas Dermatology Interest Group blog was estab - lished in  2004 for the purposes of increasing communication and collaboration between medi - cal students and dermatology faculty, residents, and alumni, as well as to promote educational  opportunities and the missions for which the interest group was created.",Non-OADS,/arxiv_data1/oa_pdf/b1/01/amep-5-331.PMC4186492.pdf
Available from: http://www.webicina.com/dermatology/dermatology- in-the-blogosphere /.,Non-OADS,/arxiv_data1/oa_pdf/b1/01/amep-5-331.PMC4186492.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/advances-in-medical-education-and-practice-journa lAdvances in Medical Education and Practice is an international, peer- reviewed, open access journal that aims to present and publish research  on Medical Education covering medical, dental, nursing and allied  health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/b1/01/amep-5-331.PMC4186492.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b1/01/amep-5-331.PMC4186492.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pAdolescent Health, Medicine and Therapeutics 2014:5 171–182Adolescent Health, Medicine and Therapeutics Dove press submit your manuscript | www.dovepress.co m Dove press  171Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AHMT .S4980 7Metabolic consequences of second-generation  antipsychotics in youth: appropriate monitoring  and clinical management Rebecca A Krill Sanjiv Kumra Department of Psychiatry, University  of Minnesota, Minneapolis, MN, USA Correspondence: Sanjiv Kumra   Department of Psychiatry, University   of Minnesota, F-282/2A west,    2450 Riverside Avenue, Minneapolis,   MN 55454, USA   email kumra002@umn.ed uObjective:  To review the metabolic consequences of second-generation antipsychotics in youth  and current monitoring and intervention guidelines for optimal treatment.",Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"With the exception  of paliperidone and the newer SGAs, CAMESA has made  available monitoring spreadsheets to the public based on  their rigorous analysis of each individual SGA safety profile  (http://camesaguideline.org/information-for-doctors ).8 Once significant weight gain has occurred, there are  three possible interventions for management:  1) behavioral  interventions,  2) switching to a more weight-neutral anti- psychotic, and  3) adding a pharmacologic weight-loss agent.",Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"Available  from: http://psychopharmacologyinstitute.com/antipsychotics-videos/ neurological-side-effects-akathisia-dystonia-and-parkinsonis m.  Accessed May  12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"Available from: http://www.cdc.gov/obesity/data/childhood.htm l.  Accessed May  12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"Adolescent Health, Medicine and Therapeutics Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/adolescent-health-medicine-and-therapeutics-journa lAdolescent Health, Medicine and Therapeutics is an international,  peer-reviewed, open access journal focusing on health, pathology,  and treatment issues specific to the adolescent age group.",Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
Available from:  http://www.ama-assn.org/ama/pub/physician-resources/public-health/ promoting-healthy-lifestyles/obesity/childhood-obesity/assessment- prevention-treatment.pag e?.,Non-OADS,/arxiv_data1/oa_pdf/ae/01/ahmt-5-171.PMC4186493.pdf
"Journal of  Preventive Medicine  & Public Health 258 Copyright © 2014  The Korean Society for Preventive MedicineJ Prev Med Public Health 2014;47:258-265   •  http://dx.doi.org/10.3961/jpmph.14.002 Influence of the Nursing Practice Environment on Job  Satisfaction and Turnover Intention Sang-Yi Lee1, Chul-Woung Kim2,3, Jeong-Hee Kang4*, Tae-Ho Yoon5, Cheoul Sin Kim6 1Department of Health Policy and Management, Jeju National University School of Medicine, Jeju; 2Department of Preventive Medicine, Chungnam  National University School of Medicine, Daejeon; 3Research Institute for Medical Sciences, Chungnam National University School of Medicine ,   Daejeon; 4Department of Nursing Science, Gyeongju University, Gyeongju; 5Department of Preventive Medicine & Occupational Medicine, Yangsan  Campus of Pusan National University School of Medicine, Yangsan; 6Research Institute for Dental Care, Korean Dental Association, Seoul, KoreaOriginal Article Objectives: To examine whether the nursing practice environment at the hospital-level affects the job satisfaction and turnover in - tention of hospital nurses.",Non-OADS,/arxiv_data1/oa_pdf/38/a6/jpmph-47-5-258.PMC4186551.pdf
"Key words:  Multilevel analysis, Nursing practice environment,  Job satisfaction, Turnover intention, Hierarchical generalized linear model Received:  January 25, 2014 Accepted:  May 13, 2014 Corresponding author:  Chul-Woung Kim, MD, PhD 266 Munhwa-ro, Jung-gu, Daejeon 301-747, Korea Tel: +82-42-580-8268, Fax: +82-42-583-7561 E-mail : woung@cnu.ac.kr *Current affiliation: Department of Nursing Science, Youngdong University,   Yeongdong, Korea This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.INTRODUCTION Currently, the chronic shortage of nurses in South Korea pISSN 1975-8375 eISSN 2233-4521  (hereafter Korea) is not only a domestic issue but also an inter - national one in countries including the United States, Canada,  and throughout Europe [1].",Non-OADS,/arxiv_data1/oa_pdf/38/a6/jpmph-47-5-258.PMC4186551.pdf
Available from: http://www.hira.,Non-OADS,/arxiv_data1/oa_pdf/38/a6/jpmph-47-5-258.PMC4186551.pdf
"Journal of  Preventive Medicine  & Public Health 245 Copyright © 2014  The Korean Society for Preventive MedicineJournal of  Preventive Medicine  & Public Health PB Copyright © 2014  The Korean Society for Preventive MedicineJ Prev Med Public Health 2014;47:245-252   •  http://dx.doi.org/10.3961/jpmph.14.035 Health Effects of Chronic Arsenic Exposure Young-Seoub Hong1,2, Ki-Hoon Song3, Jin-Yong Chung1 1Heavy Metal Exposure Environmental Health Center, Dong-A University, Busan; 2Department of Preventive Medicine, Dong-A University College of  Medicine, Busan; 3Department of Dermatology, Dong-A University College of Medicine, Busan, Korea Special Article Arsenic is a unique element with distinct physical characteristics and toxicity whose importance in public health is well recognized.",Non-OADS,/arxiv_data1/oa_pdf/6b/76/jpmph-47-5-245.PMC4186552.pdf
"Key words:  Arsenic, Health effects, Carcinogenicity  Received:  August 17, 2014  Accepted:  September 3, 2014 Corresponding author:  Young-Seoub Hong,  MD, PhD 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea Tel: +82-51-240-2888, Fax: +82-51-253--5729 E-mail : yshong@dau.ac.kr This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.INTRODUCTION Given its well-established toxicity and know hazards, knowl - edge about arsenic is of great importance in the field of envi - ronmental health.",Non-OADS,/arxiv_data1/oa_pdf/6b/76/jpmph-47-5-245.PMC4186552.pdf
Available from:  http://www.atsdr.cdc.gov/toxprofiles/tp2.pdf.,OADS,/arxiv_data1/oa_pdf/6b/76/jpmph-47-5-245.PMC4186552.pdf
Available from: http://monographs.iarc.fr/ENG/ Monographs/vol83/mono83.pdf.,Non-OADS,/arxiv_data1/oa_pdf/6b/76/jpmph-47-5-245.PMC4186552.pdf
Available from:  http://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey =2000M05S.TXT.,OADS,/arxiv_data1/oa_pdf/6b/76/jpmph-47-5-245.PMC4186552.pdf
"Journal of  Preventive Medicine  & Public Health 253 Copyright © 2014  The Korean Society for Preventive MedicineJournal of  Preventive Medicine  & Public Health PB Copyright © 2014  The Korean Society for Preventive MedicineJ Prev Med Public Health 2014;47:253-257   •  http://dx.doi.org/10.3961/jpmph.14.036 Environmental Source of Arsenic Exposure Jin-Yong Chung1, Seung-Do Yu2, Young-Seoub Hong1,3 1Heavy Metal Exposure Environmental Health Center, Dong-A University, Busan; 2National Institute of Environmental Research, Incheon;   3Department of Preventive Medicine, Dong-A University College of Medicine, Busan, Korea Special Article Arsenic is a ubiquitous, naturally occurring metalloid that may be a significant risk factor for cancer after exposure to contaminated  drinking water, cigarettes, foods, industry, occupational environment, and air.",Non-OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
"Key words:  Arsenic, Arsenic exposure, Drinking water, Cosmetics, Particulate matter Received:  August 19, 2014 Accepted:  September 6, 2014 Corresponding author:  Young-Seoub Hong, MD, PhD 26 Daesingongwon-ro, Seo-gu, Busan 602-715, Korea Tel: +82-51-240-2888, Fax: +82-51-253-5729 E-mail : yshong@dau.ac.kr This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by- nc/3.0/) which permits unrestricted non-commercial use, distribution, and repro - duction in any medium, provided the original work is properly cited.INTRODUCTION Arsenic, a metalloid and naturally occurring element, is one  of the most abundant elements in the earth’s crust and is found  throughout our environment.",Non-OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
Available from: http://www.atsdr.cdc.gov/phs/phs.asp?id =18&tid =3.,OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
Available  from: http://yosemite.epa.gov/water/owrcCatalog.nsf/9da204 a4b4406ef885256ae0007a79c7/490344d9eaf40d4e85256b06 00724162!OpenDocument.,OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
Available from: http://www.cosmet - icsandtoiletries.com/research/biology/42552997.html.,Non-OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
Available from: http://www.epa.gov/teach/chem_summ/ Arsenic_summary.pdf.,OADS,/arxiv_data1/oa_pdf/4b/71/jpmph-47-5-253.PMC4186553.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/93/54/ceg-7-385.PMC4186570.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical and Experimental Gastroenterology 2014:7 385–394Clinical and Experimental Gastroenterology Dove press submit your manuscript | www.dovepress.co m Dove press  385OriG inal rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEG.S6471 3Psychometric validation of patient-reported  outcome measures assessing chronic constipation lauren M nelson1 Valerie sl Williams1 sheri E Fehnel1 robyn T Carson2 James MacDougall3 Mollie J Baird3 stavros T ourkodimitris2 Caroline B Kurtz3 Jeffrey M Johnston3 1rTi health solutions, Durham, nC,   Usa;  2Forest research institute,   Jersey City, nJ, Usa;  3ironwood  Pharmaceuticals, Cambridge, M a, Usa Correspondence: Valerie sl Williams   rTi health solutions,  3040 Cornwallis  road, PO Box  12194, research Triangle  Park, nC  27709, Usa   Tel +1 919 316 3820  Fax +1 919 541 7222  Email vwilliams@rti.or gBackground:  Measures assessing treatment outcomes in previous CC clinical trials have not  met the requirements described in the US Food and Drug Administration’ s guidance on patient‐ reported outcomes.",Non-OADS,/arxiv_data1/oa_pdf/93/54/ceg-7-385.PMC4186570.pdf
"Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/202811s000lbl.pd f. Accessed August 4, 2014.",Non-OADS,/arxiv_data1/oa_pdf/93/54/ceg-7-385.PMC4186570.pdf
"Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-and-experimental-gastroenterology-journa lClinical and Experimental Gastroenterology is an international, peer ‐ reviewed, open access journal, publishing all aspects of gastroenterology  in the clinic and laboratory, including: Pathology, pathophysiology  of gastrointestinal disease; Investigation and treatment of gastointes ‐ tinal disease; Pharmacology of drugs used in the alimentary tract; Immunology/genetics/genomics related to gastrointestinal disease.",Non-OADS,/arxiv_data1/oa_pdf/93/54/ceg-7-385.PMC4186570.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real  quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/93/54/ceg-7-385.PMC4186570.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b5/72/clep-6-333.PMC4186571.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Epidemiology 2014:6 333–341Clinical Epidemiology Dove press submit your manuscript | www.dovepress.co m Dove press  333Original rEsEarChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CLEP .S6404 9Physician practicing preferences for   conventional or homeopathic medicines   in elderly subjects with musculoskeletal   disorders in the EPi3-MsD cohort Karine Danno1 Clementine Joubert1 gerard Duru2 Jean-Marie Vetel3 1laboratoires Boiron, Messimy, France;   2Cyklad group, lyon, France;  3Centre  hospitalier du Mans, le Mans, France Correspondence: Karine Danno   laboratoires Boiron,  2 avenue de l’Ouest  lyonnais  69510, Messimy, France   Tel +33 4 72 16 40 66  Email karine.danno@boiron.f rBackground:  Musculoskeletal pain is common in elderly persons.",Non-OADS,/arxiv_data1/oa_pdf/b5/72/clep-6-333.PMC4186571.pdf
"Clinical Epidemiology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-epidemiology-journa lClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica - tion of risk factors and screening procedures to develop optimal pre - ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/b5/72/clep-6-333.PMC4186571.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cd/17/copd-9-1045.PMC4186572.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2014:9 1045–1051International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1045OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S7062 0relationship between the gOlD   combined COPD assessment staging   system and bacterial isolation Yusuf aydemir1 Özlem aydemir2 Fatma Kalem3 1Department of respiratory Medicine,   sakarya University, sakarya, T urkey;   2Department of Microbiology,   sakarya University, sakarya, T urkey;   3Department of Microbiology, Konya  numune hospital, Konya, T urkey Correspondence: Yusuf aydemir   Department of respiratory Medicine,   sakarya University hospital,   54100 sakarya, Turkey   Tel +90 264 295 6630   Fax +90 264 295 6629   email dryaydemir@yahoo.co mBackground:  Acute exacerbations, which are a significant cause of mortality and morbidity,  adversely affect chronic obstructive pulmonary disease (COPD) prognosis by accelerating loss  of lung function.",Non-OADS,/arxiv_data1/oa_pdf/cd/17/copd-9-1045.PMC4186572.pdf
"Available  from: http://www.goldcopd.org/guidelin es-global-s trategy- for-diagnosis-management.htm l. Accessed August 15, 2014.",Non-OADS,/arxiv_data1/oa_pdf/cd/17/copd-9-1045.PMC4186572.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/cd/17/copd-9-1045.PMC4186572.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/17/copd-9-1045.PMC4186572.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/72/ce/cmar-6-373.PMC4186574.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pCancer Management and Research 2014:6 373–387Cancer Management and Research Dove press submit your manuscript | www.dovepress.co m Dove press  373Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CMAR.S3930 6The impact of bevacizumab treatment   on survival and quality of life in newly   diagnosed glioblastoma patients Hans Skovgaard Poulsen1,2,* Thomas Urup1,2,* Signe Regner Michaelsen1,2 Mikkel Staberg1,2 Mette villingshøj1,2 Ulrik Lassen1–3 1Department of Radiation Biology,   2Department of Oncology,  3Phase i  Unit, The Finsencenter, Copenhagen  University Hospital, Copenhagen,   Denmark *These authors contributed equally to  this work Correspondence: Hans Skovgaard Poulsen  Department of Radiation Biology, The  Finsencenter, Section  6321, Copenhagen  University Hospital, Blegdamsvej  9, 2100  Copenhagen, Denmark   Tel +45 3545 6303  Fax +45 3545 6301  email hans.skovgaard.poulsen@regionh.d k  Homepage http:// www.radiationbiology.d kAbstract:  Glioblastoma multiforme (GBM) remains one of the most devastating tumors,  and patients have a median survival of  15 months despite aggressive local and systemic  therapy, including maximal surgical resection, radiation therapy, and concomitant and adjuvant  temozolomide.",Non-OADS,/arxiv_data1/oa_pdf/72/ce/cmar-6-373.PMC4186574.pdf
"Cancer Management and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/cancer-management-and-research-journa lCancer Management and Research is an international, peer-reviewed  open access journal focusing on cancer research and the optimal use of  preventative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/72/ce/cmar-6-373.PMC4186574.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/ce/cmar-6-373.PMC4186574.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d3/34/copd-9-1033.PMC4186575.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of COPD 2014:9 1033–1043International Journal of COPD Dove press submit your manuscript | www.dovepress.co m Dove press  1033OrIg Inal researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/COPD.S6822 6Sex-specific relationships between adverse  childhood experiences and chronic obstructive  pulmonary disease in five states Timothy J Cunningham1 earl s Ford1 Janet B Croft1 Melissa T Merrick2 Italia V rolle3 Wayne h giles1 1Division of Population Health,   National Center for Chronic Disease  Prevention and Health Promotion,   Centers for Disease Control and  Prevention, Atlanta, GA, USA;   2Division of Violence Prevention,   national Center for Injury Prevention  and Control, Centers for Disease  Control and Prevention, Atlanta, GA,   USA;  3Office on Smoking and Health,   National Center for Chronic Disease  Prevention and Health Promotion,   Centers for Disease Control and  Prevention, Atlanta, GA, USA Correspondence: Timothy J   Cunningham   Centers for Disease Control   and Prevention,  4770 Buford Highway,   Mailstop F78, Atlanta, GA  30341, USA   Tel +1 770 488 5397  Fax +1 770 488 5965  email t jcunningham@cdc.go vPurpose:  Adverse childhood experiences (ACEs) before age  18 have been repeatedly associated  with several chronic diseases in adulthood such as depression, heart disease, cancer, diabetes,  and stroke.",Non-OADS,/arxiv_data1/oa_pdf/d3/34/copd-9-1033.PMC4186575.pdf
"International Journal of COPD Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-copd-journa lThe International Journal of COPD is an international, peer-reviewed  journal of therapeutics and pharmacology focusing on concise rapid  reporting of clinical studies and reviews in COPD.",Non-OADS,/arxiv_data1/oa_pdf/d3/34/copd-9-1033.PMC4186575.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/34/copd-9-1033.PMC4186575.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2014:6 415–422ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  415ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S6624 7laparoscopic versus open colorectal resection   for cancer and polyps: a cost-effectiveness study Jake Jordan1 henry Dowson2 heather gage3 Daniel Jackson3 Timothy Rockall4 1health Economics Research  group, Brunel University, Uxbridge,   Middlesex, England;  2Frimley Park  hospital, surrey, England;  3school  of Economics, University of surrey,   surrey, England;  4Royal surrey County  hospital, surrey, England Correspondence: heather gage   school of Economics, University   of surrey, staghill, guildford, surrey,   gU2 7Xh, England   Tel 44 1483 686948   Fax 44 1483 689548   Email h.gage@surrey.ac.u kBackground:  Available evidence that compares outcomes from laparoscopic and open surgery  for colorectal cancer shows no difference in disease free or survival time, or in health-related  quality of life outcomes, but does not capture the short term benefits of laparoscopic methods  in the early postoperative period.",Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
Available from:  http://www.nice.org.uk/guidance/TA10 5.,Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
"Available from: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/191504/NICE_guide_to_the_meth - ods_of_technology_appraisal.pd f. Accessed July 1, 2014.",Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
Available from: http://www.nice.,Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/40/ceor-6-415.PMC4186576.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e5/e1/cpaa-6-139.PMC4186621.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Pharmacology: Advances and Applications 2014:6 139–148Clinical Pharmacology: Advances and Applications Dove press submit your manuscript | www.dovepress.co m Dove press  139Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CPAA.S4437 7Arbekacin: another novel agent for treating  infections due to methicillin-resistant  Staphylococcus aureus  and multidrug-resistant  Gram-negative pathogens T etsuya Matsumoto Department of Microbiology, Tokyo  Medical University, Tokyo, Japan Correspondence: Tetsuya Matsumoto   Department of Microbiology, Tokyo  Medical University, 6-1-1 Shinjuku,  Shinjuku-ku, Tokyo 160-8402, Japan   Tel +81 3 3352 6141   Fax +81 3 3352 6160   email tetsuya@tokyo-med.ac.j pAbstract:  Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and  was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes.",Non-OADS,/arxiv_data1/oa_pdf/e5/e1/cpaa-6-139.PMC4186621.pdf
"Clinical Pharmacology: Advances and Applications Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-pharmacology-advances-and-applications-journa lClinical Pharmacology: Advances and Applications is an international,  peer-reviewed, open access journal publishing original research, reports,  reviews and commentaries on all areas of drug experience in humans.",Non-OADS,/arxiv_data1/oa_pdf/e5/e1/cpaa-6-139.PMC4186621.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/e5/e1/cpaa-6-139.PMC4186621.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseJune 2014 |  88  | e51236 | Page 1 of 12Video Article Measuring Oral Fatty Acid Thresholds, Fat Perception, Fatty Food Liking, and Papillae Density in Humans Rivkeh Y. Haryono1, Madeline A. Sprajcer1, Russell S. J. Keast1 1School of Exercise and Nutrition Sciences, Deakin University Correspondence to: Russell S. J. Keast at russell.keast@deakin.edu.au URL: http://www.jove.com/video/51236 DOI: doi:10.3791/51236 Keywords: Neuroscience, Issue 88, taste, overweight and obesity, dietary fat, fatty acid, diet, fatty food liking, detection threshold Date Published: 6/4/2014 Citation: Haryono, R.Y., Sprajcer, M.A., Keast, R.S.J.",Non-OADS,/arxiv_data1/oa_pdf/40/30/jove-88-51236.PMC4186631.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51236/ Introduction Excessive dietary fat consumption is a potential contributor to weight gain1-3 and obesity has become a modern day global epidemic.,Non-OADS,/arxiv_data1/oa_pdf/40/30/jove-88-51236.PMC4186631.pdf
<http://apps.who.int/bmi/index.jsp?,Non-OADS,/arxiv_data1/oa_pdf/40/30/jove-88-51236.PMC4186631.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseJune 2014 |  88  | e51541 | Page 1 of 8Video Article Laboratory Drop Towers for the Experimental Simulation of Dust-aggregate Collisions in the Early Solar System Jürgen Blum1, Eike Beitz1, Mohtashim Bukhari1, Bastian Gundlach1, Jan-Hendrik Hagemann1, Daniel Heißelmann1, Stefan Kothe1, Rainer Schräpler1, Ingo von Borstel1, René Weidling1 1Institut für Geophysik und extraterrestrische Physik, Technische Universität Braunschweig Correspondence to: Jürgen Blum at j.blum@tu-bs.de URL: http://www.jove.com/video/51541 DOI: doi:10.3791/51541 Keywords: Physics, Issue 88, astrophysics, planet formation, collisions, granular matter, high-speed imaging, microgravity drop tower Date Published: 6/5/2014 Citation: Blum, J., Beitz, E., Bukhari, M., Gundlach, B., Hagemann, J.H., Heißelmann, D., Kothe, S., Schräpler, R., von Borstel, I., Weidling, R. Laboratory Drop Towers for the Experimental Simulation of Dust-aggregate Collisions in the Early Solar System.",Non-OADS,/arxiv_data1/oa_pdf/83/9e/jove-88-51541.PMC4186681.pdf
Video Link The video component of this article can be found at http://www.jove.com/video/51541/ Introduction It is generally accepted that planet formation starts with the non-gravitational accumulation of microscopically small dust grains into larger dust aggregates (see review by Blum & Wurm)1.,Non-OADS,/arxiv_data1/oa_pdf/83/9e/jove-88-51541.PMC4186681.pdf
http://creativecommons.org/licenses/by-nc-nd/3.0.,Non-OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
Available from:http://www.abs.gov.au/websitedbs/censushome.nsf/home/ seifa?opendocument&navpos=260.,OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/Latestproducts/ http://www.acsm-msse.org 1568 Official Journal of the American College of Sports MedicineEPIDEMIOLOGY,Non-OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pubhlth-strateg-phys-act- guidelines.,Non-OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
Available from: http://www.ijbnpa.org/content/7/1/40.doi: 10.1186/1479-5868-7-40.,Non-OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
Available from: http://www.biomedcentral.com/1471-2458/11/759.,Non-OADS,/arxiv_data1/oa_pdf/e8/c8/mss-46-1564.PMC4186722.pdf
"The mouseWP dose (4.1 g Ikg j1) used in this study was converted from a human equivalent dose on the basis of body surface area by the following formula from the US Food and Drug Adminis- tration (available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm078932.pdf): assuming a human weight of 60 kg, the human equivalent dose for 20 g /C260 kg j1(0.333 g Ikgj1)= 0.333/C212.3 = a mouse dose of 4.1 g Ikgj1; the conversion coefficient 12.3 was used to account for differences in body surface area between a mouse and a human.",Non-OADS,/arxiv_data1/oa_pdf/6d/bd/mss-46-1517.PMC4186725.pdf
Further details of these clinical trials can be found in the clinical trial registry ( http://www.lillytrials.com/results/ZyprexaLAI.pdf ).,Non-OADS,/arxiv_data1/oa_pdf/8a/c7/yic-29-299.PMC4186727.pdf
"Indianapolis, IN: Eli Lilly & Company 2011; http://pi.lilly.com/us/zyprexa_relprevv.pdf .",Non-OADS,/arxiv_data1/oa_pdf/8a/c7/yic-29-299.PMC4186727.pdf
"Indianapolis, IN: Eli Lilly and Company 2013; Available at: http://pi.lilly.com/us/zyprexa- pi.pdf .",Non-OADS,/arxiv_data1/oa_pdf/8a/c7/yic-29-299.PMC4186727.pdf
Basingstoke (UK): Eli Lilly and Company Limited 2013; Availableat:http://www.medicines.org.uk/emc/medicine/21361/SPC .,Non-OADS,/arxiv_data1/oa_pdf/8a/c7/yic-29-299.PMC4186727.pdf
Available at: http://www.whocc.no .,Non-OADS,/arxiv_data1/oa_pdf/e5/90/meg-26-1260.PMC4186732.pdf
Available at: http://www.statehealthfacts.org/comparemaptable.jsp?ind = 183&cat =4.,Non-OADS,/arxiv_data1/oa_pdf/e5/90/meg-26-1260.PMC4186732.pdf
"The present paper presents final results from a 6-year, open-label clinical trial of olanzapine LAI in theTrial registration: http://www.clinicaltrials.gov .",Non-OADS,/arxiv_data1/oa_pdf/cc/c1/yic-29-322.PMC4186735.pdf
Available at: http://globocan.iarc.fr .,Non-OADS,/arxiv_data1/oa_pdf/27/9f/cej-23-516.PMC4186737.pdf
"105Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Intratumoral steroidogenesis in castration-resistant   prostate cancer: a target for therapy Inna Armandari1, Agus Rizal Hamid1,2, Gerald Verhaegh1,3, Jack Schalken1,3 1Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands  2Department of Urology, Ciptomangunkusumo Hospital, University of Indonesia Faculty of Medicine, Jakarta, Indonesia 3Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands Development of castration-resistant prostate cancer (CRPC) in a low androgen environment, arising from androgen deprivation  therapy (ADT), is a major problem in patients with advanced prostate cancer (PCa).",Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
"Keywords:  Castration-resistant prostatic neoplasms, Enzyme inhibitors, Steroidogenesis, Molecular targeted therapy Prostate Int 2014;2(3):105-113 • http://dx.doi.org/10.12954/PI.14063Review Article Corresponding author:  Jack Schalken Department of Urology, Radboud University Medical Center, P.O.",Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
Steroidogenesis in prostate cancer 106PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063and survival [20].,Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
"3 / September 2014 107PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063uct, is produced by reduction of T, a reaction catalyzed by the  5α-reductase (SRD5A) enzyme (Fig.",Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
Steroidogenesis in prostate cancer 108PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063SRD5A1 in the backdoor pathway synthesis of DHT was shown  by knockdown of the SRD5A1  gene in LNCaP and LAPC4 cells.,Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
3 / September 2014 109PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.140632.,OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
Steroidogenesis in prostate cancer 110PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063in CRPC tissue samples [53].,Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
3 / September 2014 111PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063gen deprivation in prostate cancer.,Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
Steroidogenesis in prostate cancer 112PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14063Bioorg Med Chem 2011;19:6383-99.,Non-OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
3 / September 2014 113PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.1406362.,OADS,/arxiv_data1/oa_pdf/3f/69/pi-2-3-105.PMC4186953.pdf
"114Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Analysis of prostate cancer localization toward improved  diagnostic accuracy of transperineal prostate biopsy Yoshiro Sakamoto1,2, Kaori Fukaya1, Masaki Haraoka1, Kosuke Kitamura1, Yoichiro Toyonaga1, Michio Tanaka1,   Shigeo Horie2 1Department of Urology, Juntendo University Nerima Hospital, Tokyo, Japan 2Department of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan Purpose:  Delineating the precise localization of prostate cancer is important in improving the diagnostic accuracy of prostate biopsy.",Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"Keywords:  Needle biopsy, Prostatectomy, Prostate neoplasmsProstate Int 2014;2(3):114-120 • http://dx.doi.org/10.12954/PI.14052Original Article Corresponding author:  Yoshiro Sakamoto Department of Urology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima-ku, Tokyo 177-8521, Japan   E-mail: miandyo@juntendo.ac.jp / Tel: +81-3-5923-3111 / Fax: +81-3-5923-3217 Submitted: 23 April 2014  / Accepted after revision: 17 June 2014INTRODUCTION Systematic transrectal biopsy was first introduced by Hodge  et al.",Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"3 / September 2014 115PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052performing biopsies in the Apex, Apex–Mid, and Mid regions  (Fig.",Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"Transperineal prostate biopsy 116PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052gions, 95.5% was detected in the Apex–Mid and Mid regions,  and 84.3% was detected in the Mid and Mid–Base regions  (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"3 / September 2014 117PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052no cases where cancer was detected in the Mid, Mid–Base, or  Base alone.",Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
Transperineal prostate biopsy 118PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052digital rectal examination.,Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"3 / September 2014 119PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052sensitivity, and 96.6% specificity, with a 92.2% PPV and 85.5%  NPV , showing comparatively favorable results.",OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
Transperineal prostate biopsy 120PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14052tended transperineal prostate biopsy.,Non-OADS,/arxiv_data1/oa_pdf/28/e2/pi-2-3-114.PMC4186954.pdf
"121Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Comparison of plasmakinetic transurethral resection of  the prostate with monopolar transurethral resection of  the prostate in terms of urethral stricture rates in   patients with comorbidities Orhun Sinanoglu, Sinan Ekici, M.B.",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"Keywords:  Prostatic hyperplasia, Comorbidity, Transurethral resection of prostate, Urethral strictureProstate Int 2014;2(3):121-126 • http://dx.doi.org/10.12954/PI.14043Original Article Corresponding author:  Orhun Sinanoglu Department of Urology, Maltepe University School of Medicine, Feyzullah Caddesi, No: 39, PK:34843, Istanbul, Turkey  E-mail: orhundr@hotmail.com / Tel: +90 533 658 69 22 / Fax: +90 216 383 02 70 Submitted: 4 March 2014  / Accepted after revision: 2 May 2014INTRODUCTION For many years, monopolar transurethral resection of the  prostate (M-TURP) has been the standard method for treating  lower urinary tract symptoms (LUTS) resulting from benign  prostatic hyperplasia (BPH) with immediate success in re - lieving the obstruction and with improvement of symptoms  and voiding variables in the long run [1].",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"Urethral stricture in PK-TURP vs. M-TURP 122PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14043mented or suspected prostate cancer, neurogenic bladder,  bladder stone or diverticula, urethral stricture, and maximal  bladder capacity > 500 mL.",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"3 / September 2014 123PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14043ment arms (20.0 ± 5.0 vs. 19.1 ± 6.2, respectively).",OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"Urethral stricture in PK-TURP vs. M-TURP 124PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14043patients with concomitant cardiovascular, pulmonary, and  other organ diseases.",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"3 / September 2014 125PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14043However, the mean operative times in both groups were  similar, although the prostate volume in the PK-TURP arm  was higher and the time interval for a given unit of resected  tissue was shorter.",Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
Urethral stricture in PK-TURP vs. M-TURP 126PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14043Transurethral resection of prostate: technical progress and  clinical experience using the bipolar Gyrus plasmakinetic tis - sue management system.,Non-OADS,/arxiv_data1/oa_pdf/7b/ae/pi-2-3-121.PMC4186955.pdf
"127Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Feasibility of robot-assisted radical prostatectomy for  very-high risk prostate cancer: surgical and oncological  outcomes in men aged ≥70 years Kyo Chul Koo, Dae Chul Jung1, Seung Hwan Lee, Young Deuk Choi, Byung Ha Chung, Sung Joon Hong,   Koon Ho Rha Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea 1Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea Purpose:  Robot-assisted radical prostatectomy with pelvic lymph node dissection (RALP-PLND) is a feasible treatment option  for high-risk prostate cancer (HPCa), but remains controversial for very high-risk prostate cancer (VHPCa).",Non-OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
"Keywords:  Aged, Prostate neoplasms, Robotics, Treatment outcomeProstate Int 2014;2(3):127-132 • http://dx.doi.org/10.12954/PI.14050Original Article Corresponding author:  Koon Ho Rha Department of Urology, Urological Science Institute, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea E-mail: khrha@yuhs.ac / Tel: +82-2-2228-2310 / Fax: +82-2-312-2538 Submitted: 15 April 2014  / Accepted after revision: 21 May 2014INTRODUCTION Prostate cancer (PCa) is the most common malignancy among  elderly men and the second most common cause of cancer- related death in industrialized nations [1].",Non-OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
Surgery for very high risk prostate cancer 128PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.140502.,Non-OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
3 / September 2014 129PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.140502.,OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
Surgery for very high risk prostate cancer 130PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.140503.,Non-OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
Surgery for very high risk prostate cancer 132PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14050cancer?,Non-OADS,/arxiv_data1/oa_pdf/ab/be/pi-2-3-127.PMC4186956.pdf
"133Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Correlation and diagnostic performance of the   prostate-specific antigen level with the diagnosis,   aggressiveness, and bone metastasis of prostate cancer in  clinical practice  Bannakij Lojanapiwat, Wisan Anutrakulchai, Wilaiwan Chongruksut, Chaichawan Udomphot Division of Urology, Department of Surgery, Chiang Mai University, Chiang Mai, Thailand Purpose:  The common tool for diagnosing prostate cancer is serum prostate-specific antigen (PSA) testing and digital rectal  examination, but the disadvantage of the high sensitivity and low specificity of PSA testing in the diagnosis of prostate cancer  is a problem in clinical practice.",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"Keywords:  Prostate-specific antigen, Diagnosis, Gleason scoreProstate Int 2014;2(3):133-139 • http://dx.doi.org/10.12954/PI.14054Original Article Corresponding author:  Bannakij Lojanapiwat  Division of Urology, Department of Surgery, Chiangmai University, 110 intravaroros Suthep Muang, Chiang Mai 50200, Thailand   E-mail: dr.bannakij@gmail.com / Tel: +66-53-945532 / Fax: +66-53-213388 Submitted: 17 May 2014  / Accepted after revision: 30 July 2014INTRODUCTION The prevalence of prostate cancer is increasing in Asia [1-4].",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"PSA, diagnosis, tumor aggressiveness, bone metastasis 134PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054Board) of the Faculty of Medicine, Chiang Mai University.",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
3 / September 2014 135PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054more than 5.0 (theoretical suggested LHR+) for a  PSA level  higher than 20 ng/mL (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"PSA, diagnosis, tumor aggressiveness, bone metastasis 136PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054DISCUSSION  Nowadays, the accepted tools for the diagnosis of prostate  cancer are the DRE and serum PSA.",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"3 / September 2014 137PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054of 95% in men with PSA between 4 and 10 ng/mL, the speci - ficity of proPSA, total PSA, and free PSA alone is 37%, 15%,  and 27%, respectively [29,30].",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"PSA, diagnosis, tumor aggressiveness, bone metastasis 138PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054Asia: resource-stratified guidelines from the Asian Oncology  Summit 2013.",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
http://dx.doi.org/10.1016/j.eururo.2013.12.055 .,OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"3 / September 2014 139PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14054cific antigen isoform [-2]proPSA (p2PSA) and its derivatives,  %p2PSA and the prostate health index (PHI), in men with a  family history of prostate cancer: results from a multicentre  European study, the PROMEtheuS project.",Non-OADS,/arxiv_data1/oa_pdf/dc/6e/pi-2-3-133.PMC4186957.pdf
"140Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Honokiol, a constituent of Magnolia  species, inhibits   adrenergic contraction of human prostate strips and   induces stromal cell death Daniel Herrmann, Andrea Schreiber, Anna Ciotkowska, Frank Strittmatter, Raphaela Waidelich, Christian G. Stief,  Christian Gratzke, Martin Hennenberg Department of Urology, Ludwig-Maximilians University, Munich, Germany Purpose:  Smooth muscle contraction and prostate growth are important targets for medical therapy of lower urinary tract  symptoms (LUTS) in patients with benign prostatic hyperplasia.",Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
"Keywords:  Magnolia, Honokiol, Prostatic hyperplasia, Lower urinary tract symptoms, Adrenergic alpha-1 receptorsProstate Int 2014;2(3):140-146 • http://dx.doi.org/10.12954/PI.14055Original Article Corresponding author:  Christian Gratzke Department of Urology, Ludwig-Maximilians University, Marchioninistr.",Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
"3 / September 2014 141PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055the equilibration period, spontaneous decreases in tone are  usually observed.",Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
Honokiol effects in the human prostate 142PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055α1-adrenoceptor.,Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
3 / September 2014 143PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055man prostate strips (Fig.,Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
"Honokiol effects in the human prostate 144PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055tors are applied to patients, where monotherapy with α1- blockers is insufficient [17].",Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
"3 / September 2014 145PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055trations of honokiol may be up to six times higher compared  to oral application, what may be interesting for applications  in LUTS therapy [30].",Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
Honokiol effects in the human prostate 146PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14055Inhibitory effects of magnolol on distal colon of guinea pig in  vitro.,Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
http://dx.doi.org/10.1002/bmc.3179.,Non-OADS,/arxiv_data1/oa_pdf/5c/33/pi-2-3-140.PMC4186958.pdf
"147Copyright © 2014 Asian Pacific Prostate Society (APPS) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.http://p-international.org/ pISSN: 2287-8882 • eISSN: 2287-903X  PROSTATE  INTERNATIONAL Circulating tumor cell count during zoledronic acid   treatment in men with metastatic prostate cancer:   a pilot study Hisamitsu Ide, Yan Lu, Toshiaki Tanaka1, Yoshiaki Wakumoto2, Kosuke Kitamura, Satoru Muto, Raizo Yamaguchi,  Naoya Masumori1, Shigeo Horie2 Department of Urology, Teikyo University School of Medicine, Tokyo, Japan 1Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan 2Department of Urology, Juntendo University, Graduate School of Medicine, Tokyo, Japan Purpose:  Recent clinical trials have demonstrated that zoledronic acid (ZOL) significantly prolongs survival in prostate cancer  patients undergoing androgen deprivation therapy.",Non-OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
"Keywords:  Zoledronic acid, Circulating neoplatic cells, Prostate neoplasmsProstate Int 2014;2(3):147-151 • http://dx.doi.org/10.12954/PI.14056Original Article Corresponding author:  Shigeo Horie Department of Urology, Juntendo University, Graduate School of Medicine, 2-1-1 Bunkyo-ku, Hongo, Tokyo 1138421, Japan E-mail: shorie@juntendo.ac.jp / Tel: +81-3-3813-3111 / Fax: +81-3-5802-1227   Submitted: 17 June 2014  / Accepted after revision: 21 August 2014INTRODUCTION Increasingly malignant cancer cells create an intravascular  influx as they permeate blood vessels [1].",Non-OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
"CTC count during zoledronic acid treatment     148PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14056venous ZOL administration in 4-week intervals (on days 0, 28,  and 56) at our hospitals (Teikyo University School of Medicine,  Sapporo Medical University School of Medicine, and Juntendo  University, Graduate School of Medicine).",Non-OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
3 / September 2014 149PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14056predictive factor in CRPC prognosis [28].,OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
CTC count during zoledronic acid treatment     150PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14056Urol 2008;179:2187-91.,Non-OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
3 / September 2014 151PROSTATE INTERNATIONAL http://dx.doi.org/10.12954/PI.14056spective clinical trial.,Non-OADS,/arxiv_data1/oa_pdf/a0/4d/pi-2-3-147.PMC4186959.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/2c/1f/aps201469a.PMC4186986.pdf
"Indeed, the National Cancer Institute has  recently committed resources to a Ras Initiative to examine the  GTPase Ras as a therapeutic target in cancer (http://frederick.can - cer.gov/RASGreenLight.aspx).",Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
"Cellular Logistics 2013; 3:e27609; http://dx.doi.org/10.4161/cl.27609Quantitative a nalysis of Guanine Nucleotide  exchange Factors (G eFs) as e nzymes Paul a  Randazzo1,*, Xiaoying Jian1, Pei-Wen c hen1, Peng Zhai1, Olivier s oubias2 and John K Northup2 1Laboratory of c ellular and Molecular Biology; National c ancer Institute; Bethesda, MD U sa; 2Laboratory of Membrane Biochemistry and Biophysics;   National Institute on a lcohol a buse and a lcoholism; Rockville, MD U sa The proteins that possess guanine nucleotide exchange factor (G eF) activity, which include about ~800 G protein  coupled receptors (GP cRs),1 15 a rf GeFs,2 81 Rho G eFs,3 8 Ras G eFs,4 and others for other families of GTPases,5 catalyze the  exchange of GTP for GDP on all regulatory guanine nucleotide binding proteins.",Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Nat  Rev Mol Cell Biol 2008; 9:60-71;  PMID:18043707 ;  http://dx.doi.org/10.1038/nrm2299 2.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Nat Rev Mol Cell Biol 2005; 6:167- 80; PMID :15688002 ; http://dx.doi.org/10.1038/ nrm1587 4.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Cell 2007; 129:865-77;  PMID:17540168 ;  http://dx.doi.org/10.1016/j.cell.2007.05.018 6.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 1995; 34:12543- 52; PMID:7548002 ; http://dx.doi.org/10.1021/ bi00039a008 7.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 1998; 37:7420-30;  PMID:9585556 ;  http://dx.doi.org/10.1021/bi972621j 8.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
EMBO  J 2006; 25:1445-55;  PMID:16541104 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Mol Biol  2007; 365:1359-67;  PMID:17134721 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Mol Biol 2001; 310:141-56;  PMID:11419942 ;  http://dx.doi.org/10.1006/jmbi.2001.4735 11.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Mol Biol 2009; 389:275- 88; PMID:19361519 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J  Biol Chem 2012; 287:24273-83;  PMID:22613714 ;  http://dx.doi.org/10.1074/jbc.M112.368084 13.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry  2002; 41:162-9;  PMID:11772013 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Eur Biophys J 2002; 31:268- 74; PMID:12122473 ; http://dx.doi.org/10.1007/ s00249-002-0225-316.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Hum  Mol Genet 2012; 21:2768-78;  PMID:22422767 ;  http://dx.doi.org/10.1093/hmg/dds105 17.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
"Nat Rev Endocrinol 2011; 7:701-14;   PMID:21727914 ; http://dx.doi.org/10.1038/ nrendo.2011.100 18. van Rhee AM, Jacobson KA.",OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Drug  Dev Res 1996; 37:1-38;  PMID:21921973 ;  http://dx.doi.org/10.1002/(SICI)1098- 2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S 19.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Nat Rev Mol Cell Biol  2011; 12:362-75;  PMID :21587297 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry  2005; 44:15423-9;  PMID:16300389 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Methods Enzymol 2008; 438:41- 56; PMID:18413240 ; http://dx.doi.org/10.1016/ S0076-6879(07)38004-X 23.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Biol Chem 1998; 273:26543- 8; PMID:9756891 ; http://dx.doi.org/10.1074/ jbc.273.41.26543 24.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Biol Chem 1999; 274:12438-44;  PMID:10212218 ;  http://dx.doi.org/10.1074/jbc.274.18.12438 25.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Mol Cell 2007; 28:569- 83; PMID:18042453 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
EMBO J 1998; 17:3651- 9; PMID:9649435 ; http://dx.doi.org/10.1093/ emboj/17.13.3651 27.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J  Biol Chem 1997; 272:22221-6;  PMID:9268368 ;  http://dx.doi.org/10.1074/jbc.272.35.22221 28.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Cell Signal 2008; 20:1968-77;  PMID:18675341 ;  http://dx.doi.org/10.1016/j.cellsig.2008.07.007 30.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochem J 2007; 402:439-47;  PMID:17112341 ;  http://dx.doi.org/10.1042/BJ20061217 31.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Methods Enzymol  1982; 81:150-3;  PMID:7098858 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Gen Physiol 1953; 37:189-200;   PMID :13109155 ; http://dx.doi.org/10.1085/ jgp.37.2.189 33.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 1990; 29:3804-12;  PMID:2187531 ;  http://dx.doi.org/10.1021/bi00467a030 34.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Biol Chem 2009; 284:1652- 63; PMID:19017632 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Traffic  2010; 11:732-42;  PMID:20214751 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biophys J 2010; 99:817- 24; PMID:20682259 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Biol Chem 2011; 286:34335-45;   PMID:21795701 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Cell 1998; 95:237- 48; PMID:9790530 ; http://dx.doi.org/10.1016/ S0092-8674(00)81754-7 42.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Mol Cell 2003; 12:1403- 11; PMID:14690595 ; http://dx.doi.org/10.1016/ S1097-2765(03)00475-1 43.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Cell 1998; 92:415-23;  PMID:9476900 ;  http://dx.doi.org/10.1016/S0092-8674(00)80933-2,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 2000; 39:11348- 59; PMID:10985780 ; http://dx.doi.org/10.1021/ bi0007573 45.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 1983; 22:600-11;  PMID : 6301523 ;  http://dx.doi.org/10.1021/bi00272a012 47.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Methods Enzymol 2001; 329:14- 31; PMID:11210530 ; http://dx.doi.org/10.1016/ S0076-6879(01)29062-449.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
J Mol Biol 2002; 324:763- 74; PMID:12460576 ; http://dx.doi.org/10.1016/ S0022-2836(02)01136-1 50.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry 1997; 36:4535-41;  PMID:9109662 ;  http://dx.doi.org/10.1021/bi962556y 51.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Curr Biol  2005; 15:2164-9;  PMID:16332543 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Biochemistry  2002; 41:3605-12;  PMID:11888276 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2c/8c/cl-3-e27609.PMC4187004.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/e6/f2/srep06541.PMC4187007.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6541 | DOI: 10.1038/srep06541 5",Non-OADS,/arxiv_data1/oa_pdf/e6/f2/srep06541.PMC4187007.pdf
"(http://llnl.confex.com/llnl/ams10/techprogram/P1592.HTM) (2005, September5–10).",Non-OADS,/arxiv_data1/oa_pdf/f5/51/srep06511.PMC4187008.pdf
http://www.biogeosciences-discuss.,Non-OADS,/arxiv_data1/oa_pdf/f5/51/srep06511.PMC4187008.pdf
http://www.biogeosciences-discuss.net/9/ C5612/2012/ (2012) Date of access: 12 November 2012.,Non-OADS,/arxiv_data1/oa_pdf/f5/51/srep06511.PMC4187008.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/f5/51/srep06511.PMC4187008.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6511 | DOI: 10.1038/srep06511 5",Non-OADS,/arxiv_data1/oa_pdf/f5/51/srep06511.PMC4187008.pdf
"Cellular Logistics 2013; 3:e27687; http://dx.doi.org/10.4161/cl.27687Binding of the vesicle docking protein p1 15 to the GTPase Rab1b regulates membrane recruitment of the COPI vesicle coatYusong Guo1,† and Adam D Linstedt1,*1Department of Biological Sciences; Carnegie Mellon University; Pittsburgh, PA USA; †Current affiliation: Department of Molecular and Cell Biology and Howard Hughes Medical Institute; UC Berkeley; Berkeley, CA USAKeywords: vesicle tether, vesicle coat complex, RabGTPase, p115, COPIMembrane recruitment of the COPI vesicle coat is fundamental to its function and contributes to compartment identity in the early secretory pathway.",OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Capacity of the golgi appara-tus for biogenesis from the endoplasmic reticulum.MolBiol Cell2003; 14:5011-8; P M I D : 1 4 5 6 5 9 7 3; http://dx.doi.org/10.1091/mbc.E03-06-04372.,Non-OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Reconstitution of COPII vesicle fusion to generate a pre-Golgi intermediate compartment.J Cell Biol2004; 167:997-1003; P M I D : 1 5 6 1 1 3 2 9; http://dx.doi.org/10.1083/jcb.2004081353.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Sequential coupling between COPII and COPI vesicle coats in endoplasmic reticulum to Golgi transport.J Cell Biol1995; 131:875-93; P M I D : 7 4 9 0 2 9 1; http://dx.doi.org/10.1083/jcb.131.4.8754.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
The mechanisms of ves-icle budding and fusion.Cell2004; 116:153-66; PMID:14744428; http://dx.doi.org/10.1016/S0092-8674(03)01079-15.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Subcompartmentalizing the Golgi appara-tus.CurrOpin Cell Biol2005; 17:369-75; PMID:15975779; http://dx.doi.org/10.1016/j.ceb.2005.06.0066.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
The COPI system: molecular mechanisms and function.FEBS Lett2009; 583:2701-9; P M I D : 1 9 6 3 1 2 1 1; http://dx.doi.org/10.1016/j.febslet.2009.07.0328.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Bi-directional protein transport between the ER and Golgi.Annu Rev Cell Dev Biol2004; 20:87-123; P M I D : 1 5 4 7 3 8 3 6; http://dx.doi.org/10.1146/annurev.cellbio.20.010403.1053079.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
COPI recruitment is modulated by a Rab1b-dependent mechanism.MolBiol Cell2003; 14:2116-27; PMID:12802079; http://dx.doi.org/10.1091/mbc.E02-09-062510.,Non-OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Rab1b inter-acts with GBF1 and modulates both ARF1 dynamics and COPI association.MolBiol Cell2007; 18:2400-10; P M I D : 1 7 4 2 9 0 6 8; http://dx.doi.org/10.1091/mbc.E06-11-100511.,Non-OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Controlling the loca-tion and activation of RabGTPases.CurrOpin Cell Biol2004; 16:451-7; PMID:15261679; http://dx.doi.org/10.1016/j.ceb.2004.06.01412.,OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
"WurmserAE, SatoTK, EmrSD.New component of the vacuolar class C-Vps complex couples nucleotide exchange on the Ypt7 GTPase to SNARE-dependent docking and fusion.J Cell Biol2000; 151:551-62; P M I D : 1 1 0 6 2 2 5 7; http://dx.doi.org/10.1083/jcb.151.3.55114.",OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
Functional synergy between Rab5 effector Rabaptin-5 and exchange factor Rabex-5 when physically asso-ciated in a complex.MolBiol Cell2001; 12:2219-28; P M I D : 1 1 4 5 2 0 1 5; http://dx.doi.org/10.1091/mbc.12.7.221915.,Non-OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
The rab exchange factor Sec2p reversibly associates with the exocyst.MolBiol Cell2006; 17:2757-69; PMID:16611746; http://dx.doi.org/10.1091/mbc.E05-10-091716.,Non-OADS,/arxiv_data1/oa_pdf/1a/bc/cl-3-e27687.PMC4187009.pdf
